Original Article

Male reproductive health and infertility

pISSN: 2287-4208 / eISSN: 2287-4690 World J Mens Health 2023 Jan 41(1): 14-48 https://doi.org/10.5534/wjmh.220067



Impact of Antioxidant Therapy on Natural Pregnancy Outcomes and Semen Parameters in Infertile Men: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Ashok Agarwal¹, Rossella Cannarella^{2,3}, Ramadan Saleh^{4,5}, Ahmed M. Harraz^{6,7,8}, Hussein Kandil⁹, Gianmaria Salvio¹⁰, Florence Boitrelle^{11,12}, Shinnosuke Kuroda³⁰, Ala'a Farkouh¹⁰, Amarnath Rambhatla¹³, Armand Zini¹⁴, Giovanni Colpi¹⁵, Murat Gül¹⁶, Parviz Kavoussi¹⁷, Taha Abo-Almagd Abdel-Meguid Hamoda^{18,19}, Edmund Ko²⁰, Gokhan Calik²¹, Tuncay Toprak²², Germar-Michael Pinggera²³, Hyun Jun Park^{24,25}, Ramy Abou Ghayda²⁶, Suks Minhas²⁷, Gian Maria Busetto²⁸, Mustafa Emre Bakırcıoğlu²⁹, Ates Kadioglu³⁰, Eric Chung³¹, Giorgio Ivan Russo³², Aldo E. Calogero²⁰, Rafael F. Ambar^{33,34}, Channa N. Jayasena^{35,36}, Rupin Shah³⁷

¹American Center for Reproductive Medicine, Global Andrology Forum, Moreland Hills, OH, USA, ²Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy, ³Glickman Urological & Kidney Institute, Cleveland Clinic Foundation, Cleveland, OH, USA, ⁴Department of Dermatology, Venereology and Andrology, Faculty of Medicine, Sohag University, Sohag, Egypt, ⁵Ajyal IVF Center, Ajyal Hospital, Sohag, Egypt, ⁶Department of Urology, Mansoura University Urology and Nephrology Center, Mansoura, Egypt, ⁷Department of Surgery, Urology Unit, Farwaniya Hospital, Farwaniya, Kuwait, ⁸Department of Urology, Sabah Al Ahmad Urology Center, Kuwait City, Kuwait, ⁹Fakih IVF Fertility Center, Abu Dhabi, UAE, ¹⁰Department of Endocrinology, Polytechnic University of Marche, Ancona, Italy, ¹¹Reproductive Biology, Fertility Preservation, Andrology, CECOS, Poissy Hospital, Poissy, France, ¹²Department of Biology, Reproduction, Epigenetics, Environment and Development, Pari. Saclay University, UVSQ, INRAE, BREED, Jouy-en-Josas, France, ¹³Department of Urology, Vattikuti Urology Institute, Henry Ford Health System, Detroit, MI, USA, ¹⁴Division of Urology, Department of Surgery, McGill University, Montreal, QC, Canada, ¹⁵Next Fertility Procrea, Lugano, Switzerland, ¹⁶Department of Urology, Selcuk University School of Medicine, Konya, Turkey, ¹⁷Austin Fertility & Reproductive Medicine/Westlake IVF, Austin, TX, USA, ¹⁸Department of Urology, King Abdulaziz University, Jeddah, Saudi Arabia, ¹⁹Department of Urology, Faculty of Medicine, Minia University, Minia, Egypt, ²⁰Department of Urology, Loma Linda University Health, Loma Linda, CA, USA, ²¹Department of Urology, Faculty of Medicine, Istanbul Medipol University, Istanbul, Turkey, ²²Department of Urology, Fatih Sultan Mehmet Training and Research Hospital, University of Health Sciences, Istanbul, Turkey, ²³Department of Urology, Medical University Innsbruck, Innsbruck, Austria, ²⁴Department of Urology, Pusan National University School of Medicine, Busan, Korea, ²⁵Medical Research Institute of Pusan National University Hospital, Busan, Korea, ²⁶Urology Institute, University Hospitals, Case Western Reserve University, Cleveland, OH, USA, ²⁷Division of Surgery, Department of Surgery and Cancer, Imperial College, London, UK, ²⁸Department of Urology and Organ Transplantation, University of Foggia, Ospedali Riuniti of Foggia, Foggia, Italy, ²⁹SENSART Clinic, Istanbul, Turkey, ³⁰Section of Andrology, Department of Urology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey, ³¹Department of Urology, Princess Alexandra Hospital, University of Queensland, Brisbane, Australia, ³²Urology Section, University of Catania, Catania, Italy, ³³Department of Urology, Centro Universitario em Saude do ABC, Santo André, Brazil, ³⁴Andrology Group at Ideia Fertil Institute of Human Reproduction, Santo André, Brazil, ³⁵Department of Reproductive Endocrinology and Andrology, Imperial College London, London, UK, ³⁶Department of Andrology, Hammersmith & St. Mary's Hospitals, London, UK, ³⁷Division of Andrology, Department of Urology, Lilavati Hospital and Research Centre, Mumbai, India

Received: Apr 12, 2022 Revised: Apr 24, 2022 Accepted: May 12, 2022 Published online Sep 7, 2022 Correspondence to: Ashok Agarwal Dhttps://orcid.org/0000-0003-0585-1026 American Center for Reproductive Medicine, Global Andrology Forum, 130 West Juniper Lane, Moreland Hills, OH 44022, USA. Tel: +1-216-312-5829, E-mail: agarwaa32099@outlook.com, Website: https://www.globalandrologyforum.com **Purpose:** Seminal oxidative stress (OS) is a recognized factor potentially associated with male infertility, but the efficacy of antioxidant (AOX) therapy is controversial and there is no consensus on its utility. Primary outcomes of this study were to investigate the effect of AOX on spontaneous clinical pregnancy, live birth and miscarriage rates in male infertile patients. Secondary outcomes were conventional semen parameters, sperm DNA fragmentation (SDF) and seminal OS.

Materials and Methods: Literature search was performed using Scopus, PubMed, Ovid, Embase, and Cochrane databases. Only randomized controlled trials (RCTs) were included and the meta-analysis was conducted according to PRISMA guide-lines.

Results: We assessed for eligibility 1,307 abstracts, and 45 RCTs were finally included, for a total of 4,332 infertile patients. We found a significantly higher pregnancy rate in patients treated with AOX compared to placebo-treated or untreated controls, without significant inter-study heterogeneity. No effects on live-birth or miscarriage rates were observed in four studies. A significantly higher sperm concentration, sperm progressive motility, sperm total motility, and normal sperm morphology was found in patients compared to controls. We found no effect on SDF in analysis of three eligible studies. Seminal levels of total antioxidant capacity were significantly higher, while seminal malondialdehyde acid was significantly lower in patients than controls. These results did not change after exclusion of studies performed following varicocele repair.

Conclusions: The present analysis upgrades the level of evidence favoring a recommendation for using AOX in male infertility to improve the spontaneous pregnancy rate and the conventional sperm parameters. The failure to demonstrate an increase in live-birth rate, despite an increase in pregnancy rates, is due to the very few RCTs specifically assessing the impact of AOX on live-birth rate. Therefore, further RCTs assessing the impact of AOX on live-birth rate and miscarriage rate, and SDF will be helpful.

Keywords: Antioxidants; Male infertility; Meta-analysis; Pregnancy; Semen parameters; Sperm DNA fragmentation

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

INTRODUCTION

Infertility affects about one in six couples worldwide, and approximately 50% of infertility is due to male factor [1,2]. Many causes have been attributed to male factor infertility, such as varicocele, endocrine disturbances, genetic abnormalities, immunological factors, urogenital abnormalities or infections, lifestyle, malignancy, systemic disease, gonadotoxins, or obstruction of the reproductive tract [1]. About 30% to 40% of cases are labeled as idiopathic male infertility (IMI) which is diagnosed when there are normal findings on physical examination, and on genetic and hormonal evaluation, but semen analysis reveals abnormal parameters with failure to achieve fatherhood despite unprotected sexual intercourse [3].

Seminal oxidative stress (OS) is now recognized as a potential contributing factor to the various causes of infertility, including IMI. Seminal reactive oxygen species (ROS) are produced by immature sperm, leukocytes, and as by-products of metabolic pathways, and are needed for the normal function of spermatozoa [4]. Excess production of ROS occurs under several circumstances, including smoking, alcohol, other lifestyle factors, varicocele, radiation exposure, and several other conditions [5]. OS occurs when there is a high concentration of ROS leading to an imbalance between ROS and antioxidants (AOXs) [5]. Several studies have suggested that OS plays a significant role in male infertility [6-8]. OS can interfere with capacitation, sperm DNA integrity, and cause sperm membrane damage and this can impact the fertilization process [9,10]. Spermatozoa are particularly susceptible to the action of high concentrations of ROS due to the presence of a large amount of polyunsaturated fatty acids in their plasma membrane as well as a low concentration of enzymes in the cytoplasm that can neutralize ROS [11]. Recently, the term Male Oxidative Stress Infertility (MOSI) was proposed by Agarwal et al [12] to encompass men with abnormal semen analysis and high OS, who were previously classified as having IMI.

The rational for AOX therapy is based on the understanding that AOXs may neutralize these potentially harmful oxidants. An AOX is a substance that neutralizes or protects the cells against the detrimental effects of oxidation and free radicals. The AOX system has enzymatic or non-enzymatic factors. Enzymatic AOXs include superoxide dismutase, catalase, glutathione peroxidase, and glutathione reductase. Non-enzymatic AOXs include glutathione, cysteine, N-acetylcysteine (NAC), carotenoids, vitamin C, vitamin E, carnitine, ferritin, L-arginine, transferrin, coenzyme Q10 (CoQ10), myo-inositol, lycopene, selenium, zinc, and folate [13,14]. The mechanism of action of these AOXs includes free radical scavenging and neutralization as well as preserving sperm DNA integrity and mitochondrial transport [15].

In 2021, a systematic review by Agarwal et al [16] identified 97 clinical trials (52 uncontrolled, 12 unblinded and 33 blinded randomized controlled trials [RCTs]) evaluating the efficacy of a single or combined AOXs for treatment of male infertility. By conducting a qualitative analysis of the evidence, they suggested that a review of the guidelines is needed, as the role of AOXs should be supported in case of (1) abnormal semen quality (grade C recommendation), (2) varicocele (grade C recommendation), and (3) idiopathic and unexplained male infertility (grade B recommendation) [16]. Studies on single supplements or on specific clinical contexts have demonstrated the positive role of AOXs on semen quality and reproductive outcomes. Thus, two recent meta-analyses of RCTs showed a significant positive effect of NAC and L-carnitine/L-acetyl-carnitine (LC/ LAC) on semen parameters [17,18]. In addition, a metaanalysis of six studies with a total of 576 patients, found that the administration of AOXs after varicocelectomy resulted in a greater improvement in sperm concentration (p<0.0001), total sperm motility (p=0.03), progressive sperm motility (p<0.00001), and sperm morphology (p<0.00001) compared to placebo [19]. Furthermore, AOXs improved progressive sperm motility and sperm vitality, and significantly reduced sperm DNA fragmentation (SDF) when used in patients undergoing sperm freezing and thawing [20].

The 2019, Cochrane review assessed the benefit of different AOXs on pregnancy, live-birth, and miscarriage rates [14]. Despite the low quality of the evidence, this latest Cochrane review validated the efficacy of AOXs in improving the pregnancy rate (odds ratio [OR] 2.97, 95% confidence interval [CI] 1.91–4.63). However, the review failed to provide evidence of improvement of live-birth rate because of the low quality of the

The World Journal of MEN'S HEALTH

studies and limited amount of data available.

Despite these potential benefits, the role of AOX treatment in male infertility is still controversial. Major scientific societies, including the European Association of Urology (EAU) [21] and the American Urological Association/American Society for Reproductive Medicine (AUA/ASRM) [22], are not supporting the routine use of AOXs in infertile men, mainly due to the heterogeneity of data. Hence, there is a need for further studies.

The aim of the present systematic review and metaanalysis is to provide an updated, analysis on the impact of AOX therapy for male infertility as compared to placebo or no treatment. Spontaneous clinical pregnancy rate, live-birth, and miscarriage rates were selected as primary outcomes, while conventional sperm parameters, SDF, and seminal OS indices were considered as secondary outcomes. To the best of our knowledge, this is the first study conducting a metaanalysis of seminal OS indices in infertile men after AOX therapy.

MATERIALS AND METHODS

1. Protocol and outcome measures

This meta-analysis was conducted on previously published articles investigating the role of AOX therapy in the management of male infertility and followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) protocols [23]. The PRISMA checklist has been included as Supplement Table 1. The primary outcome was defined as the impact of AOXs on spontaneous clinical pregnancy rate, live-birth rate, and miscarriage rate. Secondary outcomes were the impact on basic semen parameters (sperm concentration, progressive sperm motility, total sperm motility, sperm morphology using the percentage of normal sperm forms), SDF, and indices of seminal OS such as seminal total AOX capacity (TAC) and malondialdehyde acid (MDA). This protocol has been registered in the PROS-PERO database (PROSPERO registration number: CRD42022304600).

2. Eligibility criteria

This systematic review and meta-analysis included all English-language RCTs on male factor subfertility/infertility published until July 2021 that reported spontaneous pregnancy outcomes, and conventional



semen parameters, SDF, or seminal OS in AOX-treated patients vs. placebo-treated or untreated controls. AOX is defined as a supplement (containing a single or a combination of compounds) that can be obtained without a prescription, is not regulated as a pharmaceutical drug, and has an AOX effect. Combined AOXs are those that are composed of two or more AOXs. All RCT studies were included regardless of the type or dose of the oral AOX. Studies that include AOXs plus a plant extract were included if the AOX was the main compound used in the intervention group. All different study designs other than RCTs, animal studies, in vitro studies, case reports, case series, studies of plant extracts or herbal substances, and studies enrolling men taking hormonal or any other fertility drugs were excluded.

3. Search strategy

A systematic search was conducted using Scopus, PubMed, Ovid, Embase, and Cochrane databases. The initial query string on Scopus search was: (((TITLE-ABS-KEY (antioxidant) AND TITLE-ABS-KEY (infertil*) AND TITLE-ABS-KEY ((male) OR (man) OR (men))) AND NOT (TITLE-ABS-KEY ((mouse) OR (mice) OR (rat) OR (animal)))) AND NOT (TITLE-ABS-KEY ((meta-analysis)) OR (metaanalysis)))) AND (TITLE-ABS-KEY ((year*) OR (month*) OR (day*) OR (year*) OR (time) OR (duration))) AND (LIMIT-TO (DOCTYPE,"ar")) AND (EXCLUDE (SUBJAREA, "AGRI") OR EXCLUDE (SUBJAREA, "ENVI")) AND (EXCLUDE (SUBJAREA, "CENG")) AND (EXCLUDE (SUBJAREA, "ENGI")) AND (EXCLUDE (SUBJAREA, "COMP")) AND (EX-CLUDE (SUBJAREA,"IMMU")) AND (EX-CLUDE (SUBJAREA, "HEAL")) AND (EXCLUDE (SUBJAREA, "SOCI")) AND (EXCLUDE (SUBJAREA, "MATE")) AND (EXCLUDE (SUBJAREA, "MULT") OR EX-CLUDE (SUBJAREA, "VETE")) AND (EX-CLUDE (LANGUAGE, "Portuguese")) AND (EXCLUDE (LANGUAGE, "Turkish") OR EX-CLUDE (LANGUAGE, "Chinese") OR EX-CLUDE (LANGUAGE, "Dutch") OR EXCLUDE (LANGUAGE, "German")) AND (EXCLUDE (LANGUAGE,"Hungarian")) AND (EXCLUDE (LANGUAGE, "French")) AND (EXCLUDE (LANGUAGE,"Persian")). PubMed, Ovid, Embase, and Cochrane's search string used was: ((antioxidant) AND (infertil*) AND ((male) OR (man) OR (men))) AND (((year*) OR (month*) OR (day*) OR (year*) OR (time) OR (duration))).

All the eligible studies were selected following the PICO (Population, Intervention, Comparison/Comparator, Outcomes) model (Supplement Table 2). Abstracts of the retrieved articles were independently screened and assessed to confirm their eligibility by four researchers (GS, AF, SK, AR). They worked in pairs, and disagreements were resolved by the fifth researcher (RC).

4. Assessment of quality of included studies

To evaluate the quality of evidence (QoE) of the included studies three tools were used: the Cochrane Risk of Bias of RCTs [24], the JADAD score [25], and CON-SORT guidelines [26]. The QoE was assessed by four researchers (GS, AF, SK, AR) who worked in pairs. Disagreements were resolved by a fifth researcher (RC).

5. Data extraction

Data extraction was conducted for all eligible articles with full-text availability. Extracted information included the following: first author, year of publication, country, study design, the total number of patients, types of AOX, duration of treatment in months, semen parameters (volume, total motility, progressive motility, concentration, and morphology), OS indices (TAC and MDA), SDF, and pregnancy-related outcomes (pregnancy rate, live-birth rate, and miscarriage rate).

6. Accuracy of data collection

To ensure accuracy of search results and to reduce potential errors due to manual collection, screening for eligibility, data extraction, and quality assessment were done in duplicates and cross-matched in each subgroup. In case of discrepancy between screener and verifier, the results in dispute were verified by a third senior author to make a final decision.

7. Statistical analysis

The meta-analysis was performed using the random effect model. Measures of heterogeneity included Cochrane-Q test and I^2 statistics. The weight of each individual study was determined using the inverse variance method and the Mantel-Haenszel methods for continuous and binary data, respectively. The publication bias was assessed with the color-contoured funnel plot and the asymmetry of the plot was tested by the Egger and Harbord tests for mean difference (MD) and log-OR respectively. For the SDF, we used the standardized mean difference (SMD), as this outcome was evaluated using different protocols. A subgroup analysis was performed as a sensitivity analysis and to determine the importance of subgroups on the pooled effect size. All p-values lower than 0.05 were considered statistically significant. The analysis was performed using RevMan software v. 5.4 (Cochrane Collaboration, Oxford, UK) and the IBM v 25 statistical software (IBM Corp., Armonk, NY, USA) and R-programing language v 4.10.

RESULTS

Using the above-mentioned search strategy, we extracted 1,307 abstracts. After the exclusion of 328 duplicates, the remaining 979 abstracts were assessed for inclusion in the meta-analysis. Of these, 868 were judged not eligible based on their title and the abstract, or because they were narrative reviews, comments, systematic reviews and meta-analyses, or letters to the editor. Among the remaining 111 articles that were initially deemed eligible, 66 were excluded due to unavailable full-text, absence of untreated or placebo-treated control group, non-RCT study design, not extractable

data or presence of fertile men in the control group. Finally, 45 RCTs met the study inclusion criteria and were included in the meta-analysis, for a total of 4,332 infertile patients (Fig. 1).

Six of the included studies were performed in an infertile population receiving AOX or no treatment following varicocele repair [27-32]. Therefore, for each outcome which included a varicocele repair group we performed a sub-analysis after exclusion of these studies. The main characteristics of the included studies are shown in Table 1. The duration of AOX therapy of the analyzed studies ranged from 1 to 12 months. The quality of the included studies is shown in Table 2. The inclusion and exclusion criteria for each included study are detailed in Supplement Table 3.

1. Spontaneous pregnancy rate

Sixteen studies [28,29,32-45] assessed spontaneous pregnancy rate in association with AOX, including 1,355 infertile patients (761 in the AOX-treated group and 594 in the untreated or placebo-treated control group) and 190 pregnancies were recorded. We found a positive effect of AOX treatment on spontaneous pregnancy rate (OR 1.97 [95% CI: 1.28, 3.04]; p<0.01), with absence of significant inter-study heterogeneity ($I^2=20\%$; $\chi^2 p=0.20$) (Fig, 2). There was no significant publication bias (Fig. 3).

The sub-analysis performed after the exclusion of





Reference	Year	Population	Intervention	Control	Duration (mo)	Outcome
Eslamian et al [51]	2020	Idiopathic asthenozoospermic men	465 mg DHA plus 600 IU vitamin E (n=41), or 465 mg DHA plus vitamin E-resembling placebo (n=41), or 600 IU vitamin E plus DHA-resembling placebo (n=45)	Placebo (n=45)	m	Basic semen parameters, OS
Kopets et al [38]	2020	Patients with IMI	LC/LAC 1,990 mg, coQ10 40 mg, L-arginine 250 mg, glutathione 100 mg, Zinc 7.5 mg, vitamin B9 234 μ g, vitamin B12 2 μ g, Selenium 50 μ g (n=42)	Placebo (n=41)	Q	Basic semen parameters, natural pregnancy
Steiner et al [42]	2020	Patients with OAT or high SDF	500 mg of vitamin C, 400 mg of vitamin E, 0.20 mg of selenium, 1,000 mg of LC, 20 mg of zinc, 1,000 mcg of folic acid, 10 mg of lycopene daily $(n=85)$	Placebo (n=86)	Q	Semen parameters, SDF, live-birth rate
Ardestani Zadeh et al [27]	2019	Infertile patients with varicocele un- dergone to varicocele repair	Folic acid 5 mg, Selenium 200 μg, vitamin E 400 IU (n=27)	No treatment (n=30)	9	Semen parameters
Kızılay and Altay [28]	2019	Infertile patients with OAT and varico- cele, following varicocele repair	LC fumarate 2 g, LAC 1 g, fructose 2 g, citric acid 100 mg, vitamin C 180 mg, Zinc 20 mg, Folic acid 400 mcg, Selenium 100 mcg, CoQ10 40 mg, vitamin B12 3 mcg (n=62)	No treatment (n=28)	Q	Basic semen parameters, natural pregnancy/ live-birth
Nouri et al [60]	2019	Idiopathic asthenozoospermic men	Lycopene 25 mg daily (n=17)	Placebo (n=19)	ε	Basic semen parameter, OS
Blomberg Jensen et al [69]	2018	Men part of an infertile couple with impaired semen quality	Vitamin D 1,400 lU+calcium 500 mg plus vitamin D 300,000 lU oil once orally (n=136)	Placebo (n=133)	5	Semen parameters, live-birth rate (ART) $^{\mathrm{b}}$
Busetto et al [36]	2018	Infertile men with oligo- and/or as- theno- and/or teratozoospermia, divided into patients with varicocele grade I-III, and patients without vari- cocele	LC 1,000 mg, fumarate 725 mg, LAC 500 mg, fruc- tose 1,000 mg, CoQ10 20 mg, vitamin C 90 mg, zinc 10 mg, folic acid 200 µg and vitamin B12 1.5 µg/daily (n=49)	Placebo (n=45)	Q	Basic semen parameters, natural pregnancy/ live-birth, miscarriage
Lu et al [55]	2018	Infertile men with left-sided clinical varicocele	400 mg melatonin daily (n=27)	Placebo (n=27)	ε	Basic semen parameters, OS
Stenqvist et al [43]	2018	Subfertile men	Vitamin C 3 mg, vitamin E 5 mg, vitamin B12 0.5 μ g, LC 750 mg, CoQ10 10 mg, folic acid 100 μ g, zinc 5 mg, selenium 25 μ g (n=37)	Placebo (n=40)	9	Basic semen parameters, SDF, pregnancy rate
Busetto et al [35]	2017	Infertile patients with OAT	2 sachets of Proxeed Plus daily (1,000 mg l-carnitine, 725 mg fumarate, 500 mg LAC, 1,000 mg fructose, 20 mg CoQ10, 90 mg vitamin C, 10 mg zinc, 200 μ g folic acid and1.5 μ g vitamin B12) (n=52)	Placebo (n=52)	Q	Basic semen parameters, natural pregnancy/ live-birth
Barekat et al [29]	2016	Subfertile men with varicocele grade 2–3 following varicocele repair	NAC 200 mg (n=20)	No treatment (n=20)	m	Basic semen parameters, OS, SDF, natural pregnancy/live-birth

Table 1. Main characteristics of the 45 randomized controlled trials included in this meta-analysis



lable 1. Continued						
Reference	Year	Population	Intervention	Control	Duration (mo)	Outcome
Ener et al [30]	2016	Infertile men with a left-sided clinical varicocele following to varicocele repair	Vitamin E 600 mg (n=22)	No treatment (n=23)	12	Basic semen parameters, natural pregnancy/ live-birth
Boonyarangkul et al [46]	2015	Men with abnormal semen analysis	Tamoxifen citrate 20 mg (n=15) ^a or Folate 5 mg (n=15) or Tamoxifen citrate 20 mg plus Folate 5 mg (n=15) ^a	Placebo (n=15)	m	Basic semen parameters
Cyrus et al [31]	2015	Infertile men with palpable varicocele grade 2–3 underwent to varicocele repair	Vitamin C 500 mg (n=46)	Placebo (n=69)	m	Basic semen parameters
Haghighian et al [53]	2015	Infertile men with idiopathic astheno- zoospermia	ALA 600 mg (n=23)	Placebo (n=21)	ε	Basic semen parameters, OS
Moslemi Mehni et al [57]	2014	Infertile men with idiopathic OAT	Pentoxifylline 800 mg+L-carnitine 1,000 mg (n=58) or Pentoxifylline 800 mg+Placebo (n=59) or LC 1,000 mg+Placebo (n=59)	Placebo (n=59)	m	Basic semen parameters
Azizollahi et al [32]	2013	Infertile men with varicocele grade III following varicocele repair	Zinc 66 mg (n=32) or Folic acid 5 mg (n=26) or Zinc 66 mg+Folic acid 5 mg (n=29)	Placebo (n=25)	9	Sperm concentration, morphology, motility, forward progressive motility
da Silva et al [49]	2013	Subfertile men	Folic acid 5 mg daily (n=23)	Placebo (n=26)	ε	Basic semen parameters
Gopinath et al [37]	2013	Idiopathic OA	2 tablets of CoQ10 50 mg+L-carnitine 500 mg+lycopene 2.5 mg+zinc 12.5 mg (n=46) or 1 tablet (n=43)	Placebo (n=36)	9	Basic semen parameters, spontaneous preg- nancy rate
Safarinejad et al [64]	2012	Infertile men with primary infertility for at least 2 years	CoQ10 (Ubiquinol) 200 mg (n=114)	Placebo (n=114)	6.5	Basic semen parameters, seminal plasma antioxidant status
Nadjarzadeh et al [59]	2011	Infertile men with OAT who have been trying for pregnancy for >1 year of unprotected intercourse	CoQ10 200 mg (n=23)	Placebo (n=24)	m	Basic semen parameters, OS
Safarinejad [65]	2011	Infertile men with idiopathic OAT	Omega-3 fatty acids: EPA and DHA, 1.84 g per day (n=119)	Placebo (n=119)	8	Basic semen parameters, OS
Dimitriadis et al [50]	2010	Infertile men with OA	Vardenafil 10 mg $(n=23)^{a}$ or Sildenafil 50 mg $(n=25)^{a}$ or LC 1000 mg $(n=26)$	No treatment (n=22)	5.5	Basic semen parameters

https://doi.org/10.5534/wjmh.220067



SDF, basic semen parameters, antioxidant

Basic semen parameters

m

No treatment

L-arginine 1,660 mg+carnitine 150 mg+LAC 50 mg+ginseng 200 mg in one vial (n=90)

Infertile men with asthenospermia

Morgante et al [58] 2010

Infertile men

Martinez-Soto et al 2010

[56]

(n=90)

capacity

2.5

Placebo

DHA 1,000 mg+EPA 135 mg (n=35)

(n=29)

Basic semen parameters

2

Placebo

(n=15)

Basic semen parameters, spontaneous preg-

9

Placebo

Infertile men with idiopathic astheno- CoQ10 200 mg (n=30)

zoospermia

2009

Balercia et al [34]

LC 2 g (n=15)

Infertile men

2010

Peivandi et al [62]

(n=30)

nancy rate

C	V
٦	2
2	צ
ŝ	Ξ
Ŧ	2
2	5
Ċ	5
_	-
٦,	
÷	Ĕ
2	6
Ľ	_

The World Journal of **MEN's HEALTH**

Rafaranca	Voar	Domilation	Intervention	Control	Duration	Outcome
ואכובו בוורב					(mo)	Catcollie
Ciftci et al [47]	2009	IMI	NAC (600 mg daily) (n=60)	Placebo (n=60)	m	Basic semen parameters, OS
Safarinejad and Safarinejad [66]	2009	Men with idiopathic OAT, asthenosper- mia or teratospermia of 2 years dura- tion	Selenium 200 μg (n=116) or NAC 600 mg (n=118) or Selenium 200 μg+NAC 600 mg (n=116)	Placebo (n=118)	6.5	Basic semen parameters
Safarinejad [67]	2009	Subfertile men with idiopathic OAT	CoQ10 300 mg (n=106)	Placebo (n=106)	6.5	Basic semen parameters
Stanislavov et al [68]	2009	Subfertile patients	80 mg Pycnogenol and 3 g L-arginine aspartate (n=25)	Placebo (n=25)	-	Basic semen parameters
Omu et al [61]	2008	Men with asthenozoospermia attend- ing infertility and andrology clinic	Zinc 400 mg (n=11) or Zinc 400 mg+vitamin E 1 20 mg (n=12) or Zinc 400 mg+vitamin E 20 mg+vitamin C 10 mg (n=14)	Vo treatment (n=8)	m	Basic semen parameters, spontaneous preg- nancy rate, live-birth rate, miscarriage
Paradiso Galatioto et al [40]	2008	Men with persistent oligospermia (5–20 million/mL) 6 months after retrograde embolization	NAC 600 mg, vitamin C 180 mg, vitamin E 12 mg, vitamin A 3.6 IU, thiamine 24 mg, riboXavin 6 mg, piridoxin 12 mg, nicotinamide 60 mg, pantothenate 12 mg, biotin 2.4 mg, cyanocobalamin 6 mg, ergocalciferol 480 IU, calcium 60 mg, magnesium 21.5 mg, phosphate 27 mg, iron 12 mg manganese 0.6 mg, copper 1.2 mg, zinc 0.6 mg (n=20)	Vo treatment (n=22)	m	Basic semen parameters, natural pregnancy
Sigman et al [71]	2006	Subfertile men aged 18 to 65 years	LC 2,000 mg+LAC 1,000 mg (n=12)	Placebo (n=9)	4	Basic semen parameters, pregnancy rate (ART) ^b
Balercia et al [33]	2005	Subfertile men with idiopathic asthe- nozoospermia	LC 3 g (n=15) vs. LAC 3 g (n=15) vs. LC 2 g+LAC 1 g (n=14)	Placebo (n=15)	9	Basic semen parameters, spontaneous preg- nancy rate
Greco et al [52]	2005	Subfertile men	Vitamin C 1 g and Vitamin E 1 g (n=32)	Placebo (n=32)	2	Basic semen parameters, SDF
Lenzi et al [54]	2003	Subfertile men with OAT	LC 2 g+LAC 1,000 mg (n=43)	Placebo (n=43)	2	Basic semen parameters, spontaneous preg- nancy rate
Závaczki et al [45]	2003	Subfertile men	Magnesium 3,000 mg (n=10)	Placebo (n=10)	m	Basic semen parameters, spontaneous preg- nancy rate
Conquer et al [48]	2000	Healthy asthenozoospermic men who were patients of an infertility clinic	DHA 400 mg (n=9) or DHA 800 mg (n=10)	Placebo (n=9)	Ω	Basic semen parameters
Rolf et al [63]	1999	Men with infertility for over one year	Vitamin C 1,000 mg+vitamin E 800 mg (n=15)	Placebo (n=16)	2	Basic semen parameters and pregnancy rate
Omu et al [39]	1998	Men with asthenozoospermia attend- ing infertility and andrology clinic	Zinc 500 mg (n=49)	No therapy (n=48)	m	Basic semen parameters, natural pregnancy/ live-birth

Reference	Year	Population	Intervention	Control	Duration (mo)	Outcome
Scott et al [41]	1998	Men attending subfertility clinic with low sperm motility	Selenium 100 mg daily alone (n=16) or selenium 100 mg plus selenium combined with vitamins A (1 mg), C (10 mg), and E (15 mg) supplements daily (n=30)	Placebo (n=18)	m	Basic semen parameters, natural pregnancy/ live-birth
Suleiman et al [44]	1996	Asthenozospermic men attending a fertility center	Vitamin E 100 mg (n=52)	Placebo (n=35)	9	Sperm motility, spontaneous live-birth, pregnancy, miscarriage and MDA levels
Dawson et al [70]	1990	Men with sperm agglutination	Ascorbic acid 1,000 mg (n=10) or Ascorbic acid 200 mg (n=10)	Placebo (n=10)	0.75	Basic semen parameters
ALA: alpha-lipoic ac	id, ART:	assisted reproductive technique, CoQ10: c	oenzyme Q10, DHA: docosahexaenoic acid, EPA: eicos	apentaenoic,	IMI: idiopat	hic male infertility, LAC: L-acetyl-carnitine, LC:

L-carnitine, MDA: malondialdehyde acid, NAC: N-acetylcysteine, OA: oligo-asthenoteratozoospermia, OAT: oligo-asthenoteratozoospermia, OAT: oligo-asthenoteratozoospermia, OS: oxidative stress, SDF: sperm DNA fragmentation. ^aThis group was excluded from the analysis.

^bOutcome excluded from the present meta-analysis, since it does not assess spontaneous pregnancy rate.

Table 2. Quality of evidence assessment results of the Cochrane Risk of Bias for Randomized Controlled Trials [21], CONSORT guidelines [23], and JADAD score [22]

				Cochrane Rish	c of Bias for Ra	Indomized Contro	lled Trials					- -
Reference	Year	Selection bias Random sequence generation ^a	Selection bias Allocation concealment ^a	Reporting bias Selective reporting ^a	Other bias Other sources of bias ^a	Performance bias Blinding (participants and personnel) ^a	Detection bias Blinding (outcome assessment) ^a	Attrition bias Incomplete outcome data ^a	Total score (7–21)	CONSORT guideline (1–25)	JADAD (1-5)	Iotal quality score (9–51)
Eslamian et al [51]	2020	m	m	2	2	2	2	m	17	22	ъ	4
Kopets et al [38]	2020	c	£	ŝ	2	£	2	2	18	18	Ŋ	41
Steiner et al [42]	2020	£	ε	2	2	£	2	2	17	15	ŝ	35
Ardestani Zadeh et al [27]	2019	£	£	2	2	2	2	2	16	15	ŝ	34
Kızılay and Altay [28]	2019	£	2	2	2	, -	-	S	14	12	m	29
Nouri et al [60]	2019	£	2	ŝ	ŝ	£	Ω	c	20	17	Ŋ	42
Blomberg Jensen et al [69]	2018	£	£	ς	2	£	ſ	S	20	24	4	48
Busetto et al [36]	2018	£	ſ	с	2	£	ſ	S	20	20	4	44
Lu et al [55]	2018	£	£	ŝ	2	£	ſ	S	20	14	m	37
Stenqvist et al [43]	2018	2	£	ς	ς	£	ſ	S	20	21	S	46
Busetto et al [35]	2017	£	2	2	2	2	2	S	16	17	4	37
Barekat et al [29]	2016	2	2	S	2	-	-	3	14	13	2	29





Table 1. Continued 3

—
ō
ne
tin
Ē
S
5
P
ab
E.

The World Journal of **MEN's HEALTH**

				Cochrane Risl	c of Bias for Ra	ndomized Contro	lled Trials					Totol
Reference	Year	Selection bias Random sequence generation ^a	Selection bias Allocation concealment ^a	Reporting bias Selective reporting ^a	Other bias Other sources of bias ^a	Performance bias Blinding (participants and personnel) ^a	Detection bias Blinding (outcome assessment) ^a	Attrition bias Incomplete outcome data ^a	Total score (7–21)	CONSORT guideline (1–25)	JADAD (1-5)	rotar quality score (9–51)
Ener et al [30]	2016	2	2	-	2	-	-	m	12	13	7	27
Boonyarangkul et al [46]	2015	2	2	2	ŝ	2	2	£	16	13	ŝ	32
Cyrus et al [31]	2015	с	£	2	с	ſ	2	£	19	21	5	45
Haghighian et al [53]	2015	ŝ	£	ŝ	2	ſ	ſ	£	20	22	5	47
Moslemi Mehni et al [57]	2014	2	-	2	2	, -	-	2	11	13	2	26
Azizollahi et al [32]	2013	2	2	2	-	2	2	-	12	10	с	25
da Silva et al [49]	2013	с	£	2	2	ſ	2	£	18	17	5	40
Gopinath et al [37]	2013	2	2	2	2	2	2	2	14	17	с	34
Safarinejad et al [64]	2012	с	£	ς	с	ſ	ſ	£	21	20	5	46
Nadjarzadeh et al [59]	2011	2	2	с	с	ſ	ſ	£	19	19	4	42
Safarinejad [65]	2011	£	£	ŝ	£	ſ	2	£	20	19	5	44
Dimitriadis et al [50]	2010	2	-	2	2	, -	-	£	12	14	2	15
Martinez-Soto et al [56]	2010	ĸ	£	с	2	£	£	2	19	15	4	38
Morgante et al [58]	2010	2	2	2	-	-	-	£	12	6	2	23
Peivandi et al [62]	2010	2	2	2	с	ſ	ſ	£	18	8	с	29
Balercia et al [34]	2009	2	2	2	£	ſ	£	2	17	12	2	31
Ciftci et al [47]	2009	с	£	ς	-	2	2	£	17	14	4	35
Safarinejad and Safarinejad [66]	2009	ŝ	£	ŝ	2	ſ	ſ	£	20	20	4	44
Safarinejad [67]	2009	ĸ	£	m	2	ſ	£	£	20	20	4	44
Stanislavov et al [68]	2009	-	£	2	2	£	£	£	17	14	m	34
Omu et al [61]	2008	-	-	2	-	, -	-	2	6	6	2	20
Paradiso Galatioto et al [40]	2008	ĸ	£	2	£	-	-	£	16	18	с	37
Sigman et al [71]	2006	2	2	2	2	2	-	£	14	15	ŝ	32
Balercia et al [33]	2005	2	2	2	2	2	2	2	14	12	ŝ	29
Greco et al [52]	2005	2	2	2	2	2	2	£	15	13	ε	31
Lenzi et al [54]	2003	2	2	ĸ	2	2	2	£	16	15	ŝ	34
Závaczki et al [45]	2003	2	2	2	£	-	2	-	13	80	2	23
Conquer et al [48]	2000	2	2	3	2	2	2	3	16	16	m	35



				Cochrane Ris	<pre>< of Bias for Ra</pre>	indomized Control	led Trials					Tatal
Reference	Year	Selection bias Random sequence generation ^a	Selection bias Allocation concealment ^a	Reporting bias Selective reporting ^a	Other bias Other sources of bias ^a	Performance bias Blinding (participants and personnel) ^a	Detection bias Blinding (outcome assessment) ^a	Attrition bias Incomplete outcome data ^a	Total score (7–21)	CONSORT guideline (1–25)	JADAD (1-5)	otal quality score (9–51)
Rolf et al [63]	1999	2	m	2	æ	2	2	ſ	17	16	m	36
Omu et al [39]	1998	2	2	2	2	1	-	-	11	13	-	25
Scott et al [41]	1998	ŝ	£	2	2	2	2	£	17	14	4	35
Suleiman et al [44]	1996	2	2	2	-	2	2	-	12	9	m	21
Dawson et al [70]	1990	2	2	2	-	£	2	£	15	8	2	28
^a High risk of bias=1; Unclear risk c	of bias=2	; Low risk of bi	as=3.									

the studies administering AOX or no treatment following varicocele repair confirmed the benefit of AOX administration on spontaneous pregnancy rate (OR 2.12 [95% CI: 1.23, 3.65]; n=157 events; p<0.01] (Fig. 4), in the absence of significant inter-study heterogeneity (I²=36%; χ^2 p=0.08), and no significant publication bias as confirmed by the funnel plot (Fig. 5).

2. Live-birth rate

Only four studies could be included in the analysis of live-birth rate [33,34,39,42], overall including 388 infertile patients (209 in the AOX-treated group and 179 in the control one) and with 65 events (live-birth) recorded.

The analysis revealed no effect of AOX treatment on live-birth rate (OR 1.21 [95% CI: 0.53, 2.76]; p=0.64) (Fig. 6).

3. Miscarriage rate

Four studies reported data on the miscarriage rate and could be included in the analysis [36,39,42,44]. We found no effect of AOX treatment on miscarriage rate (OR 1.01 [95% CI: 0.34, 3.00]; n=13 events; p=0.98), in a total population of 459 infertile patients (Fig. 7).

4. Sperm concentration

A total of thirty-six studies were included [27-37,41,45-68], allowing to analyze this outcome in 4,310 infertile patients (2,407 AOX-treated patients and 1,903 placebo-treated or untreated controls).

We found a significantly positive effect of AOX treatment on sperm concentration (weighted MD 5.93 mil/mL [95% CI: 4.43, 7.43]; p<0.01), with the presence of significant inter-study heterogeneity ($I^2=94\%$; χ^2 p<0.01). There was no significant publication bias (p=0.5) (Fig. 8, 9).

The results of sub-group analysis performed after exclusion of 7 studies on patients with varicocele that underwent varicocele repair followed by AOX or placebo/no treatment [27,32,55] on a total of 3,653 infertile men, indicated a significant persistent positive effect of AOX supplementation on sperm concentration (weighted MD 5.55 mil/mL [95% CI: 3.87, 7.22]; 2,023 patients *vs.* 1,630 controls; p<0.01). A significant inter-study heterogeneity was also found in this subgroup analysis (I²=95%; χ^2 p<0.01), with no significant publication bias (p=0.8) (Fig. 10, 11).

Table 2. Continued 2



	40	x	/no trea	tment		Odds ratio	Odds ratio	
Study or subgroup	Events	Total	Events	Total	Weight	M-H, fixed, 95% Cl	M-H, fixed, 95% Cl	
Azizollahi 2013 [32] (1)	1	40	0	13	1.6%	1.03 [0.04, 26.70]		
Azizollahi 2013 [32] (2)	2	40	0	13	1.8%	1.75 [0.08, 38.88]		
Balercia 2005 [33] (1)	2	15	1	5	2.4%	0.62 [0.04, 8.70]		
Balercia 2005 [33] (2)	2	15	1	5	2.4%	0.62 [0.04, 8.70]		
Balercia 2005 [33] (3)	5	15	1	5	2.8%	2.00 [0.17, 22.95]		
Balercia 2009 [34]	6	30	3	30	6.4%	2.25 [0.51, 9.99]		
Barekat 2016 [29]	5	20	2	20	4.8%	3.00 [0.51, 17.74]		
Busetto 2017 [35]	10	45	2	49	5.8%	6.71 [1.38, 32.60]		
Busetto 2018 [36]	10	45	10	49	11.2%	1.11 [0.41, 2.99]	_ _	
Gopinath 2013 [37] (1)	7	43	2	36	5.5%	3.31 [0.64, 17.04]		
Gopinath 2013 [37] (2)	6	46	2	36	5.4%	2.55 [0.48, 13.47]		
Kızılay 2019 [28] (1)	18	64	5	29	9.7%	1.88 [0.62, 5.68]		
Kopets 2020 [38]	10	42	2	41	5.8%	6.09 [1.24, 29.84]		
Omu 1998 [39]	11	49	2	48	5.9%	6.66 [1.39, 31.90]		
Paradiso Galatioto 2008 [4	0] 1	20	0	22	1.6%	3.46 [0.13, 89.95]		
Scott 1998 [41] (1)	5	46	0	18	2.0%	4.90 [0.26, 93.36]		
Steiner 2020 [42]	15	85	22	86	15.1%	0.62 [0.30, 1.30]		
Stenqvist 2018 [43]	3	37	4	40	5.9%	0.79 [0.17, 3.81]		
Suleiman 1996 [44]	11	52	0	35	2.1%	19.67 [1.12, 345.85]		
Závaczki 2003 [45]	1	12	0	14	1.6%	3.78 [0.14, 101.83]		
Total (95% CI)		761		594	100.0%	1.97 [1.28, 3.04]	•	Fig. 2. Forest plot of the spontaneous
Total events	131		59					
Heterogeneity: Tau ² =0.18;	Chi ² =23.8	33, df=19	9 (p=0.20);	I ² =20%			⊢ + + +	pregnancy rate in infertile patients treat-
Test for overall effect: Z=3.0	09 (p=0.0	02)					0.01 0.1 1 10 100	⁹ ed with antioxidants (AOXs) compared to
							Favours Favours	placebo or untreated infertile controls
							placebo/no treatment AOX	placebo of untreated intertile controls.

Dissel



Fig. 3. Funnel plot of the spontaneous pregnancy rate in infertile patients treated with antioxidants compared to placebo or untreated infertile controls.

5. Progressive sperm motility

Twenty studies have been included in the analysis of the effect of AOX on progressive sperm motility [28,31-35,37,46,49,51,53,56-60,62,63,69,70], overall including 2,345 infertile patients (1,297 AOX-treated patients and 1,048 placebo-treated or untreated controls). The analysis showed a significant positive effect of AOX on progressive sperm motility (weighted MD 7.21% [95% CI: 3.66, 10.76]; p<0.01). Significant inter-study heterogeneity was observed (I²=99%; χ^2 p<0.01). The Funnel plot was significantly asymmetrical denoting the presence of publication bias (p=0.02) (Fig. 12, 13).

The benefit of AOX supplementation on progressive sperm motility was also confirmed by the analysis performed after the exclusion of studies carried out in patients with varicocele or treated with varicocele repair and AOX or placebo/no treatment [28,31,32], including a total of 1,923 infertile men (weighted MD 7.78% [95% CI: 3.86, 11.70]; 1,020 patients vs. 903 controls; p<0.01). We found significant inter-study heterogeneity (I²=99%; x^2 p<0.01) Also, significant publication bias persisted even after the exclusion of the studies with varicocele repair (Fig. 14, 15).

6. Total sperm motility

Thirty-six studies with a total of 4,452 infertile patients (2,516 AOX-treated patients and 1,936 placebotreated or untreated controls) were included in the analysis of total sperm motility [27-37,39,41,44-48,50-56,58-62,64,66,67,69-71]. We found a significant positive effect of AOX on total sperm motility (weighted MD 7.52% [95% CI: 3.11, 11.94]; p<0.01).

Significant inter-study heterogeneity was observed $(I^2=100\%; \chi^2 p<0.01)$. The asymmetry of the Funnel plot denoted significant publication bias (p<0.001) (Fig. 16, 17).

We also found a positive effect of AOX supplementation on total sperm motility after the exclusion of studies carried out in patients with varicocele or treated with varicocele repair and AOX or placebo/no treatment [27-32,50,55], including a total of 4,291 infertile men (MD 7.29% [95% CI: 2.75, 11.83]; 2,435 patients vs.



Fig. 4. Forest plot of the spontaneous pregnancy rate in infertile patients treated with antioxidants (AOXs) compared to placebo or untreated infertile con-

			Place	ode						
	AO	x	/no trea	tment		Odds ratio		Odds	s ratio	
Study or subgroup	Events	Total	Events	Total	Weight	M-H, fixed, 95% Cl		M-H, fixe	ed, 95% Cl	
Azizollahi 2013 [32] (1)	1	40	0	13	0.0%	1.03 [0.04, 26.70]				
Azizollahi 2013 [32] (2)	2	40	0	13	0.0%	1.75 [0.08, 38.88]				
Balercia 2005 [33] (1)	2	15	1	5	3.5%	0.62 [0.04, 8.70]			<u> </u>	
Balercia 2005 [33] (2)	2	15	1	5	3.5%	0.62 [0.04, 8.70]				
Balercia 2005 [33] (3)	5	15	1	5	4.0%	2.00 [0.17, 22.95]			<u> </u>	
Balercia 2009 [34]	6	30	3	30	8.0%	2.25 [0.51, 9.99]				
Barekat 2016 [29]	5	20	2	20	0.0%	3.00 [0.51, 17.74]				
Busetto 2017 [35]	10	45	2	49	7.4%	6.71 [1.38, 32.60]				_
Busetto 2018 [36]	10	45	10	49	12.0%	1.11 [0.41, 2.99]				
Gopinath 2013 [37] (1)	7	43	2	36	7.1%	3.31 [0.64, 17.04]		-	<u> </u>	
Gopinath 2013 [37] (2)	6	46	2	36	6.9%	2.55 [0.48, 13.47]			<u> </u>	
Kızılay 2019 [28] (1)	18	64	5	29	0.0%	1.88 [0.62, 5.68]				
Kopets 2020 [38]	10	42	2	41	7.4%	6.09 [1.24, 29.84]				-
Omu 1998 [39]	11	49	2	48	7.5%	6.66 [1.39, 31.90]				-
Paradiso Galatioto 2008 [4	0] 1	20	0	22	2.4%	3.46 [0.13, 89.95]				
Scott 1998 [41] (1)	5	46	0	18	2.9%	4.90 [0.26, 93.36]				
Steiner 2020 [42]	15	85	22	86	14.5%	0.62 [0.30, 1.30]			+	
Stenqvist 2018 [43]	3	37	4	40	7.5%	0.79 [0.17, 3.81]			<u> </u>	
Suleiman 1996 [44]	11	52	0	35	3.0%	19.67 [1.12, 345.85]				→
Závaczki 2003 [45]	1	12	0	14	2.4%	3.78 [0.14, 101.83]				
Total (95% CI)		597		519	100.0%	2.12 [1.23, 3.65]			•	
Total events	105		52							
Heterogeneity: Tau ² =0.39;	Chi ² =23.4	0, df=15	5 (p=0.08);	I ² =36%			—		l	
Test for overall effect: Z=2.	71 (p=0.0	07)	/				0.01	0.1	1 10	100
		,						Favours	Favours	

^{10.01} ^{0.1} ¹ ¹⁰ ¹⁰⁰ ¹⁰⁰ ¹⁰⁰ ¹⁰⁰ ¹⁰⁰ ¹⁰⁰ ¹⁰⁰ ¹⁰¹ ¹⁰⁰ ¹⁰⁰ ¹⁰¹

(Fig. 20, 21). We also found a positive effect of AOX supplementation on sperm morphology after the exclusion of studies carried out in patients with varicocele or treated with varicocele repair and AOX or placebo/no treatment [29,31,32,50,55], including a total of 1,413 infertile men (weighted MD 1.34% [95% CI: 0.13, 2.56]; 718 patients vs. 695 controls; p=0.03).

thus consistent with the presence of publication bias

The analysis showed significant inter-study heterogeneity (I^2 =88%; χ^2 p<0.01). The publication bias disappeared after the exclusion of varicocele repair studies (p=0.6) (Fig. 22, 23).

8. SDF

Only three studies, with a total of 68 AOX-treated patients and 67 placebo-treated or untreated controls, were included in the analysis of SDF [29,52,56]. All three studies used the terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) test. No effect of AOX on SDF was found compared to placebo or no treatment (SMD -0.63 [95% CI: -2.29, 1.02]; p=0.45) (Fig. 24).

We found a significant lower SDF in patients on AOX compared to controls when the analysis was



Fig. 5. Funnel plot of the spontaneous pregnancy rate in infertile patients treated with antioxidants compared to placebo or untreated infertile controls, after the removal of studies including patients with varicocele undergoing varicocele repair.

1,856 controls; p<0.01).

The analysis resulted in a significant inter-study heterogeneity (I²=100%; χ^2 p<0.01) and the publication bias persisted even after the exclusion of the studies with varicocele repair (p<0.001) (Fig. 18, 19).

7. Sperm morphology

Eighteen studies, with a total of 1828 infertile men (975 in the AOX-treated group and 853 in the placebotreated or untreated one), were included in the analysis of sperm morphology [29,31,32,35,45,49-53,55,59-



			Place	ebo							
	AO	Х	/no trea	tment		Odds ratio	Odds ratio				
Study or subgroup	Events	Total	Events Total		Weight	M-H, fixed, 95% CI	M-H, fixed,			95% CI	
Balercia 2005 [33] (1)	2	15	1	5	8.2%	0.62 [0.04, 8.70]			_		
Balercia 2005 [33] (2)	2	15	1	5	8.2%	0.62 [0.04, 8.70]			-		
Balercia 2005 [33] (3)	5	15	1	5	9.4%	2.00 [0.17, 22.95]					
Balercia 2009 [34]	6	30	3	30	19.5%	2.25 [0.51, 9.99]					
Omu 1998 [39]	8	49	2	48	17.7%	4.49 [0.90, 22.35]			-		
Steiner 2020 [42]	13	85	21	86	37.1%	0.56 [0.26, 1.21]		-	•		
Total (95% CI)		209		179	100.0%	1.21 [0.53, 2.76]			-	•	
Total events	36		29								
Heterogeneity: Tau ² =0.32	2; Chi ² =7.30), df=5 (p=0.20); l ²	=32%			H		<u> </u>	+	100
Test for overall effect: Z=	0.46 (p=0.6	64)					0.01	0.1	1	10	100
		,						Favours		Favours	
							placet	oo/no treat	tment	AOX	

Fig. 6. Forest plot of the live-birth rate in infertile patients treated with antioxidants (AOXs) compared to placebo or untreated infertile controls.

	AO	x	Place /no trea	ebo itment		Odds ratio	Odds ratio	
Study or subgroup	Events	Total	Events	Total	Weight	M-H, fixed, 95% Cl	M-H, fixed, 95% Cl	
Busetto 2018 [36]	0	52	1	52	11.4%	0.33 [0.01, 8.21]		
Omu 1998 [39]	1	49	0	48	11.3%	3.00 [0.12, 75.48]		
Steiner 2020 [42]	4	85	5	86	64.7%	0.80 [0.21, 3.09]		
Suleiman 1996 [44]	2	52	0	35	12.6%	3.51 [0.16, 75.46]		—
Total (95% CI)		238		221	100.0%	1.01 [0.34, 3.00]	-	
Total events	7		6					
Heterogeneity: Tau ² =0.00); Chi ² =1.67	7, df=3 (p=0.64); l ²	=0%			0.01 0.1 1 10	100
Test for overall effect: Z=	0.02 (p=0.9	98)					Favours Favours AOX	

Fig. 7. Forest plot of the miscarriage rate in infertile patients treated with antioxidants (AOXs) compared to placebo or untreated infertile controls.

		Mean difference	Mean difference						
Study or subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, random, 95% CI	IV, random, 95% CI
1.5.1 Three months or less									
Azizollahi 2013 [32] (1)	42.6	39.9	29	24.6	12.4	8	0.6%	18.00 [1.13, 34,87]	
Azizollahi 2013 [32] (2)	41.5	40.2	32	24.6	12.4	8	0.6%	16.90 [0.53, 33,27]	<u> </u>
Balercia 2005 [33] (1)	39.3	18.1	15	31.4	12.9	5	0.7%	7.90 [-6.65, 22.45]	<u>+</u>
Balercia 2005 [33] (2)	41	17.3	15	31.4	12.9	5	0.8%	9.60 [-4.70, 23.90]	<u>+</u>
Balercia 2005 [33] (3)	36.9	19.7	14	31.4	12.9	5	0.7%	5.50 [-9.81, 20.81]	_ <u>_</u>
Barekat 2016 [29]	45.4	27.5	15	42.2	31.4	20	0.5%	3.20 [-16.37, 22.77]	_ _
Boonyarangkul 2015 [46] (1)	66.6	29.8	15	76.2	50.7	15	0.2%	-9.60 [-39.36, 20.16]	
Ciftci 2009 [47]	21.85	11.08	60	22.32	22	60	1.8%	-0.47 [-6.70, 5.76]	+
Conquer 2000 [48] (1)	44.6	41.1	10	43.1	40.5	9	0.2%	1.50 [-35.23, 38.23]	
Cyrus 2015 [31]	58.4	24.3	41	48.7	27.8	61	1.2%	9.70 [-0.50, 19.90]	<u> </u>
da Silva 2013 [49]	26.08	24.52	23	20.04	16.35	26	1.0%	6.04 [-5.79, 17.87]	+
Dimitriadis 2010 [50]	15.4	6.7	26	16.3	7	22	2.2%	-0.90 [-4.80, 3.00]	+
Ener 2016 [30] (1)	49.5	27.9	22	30.6	23	23	0.7%	18.90 [3.92, 33.88]	
Eslamian 2020 [51] (1)	22.66	2.27	45	21.51	2.78	45	2.5%	1.15 [0.10, 2.20]	
Eslamian 2020 [51] (2)	21.21	2.66	45	21.51	2.78	45	2.5%	-0.30 [-1.42, 0.82]	ł
Eslamian 2020 [51] (3)	21.45	2.25	45	21.51	2.78	45	2.5%	-0.06 [-1.10, 0.98]	ł
Gopinath 2013 [37] (1)	26.4	8.9	46	14.9	5.9	18	2.2%	11.50 [7.75, 15.25]	
Gopinath 2013 [37] (2)	24.9	7	43	14.9	5.9	18	2.2%	10.00 [6.56, 13.44]	-
Greco 2005 [52]	27.5	24.6	32	20.3	21.2	32	1.0%	7.20 [-4.05, 18.45]	+
Haghighian 2015 [53]	26.35	3.17	23	22.89	2.74	21	2.5%	3.46 [1.71, 5.21]	-
Lu 2018 [55]	28.8	3.6	27	22.9	3.3	27	2.5%	5.90 [4.06, 7.74]	-
Martinez-Soto 2010 [56]	29.1	4.5	21	30.5	4.9	15	2.3%	-1.40 [-4.54, 1.74]	-+
Moslemi Mehni 2014 [57]	9.3	1.7	51	0.8	1.8	59	2.5%	8.50 [7.85, 9.15]	
Morgante 2010 [58]	18.2	3.5	90	19.1	3	90	2.5%	-0.90 [-1.85, 0.05]	
Nadjarzadeh 2011 [59]	16.09	12.9	23	16.21	12.7	24	1.6%	-0.12 [-7.44, 7.20]	+
Nouri 2019 [60]	18.16	10.32	17	11.89	6.37	19	1.9%	6.27 [0.59, 11.95]	
Omu 2008 [61] (1)	48	20	11	45	18	8	0.6%	3.00 [-14.18, 20.18]	
Omu 2008 [61] (2)	46	20	12	45	18	8	0.6%	1.00 [-15.84, 17.84]	
Omu 2008 [61] (3)	46	18	14	45	18	8	0.7%	1.00 [-14.64, 16.64]	
Peivandi 2010 [62]	46	3.6	15	16.5	7.3	15	2.1%	29.50 [25.38, 33.62]	
Rolf 1999 [63] (1)	20.6	13.5	14	25	17.8	15	1.0%	-4.40 [-15.85, 7.05]	-+
Rolf 1999 [63] (2)	28.3	16	14	31.5	21.8	15	0.8%	-3.20 [-17.05, 10.65]	-+-
Scott 1998 [41] (1)	48.7	8.8	16	27.5	10	18	1.8%	21.20 [14.88, 27.52]	-
Scott 1998 [41] (2)	34	6.3	30	27.5	10	18	2.0%	6.50 [1.36, 11.64]	
Stanislavov 2009 [68]	67.3	3.4	25	63.4	8.7	25	2.2%	3.90 [0.24, 7.56]	-
Závaczki 2003 [45]	16.1	10.2	10	10.9	7.4	10	1.5%	5.20 [-2.61, 13.01]	+
Subtotal (95% CI)	2		986	2		865	53.1%	5.67 [3.49, 7.85]	•
Heterogeneity: Tau = 26.97: Ch	i ⁻ =668.75	. df=35 (p	< 0.000	01): l [*] =95	5%				

Test for overall effect: Z=5.09 (p<0.00001)





repeated after the exclusion of one study carried out in patients treated with varicocele repair and AOX or placebo/no treatment [29] (SMD -1.47 [95% CI: -2.18,

-0.77]; 53 patients vs. 47 controls; p<0.01), although this analysis was performed in only two studies.

Furthermore, the analysis showed a significant

https://doi.org/10.5534/wjmh.220067



					Placebo				
		AOX		/ne	o treatm	ent		Mean difference	Mean difference
Study or subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, random, 95% CI	IV, random, 95% CI
1.5.2 Six months									
Ardestani Zadeh 2019 [27]	41.26	24.52	30	35.83	23.21	30	1.0%	5.43 [-6.65, 17.51]	_
Azizollahi 2013 [32] (4)	47.6	40.4	29	29.9	18.7	8	0.5%	17.70 [-1.90, 37.30]	
Azizollahi 2013 [32] (5)	39.6	30.5	32	29.9	18.7	8	0.6%	9.70 [-7.02, 26,42]	<u> </u>
Azizollahi 2013 [32] (6)	49.1	16.8	26	29.9	18.7	8	0.8%	19.20 [4.72, 33.68]	
Balercia 2005 [33] (4)	45.53	21.42	15	33.73	14.36	15	0.9%	11.80 [-1.25, 24.85]	<u> </u>
Balercia 2005 [33] (5)	39.57	19.99	15	33.73	14.36	15	0.9%	5.84 [-6.62, 18.30]	<u>+</u>
Balercia 2005 [33] (6)	37.4	16.42	14	33.73	14.36	15	1.0%	3.67 [-7.59, 14.93]	4-
Balercia 2009 [34]	44.9	19.3	30	46.4	19.8	30	1.2%	-1.50 [-11.39, 8.39]	
Boonyarangkul 2015 [46] (2)	53.3	22.8	15	76.1	70.8	15	0.1%	-22.80 [-60.44, 14.84]	1
Busetto 2017 [35]	51.4	13.9	45	43.7	13.6	49	1.9%	7.70 [2.13, 13,27]	
Busetto 2018 [36]	40.8	18.2	52	41.4	17.9	52	1.6%	-0.60 [-7.54, 6.34]	
Ener 2016 [30] (2)	53.9	22	22	48	34.2	23	0.6%	5 90 [-10 83 22 63]	
Gopinath 2013 [37] (1)	33.2	12.4	46	15.9	7.7	18	2.0%	17 30 [12 25 22 35]	
Gopinath 2013 [37] (2)	31.7	9.7	43	15.9	7.7	18	2.0%	15.80 [11.21, 20.39]	-
Kızılay 2019 [28] (1)	13.12	1.89	18	11.19	1.95	9	2.5%	1.93 [0.39, 3.47]	
Kızılay 2019 [28] (2)	18.19	3.3	39	15.22	3.11	17	2.5%	2.97 [1.16, 4.78]	-
Lenzi 2003 [54]	22.1	9.1	30	22.2	17	26	1.6%	-0.10 [-7.40, 7.20]	1
Safarinejad 2009 [66] (1)	26.8	5.3	105	23.5	5.8	35	2.4%	3.30 [1.13, 5.47]	-
Safarineiad 2009 [66] (2)	32.1	6.8	104	23.5	5.8	35	2.4%	8 60 [6 28 10 92]	-
Safarinejad 2009 [66] (3)	27.6	6.4	105	23.5	5.8	35	2.4%	4.10 [1.82, 6.38]	-
Safarineiad 2009 [67]	26.4	4.4	98	20.8	4.3	96	2.5%	5 60 [4 38 6 82]	-
Safarinejad 2012 [64]	28.7	4.6	101	16.8	4.4	102	2.5%	11.90 [10.66, 13,14]	
Subtotal (95% CI)			1.014			659	33.9%	6.66 [4.29, 9.02]	•
Heterogeneity: Tau ² =18.30; Chi	² =189.91	, df=21 (j	o<0.000	01); I ² =8	9%				
Test for overall effect: Z=5.52 (p	o<0.0000	1)							
1.5.3 Nine months or more									
Balercia 2005 [33] (7)	39.4	13.9	15	30.1	9.3	5	1.1%	9.30 [-1.47, 20.07]	
Balercia 2005 [33] (8)	31.2	8.6	15	30.1	9.3	5	1.3%	1.10 [-8.14, 10.34]	
Balercia 2005 [33] (9)	33.3	13.6	14	30.1	9.3	5	1.1%	3.20 [-7.63, 14.03]	+-
Balercia 2009 [34]	44.2	20.4	30	49.6	20.5	30	1.1%	-5.40 [-15.75, 4.95]	-+
Ener 2016 [30] (3)	58.6	20.2	22	47.2	27.2	23	0.8%	11.40 [-2.56, 25.36]	<u> </u>
Safarinejad 2009 [67]	22.8	3.8	98	21.2	3.8	96	2.5%	1.60 [0.53, 2.67]	·
Safarinejad 2011 [65]	28.7	4.4	101	16.8	4.4	102	2.5%	11.90 [10.69, 13.11]	•
Safarinejad 2012 [64]	22.4	4.2	112	16.2	3.7	113	2.5%	6.20 [5.17, 7.23]	-
Subtotal (95% CI)	2		407	2		379	13.0%	5.19 [0.96, 9.41]	◆
Heterogeneity: Tau ² =23.87; Chi	=163.26	, df=7 (p∙	<0.0000	1); l [*] =96	%				
Test for overall effect: Z=2.41 (p	o=0.02)								
Total (95% CI)			2 407			1 002	100.0%	E 02 [4 42 7 42]	
Heterogeneity: Tau ² =22 00: Chi	² =1 090 /	19 df=65	2,407	001)· J ² -	94%	1,903	100.0%	5.95 [4.45, 7.45]	['
Test for overall effect: 7=7.76 /r	<0.0000	1)	(p<0.00		J-1 /0				
Test for subgroup differences: (2hi ² =0.53	'/ df=2 (n=	=0 77)· 1 ²	² =0%					-100 -50 0 50 100
test ist subgroup uniciences. c	-0.00	, u-z (þ.	5.77,1	570					Favours Favours
									placeborno treatment AOX



Fig. 9. Funnel plot of the sperm concentration in infertile patients treated with antioxidants compared to placebo or untreated infertile controls.

inter-study heterogeneity both overall (I²=95%; χ^2 p<0.01), and in subgroup analysis (I²=95%; χ^2 p<0.01) (Fig. 25).

9. Seminal TAC

Six studies, with a total of 172 AOX-treated patients and 144 placebo-treated or untreated controls, were included in the analysis of seminal TAC [51,53,55,59-61]. Seminal levels of TAC were significantly higher in patients compared to controls (weighted MD 1.87 mmol Trolox/L [95% CI: 1.26, 2.48; p<0.01]). The analysis demonstrated in a significant inter-study heterogeneity (I^2 =97%; χ^2 p<0.01) (Fig. 26).

Fig. 8. Continued

10. Seminal MDA

Seven studies, with a total of 224 patients and 179 controls, analyzed levels of seminal MDA [44,51,53,55,59-61]. Seminal levels of MDA were significantly lower in patients treated with AOX compared to placebotreated or untreated controls (weighted MD -0.39 nmol/ mL [95% CI: -0.65, -0.14; p<0.01]). The analysis showed a significant inter-study heterogeneity (I^2 =96.2%; χ^2 p<0.01) (Fig. 27).



		AOX		/nc	Placebo treatme	ent		Mean difference	Mean difference
Study or subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV. random, 95% CI	IV. random, 95% CI
· · · · · · · · · · · · · · · · · · ·							mongine	,	
1.5.1 Three months or less									
Azizollahi 2013 [32] (1)	42.6	39.9	29	24.6	12.4	8	0.0%	18.00 [1.13, 34.87]	
Azizoliani 2013 [32] (2) Releveia 2005 [32] (1)	41.5	40.2	32	24.6	12.4	8	0.0%	16.90 [0.53, 33.27]	
Balercia 2005 [33] (1)	39.3	17.3	15	31.4	12.9	5	0.9%	7.90 [-6.65, 22.45]	T_
Balercia 2005 [33] (3)	36.9	19.7	14	31.4	12.5	5	0.9%	5 50 [-9 81 20 81]	
Barekat 2016 [29]	45.4	27.5	15	42.2	31.4	20	0.3%	3 20 [-16 37 22 77]	
Boonyarangkul 2015 [46] (1)	66.6	29.8	15	76.2	50.7	15	0.3%	-9.60 [-39.36, 20.16]	
Ciftci 2009 [47]	21.85	11.08	60	22.32	22	60	2.1%	-0.47 [-6.70, 5.76]	+
Conquer 2000 [48] (1)	44.6	41.1	10	43.1	40.5	9	0.2%	1.50 [-35.23, 38.23]	
Cyrus 2015 [31]	58.4	24.3	41	48.7	27.8	61	0.0%	9.70 [-0.50, 19.90]	
da Silva 2013 [49]	26.08	24.52	23	20.04	16.35	26	1.2%	6.04 [-5.79, 17.87]	
Dimitriadis 2010 [50]	15.4	6.7	26	16.3	7	22	2.5%	-0.90 [-4.80, 3.00]	-
Ener 2016 [30] (1)	49.5	27.9	22	30.6	23	23	0.0%	18.90 [3.92, 33.88]	
Eslamian 2020 [51] (1)	22.66	2.27	45	21.51	2.78	45	2.9%	1.15 [0.10, 2.20]	
Eslamian 2020 [51] (2)	21.21	2.66	45	21.51	2.78	45	2.9%	-0.30 [-1.42, 0.82]	1
Eslamian 2020 [51] (3)	21.45	2.25	45	21.51	2.78	45	2.9%	-0.06 [-1.10, 0.98]	Ì
Gopinath 2013 [37] (1)	26.4	8.9	46	14.9	5.9	18	2.6%	11.50 [7.75, 15.25]	-
Gopinath 2013 [37] (2)	24.9	7	43	14.9	5.9	18	2.6%	10.00 [6.56, 13.44]	-
Greco 2003 [52] Haghighian 2015 [53]	27.5	24.6	32	20.3	21.2	32	1.3%	7.20 [-4.05, 18.45]	<u> </u>
1 agrightan 2013 [33]	20.30	3.17	23	22.69	2.74	21	2.9%	5.40 [1.71, 5.21]	The second se
Martinez-Soto 2010 [56]	20.0	3.0	21	22.9	3.3 4 9	15	2 7%	1 40 [4 54 1 74]	1
Moslemi Mehni 2014 [57]	9.3	4.5	51	0.8	1.8	59	2.1%	8 50 [7 85 9 15]	
Morgante 2010 [58]	18.2	3.5	90	10.0	3	90	2.3%	-0.90 [-1.85, 0.05]	
Nadjarzadeh 2011 [59]	16.09	12.9	23	16 21	12.7	24	1.9%	-0.12 [-7.44, 7.20]	
Nouri 2019 [60]	18.16	10.32	17	11.89	6.37	19	2.2%	6.27 [0.59. 11.95]	<u> </u>
Omu 2008 [61] (1)	48	20	11	45	18	8	0.7%	3.00 [-14.18, 20.18]	
Omu 2008 [61] (2)	46	20	12	45	18	8	0.7%	1.00 [-15.84, 17.84]	
Omu 2008 [61] (3)	46	18	14	45	18	8	0.8%	1.00 [-14.64, 16.64]	
Peivandi 2010 [62]	46	3.6	15	16.5	7.3	15	2.5%	29.50 [25.38, 33.62]	
Rolf 1999 [63] (1)	20.6	13.5	14	25	17.8	15	1.2%	-4.40 [-15.85, 7.05]	-+
Rolf 1999 [63] (2)	28.3	16	14	31.5	21.8	15	1.0%	-3.20 [-17.05, 10.65]	-+-
Scott 1998 [41] (1)	48.7	8.8	16	27.5	10	18	2.1%	21.20 [14.88, 27.52]	
Scott 1998 [41] (2)	34	6.3	30	27.5	10	18	2.3%	6.50 [1.36, 11.64]	
Stanislavov 2009 [68]	67.3	3.4	25	63.4	8.7	25	2.6%	3.90 [0.24, 7.56]	-
Závaczki 2003 [45]	16.1	10.2	10	10.9	7.4	10	1.8%	5.20 [-2.61, 13.01]	+-
Subtotal (95% CI)	2		820			718	55.5%	5.02 [2.66, 7.39]	•
Heterogeneity: Tau =28.21; Chi	=652.53	, df=29 (p	<0.000	01); I =96	5%				
lest for overall effect: Z=4.16 (p	<0.0001)								
152 Six months									
Ardestani Zadeh 2019 [27]	41 26	24 52	30	35.83	23 21	30	0.0%	5 43 [-6 65 17 51]	
Azizollahi 2013 [32] (4)	47.6	40.4	29	29.9	18.7	8	0.0%	17 70 [-1 90 37 30]	
Azizollahi 2013 [32] (5)	39.6	30.5	32	29.9	18.7	8	0.0%	9.70 [-7.02. 2.6.42]	
Azizollahi 2013 [32] (6)	49.1	16.8	26	29.9	18.7	8	0.0%	19.20 [4.72, 33.68]	
Balercia 2005 [33] (4)	45.53	21.42	15	33.73	14.36	15	1.1%	11.80 [-1.25, 24.85]	
Balercia 2005 [33] (5)	39.57	19.99	15	33.73	14.36	15	1.1%	5.84 [-6.62, 18.30]	+
Balercia 2005 [33] (6)	37.4	16.42	14	33.73	14.36	15	1.3%	3.67 [-7.59, 14.93]	- <u>+</u>
Balercia 2009 [34]	44.9	19.3	30	46.4	19.8	30	1.5%	-1.50 [-11.39, 8.39]	-+-
Boonyarangkul 2015 [46] (2)	53.3	22.8	15	76.1	70.8	15	0.2%	-22.80 [-60.44, 14.84]	I <u> </u>
Busetto 2017 [35]	51.4	13.9	45	43.7	13.6	49	2.2%	7.70 [2.13, 13.27]	
Busetto 2018 [36]	40.8	18.2	52	41.4	17.9	52	2.0%	-0.60 [-7.54, 6.34]	+
Ener 2016 [30] (2)	53.9	22	22	48	34.2	23	0.0%	5.90 [-10.83, 22.63]	
Gopinath 2013 [37] (1)	33.2	12.4	46	15.9	7.7	18	2.3%	17.30 [12.25, 22.35]	-
Gopinath 2013 [37] (2)	31.7	9.7	43	15.9	7.7	18	2.4%	15.80 [11.21, 20.39]	-
Kizilay 2019 [28] (1)	13.12	1.89	18	11.19	1.95	9	0.0%	1.93 [0.39, 3.47]	
Kizilay 2019 [26] (2)	18.19	3.3	39	15.22	3.11	17	0.0%	2.97 [1.16, 4.78]	
Safaripoiad 2009 [66] (1)	22.1	9.1	30	22.2	1/	26	1.9%	-0.10 [-7.40, 7.20]	Ť
Safarinejad 2009 [00] (1)	20.0	5.3	105	23.5	5.6 E 0	30	2.8%	3.30 [1.13, 5.47]	
Safarinejad 2009 [00] (2) Safarinejad 2009 [66] (3)	32.1	0.0	104	23.5	5.6 E 0	30	2.8%	0.00 [0.26, 10.92]	
Safarinejad 2009 [67]	26.4	0.4	08	20.8	13	35	2.0%	4.10 [1.62, 0.36]	
Safarinejad 2012 [64]	20.4	4.4	90	16.8	4.5	102	2.9%	11 00 [10 66 13 1/]	
Subtotal (95% CI)	20.1	1.0	818	10.0		556	30.1%	7 00 [4 33 9 68]	•
Heterogeneity: Tau ² =17.60; Chi	² =123.88	, df=14 (p	< 0.000	01); I ² =89	9%	555	00.170		.
Test for overall effect: Z=5.13 (p	o<0.0000	1)							
1.5.3 Nine months or more									
Balercia 2005 [33] (7)	39.4	13.9	15	30.1	9.3	5	1.3%	9.30 [-1.47, 20.07]	<u> </u>
Balercia 2005 [33] (8)	31.2	8.6	15	30.1	9.3	5	1.6%	1.10 [-8.14, 10.34]	+
Balercia 2005 [33] (9)	33.3	13.6	14	30.1	9.3	5	1.3%	3.20 [-7.63, 14.03]	+-
Balercia 2009 [34]	44.2	20.4	30	49.6	20.5	30	1.4%	-5.40 [-15.75, 4.95]	-+
Ener 2016 [30] (3)	58.6	20.2	22	47.2	27.2	23	0.0%	11.40 [-2.56, 25.36]	
Satarinejad 2009 [67]	22.8	3.8	98	21.2	3.8	96	2.9%	1.60 [0.53, 2.67]	ł
Satarinejad 2011 [65]	28.7	4.4	101	16.8	4.4	102	2.9%	11.90 [10.69, 13.11]	-
Satarinejad 2012 [64]	22.4	4.2	112	16.2	3.7	113	2.9%	6.20 [5.17, 7.23]	
Suptotal (95% CI)	2-100 70	df=0 /	385	1). J ² -000	2/	356	14.3%	4.77 [0.40, 9.14]	•
Test for overall effect: Z=2.14 (p	= 102.70	, ui−o (p<	0.0000	1,1 =90	/0				
Total (95% CI)			0.000			4 000	400.00/	E EE I2 07 7 003	.
Heterogeneity: Tau ² =24.84: Chi	² =1 065 0	4 df=51	2,023 (n<0.00	001)· I ² -	95%	1,630	100.0%	5.55 [3.87, 7.22]	*
Test for overall effect: 7=6 48 /r	<0,00001	, u=51)	UU.U- ۹	501),1 -	5070				
Test for subgroup differences: (Chi ² =1.40.	, df=2 (p=	0.50); l ²	² =0%					-100 -50 0 50 100
									placebo/no treatment AOX





Fig. 11. Funnel plot of the sperm concentration in infertile patients treated with antioxidants compared to placebo or untreated infertile controls, after the removal of studies including patients with varico-cele undergoing varicocele repair.

DISCUSSION

1. Impact of AOX therapy on spontaneous pregnancy outcomes

When treating infertile men with AOXs, the main desired outcomes include an improvement in clinical pregnancy and live-birth rates, and a reduction in miscarriage rates. According to the results of the current meta-analysis, the odds for a spontaneous clinical pregnancy are almost double (OR 1.97 [95% CI: 1.28, 3.04]; p<0.01) in infertile men after treatment with AOX compared to controls who have received placebo or no treatment. These results are in line with the latest 2019 Cochrane review and meta-analysis by Smits et al [14], that included 11 studies and reported an increased clinical pregnancy rate with various AOX treatments (OR 2.97, p<0.0001). The latter study only analyzed 105 events from the 11 RCTs as compared to 190 events from 16 RCTs of 1,355 patients in our study.

Another meta-analysis specifically evaluating combined LC/LAC supplementation in infertile men with idiopathic oligo-asthenoteratozoospermia found significantly higher clinical pregnancy rates in the treatment group compared to the control group (OR 3.76, p=0.002) [18]. A beneficial effect of AOX therapy on clinical pregnancy after spontaneous or assisted reproduction has also been concluded by several reviews [72-74]. Conversely, the recent MOXI trial did not report a favorable effect of AOX treatment in infertile men in terms

of improving clinical pregnancy, showing similar clinical pregnancy rates in both the treatment and placebo groups (9% in both groups, p=0.98) [42]. This is likely due to evaluation of outcome after only 3 months of treatment and a small sample size. Furthermore, a meta-analysis on the effect of CoQ10 in infertile men did not report higher pregnancy rates in the treatment group despite improvement in semen parameters [75]. The recent Cochrane review also included 3 studies that found no difference in miscarriage rates between AOX and placebo or untreated groups [14]. The same meta-analysis reported significantly higher live-birth rates among the treatment group (OR 1.79, p=0.005) [14]. The MOXI trial, however, did not demonstrate any benefit of AOX in improving live-birth rates [42]. In our meta-analysis, no impact on miscarriage and livebirth rates following AOX therapy in infertile men was observed, despite higher pregnancy rates. This is likely due to the small number of studies and events.

In light of these mixed findings, there is a need for further RCTs specifically assessing these outcomes with adequate follow up as these events may not occur soon after the start of therapy. In addition, as suggested by Steiner et al [42], the lack of effect on these parameters could result from the lack of selection of patients who should receive AOXs as well as confounding factors affecting pregnancy rates. In fact, it may be hypothesized that the main beneficiaries of AOX therapy are those with high seminal OS. Future RCTs should be designed to include mainly patients with elevated OS markers.

2. Impact of AOX therapy on basic semen parameters

Semen analysis is the cornerstone of the male infertility work up and often the first laboratory test ordered. The ultimate measure of success for treatment of infertility is a clinical pregnancy or live-birth but these outcomes may need up to 10 months to manifest. In the meantime, semen parameters can be monitored to determine if the prescribed treatment is having a positive effect in improving the couple's chance to conceive. In our meta-analysis, treatment with AOX (either single or combined) significantly improved sperm concentration, progressive and total motility, and sperm morphology. Similarly, a previously published systematic review reported that vitamin E, vitamin C, NAC, carnitines, CoQ10, lycopene, selenium, and zinc





		AOX		/no	treatme	ent		Mean difference	Mean difference
Study or subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, random, 95% CI	IV, random, 95% CI
1 11 1 Three months or less									
Azizollahi 2013 [32] (1)	48.6	32.6	26	34.1	21.9	Q	1 5%	14 50 [4 52 33 52]	
Azizollahi 2013 [32] (2)	40.8	35.6	32	34.1	20.6	8	1.5%	6 70 [-12 17 25 57]	
Azizollahi 2013 [32] (3)	37.9	27.5	29	34.1	20.6	8	1.6%	3 80 [-13 63 21 23]	
Balercia 2005 [33] (1)	34.9	9.2	15	22.3	7.8	5	2.4%	12 60 [4 33 20 87]	
Balercia 2005 [33] (2)	33.9	8.4	14	22.3	7.8	5	2.4%	11.60 [3.47, 19.73]	
Balercia 2005 [33] (3)	38.9	7 1	15	22.3	7.8	5	2.1%	16 60 [8 88 24 32]	
Boonvarangkul 2015 [46] (1)	20.4	15.4	15	18.1	13.4	15	2.1%	2 30 [-8 03 12 63]	
Cyrus 2015 [31]	54.5	18.3	46	44.9	21.4	69	2.5%	9.60 [2.29, 16.91]	
da Silva 2013 [49]	48.26	10.72	23	49.65	11.93	26	2.5%	-1.39 [-7.73, 4.95]	-
Dawson 1990 [70] (1)	94	32	10	49	25.3	5	0.9%	45.00 [15.25, 74.75]	
Dawson 1990 [70] (2)	51	22.1	10	49	25.3	5	1.1%	2.00 [-24.07, 28.07]	
Eslamian 2020 [51] (1)	27.93	2.78	45	25.83	2.63	45	2.7%	2.10 [0.98, 3.22]	-
Eslamian 2020 [51] (2)	26.1	2.78	45	25.83	2.63	45	2.7%	0.27 [-0.85, 1.39]	4
Eslamian 2020 [51] (3)	25.71	3.39	45	25.83	2.63	45	2.7%	-0.12 [-1.37, 1.13]	4
Gopinath 2013 [37] (1)	27.8	15.55	46	14.39	12.29	36	2.5%	13.41 [7.38, 19.44]	
Gopinath 2013 [37] (2)	27.67	14.59	43	14.39	12.29	36	2.5%	13.28 [7.35, 19.21]	-
Haghighian 2015 [53]	33.48	2.91	23	27.14	2.36	21	2.7%	6.34 [4.78, 7.90]	-
Martinez-Soto 2010 [56]	37.8	3.2	21	44.4	2.8	15	2.7%	-6.60 [-8.57, -4.63]	-
Moslemi Mehni 2014 [57]	24.6	1.5	51	3.3	2.7	59	2.7%	21.30 [20.50, 22.10]	
Morgante 2010 [58]	40.3	6.4	90	25.1	4.2	90	2.7%	15.20 [13.62, 16.78]	
Nadjarzadeh 2011 [59]	28.9	14.8	23	24.3	13.6	24	2.4%	4.60 [-3.54, 12.74]	+-
Nouri 2019 [60]	15	8.88	17	15.15	12.61	19	2.5%	-0.15 [-7.22, 6.92]	+
Peivandi 2010 [62]	30	0.2	15	9	0.9	15	2.7%	21.00 [20.53, 21.47]	
Rolf 1999 [63] (1)	34.1	11.8	14	33.9	16.3	15	2.2%	0.20 [-10.11, 10.51]	
Rolf 1999 [63] (2)	37.6	11.1	14	35.3	15.7	15	2.3%	2.30 [-7.55, 12.15]	+-
Subtotal (95% CI)			727			640	57.5%	7.89 [3.21, 12.58]	•
Heterogeneity: Tau ² =119.89; Ch	i ² =3,260.	00, df=24	4 (p<0.0	0001); l ² :	=99%				
Test for overall effect: Z=3.30 (p	=0.0010)								
4 44 0 Civ months									
1.11.2 Six months Azizollabi 2013 [32] (4)	40.0	22.2	22	40.2	10.2		4.00/	2 00 [42 54 47 54]	
Azizollahi 2013 [32] (5)	42.3	23.2	32	40.3	19.2	0	1.0%	2.00 [-13.54, 17.54]	
Azizollahi 2013 [32] (6)	40	30.2	20	40.3	10.2	9	1.7 %	2 70 [14 56 10 06]	
Balercia 2005 [33] (4)	43.8	7 1	15	40.5	8.5	5	2 /0/	10 80 [11 53 28 07]	
Balercia 2005 [33] (5)	38.1	8.2	14	24	8.5	5	2.4%	14 10 [5 50 22 70]	
Balercia 2005 [33] (6)	37.5	9.2	15	24	8.5	5	2.4%	13 50 [4 71 22 29]	
Balercia 2009 [34]	15.1	7.3	30	10.1	3.3	30	2.0%	5 00 [2 13 7 87]	
Blomberg Jensen 2018 [69]	31	23	129	35	23	131	2.6%	-4 00 [-9 59 1 59]	_
Boonyarangkul 2015 [46] (1)	15	10.1	15	17.3	16.6	15	2.3%	-2 30 [-12 13 7 53]	
Busetto 2017 [35]	28.6	8.2	45	24.5	7.2	49	2.0%	4 10 [0 97 7 23]	-
Gopinath 2013 [37] (1)	31.77	19.04	46	16.31	13.82	36	2.5%	15 46 [8 34 22 58]	
Gopinath 2013 [37] (2)	31.45	15.93	43	16.31	13.82	36	2.5%	15 14 [8 58 21 70]	
Kızılay 2019 [28] (1)	24.17	7.31	18	23.08	4.81	9	2.6%	1.09 [-3.52, 5.70]	+
Kızılay 2019 [28] (2)	29.02	8.2	39	26.11	6.11	17	2.7%	2.91 [-0.97, 6.79]	L.
Subtotal (95% CI)			496			363	32.7%	6.56 [3.13, 9.99]	•
Heterogeneity: Tau ² =26.87; Chi	² =54.49, 0	df=13 (p<	0.0000	1); I ² =769	6				
Test for overall effect: Z=3.75 (p	=0.0002)								
1.11.3 Nine months or more									
Balercia 2005 [33] (7)	30.2	7.8	15	23.2	9	5	2.3%	7.00 [-1.82, 15.82]	<u>+-</u>
Balercia 2005 [33] (8)	28.5	8.3	14	23.2	9	5	2.3%	5.30 [-3.71, 14.31]	+-
Balercia 2005 [33] (9)	34	7	15	23.2	9	5	2.4%	10.80 [2.15, 19.45]	
Balercia 2009 [34]	10.1	3.2	30	11	3.8	30	2.7%	-0.90 [-2.68, 0.88]	t.
Suptotal (95% CI)	10 70		74	700/		45	9.8%	4.64 [-1.67, 10.95]	+
meterogeneity: Iau =28.11; Chi	=10.72, 0	л=з (р=0	.01); 1'=	12%					
rest for overall effect: ∠=1.44 (p	=0.15)								
Total (95% CI)			1 297			1 048	100.0%	7 21 [3 66 10 76]	•
Heterogeneity; Tau ² =119.39: Ch	i ² =3.734	98. df=42	2 (p<0.0	0001): I ² :	=99%	1,040	100.076		
Test for overall effect: Z=3.98 (p	<0.0001)			,, .					-100 -50 0 50 100

Placobo

Test for subgroup differences: Chi²=0.66, df=2 (p=0.72); I²=0%

were associated with improved sperm concentration, motility, and morphology [73]. The latest Cochrane database systematic review stated that there was high heterogeneity in published studies and reliable conclusions could not be drawn regarding the effect of AOX on sperm concentration, total motility, and progressive motility [14]. However, the authors suggested that carnitines and combined AOX led to improvement in sperm motility and polyunsaturated fats while zinc improved sperm concentration when compared to placebo or no treatment [14]. When taking the data from previous studies and from our new analysis together, there appears to be benefit of AOX on semen analysis parameters, regardless of the supplement used. In contrast to previous studies, our meta-analysis focused on the use of AOX in general, and not on specific molecules or combinations, for which the studies are very heterogenous.

Fig. 12. Forest plot of the sperm progressive motility in infertile patients treated with antioxidants (AOXs) compared to

placebo or untreated infertile controls.

3. Impact of AOX therapy on SDF

Favours AOX

Favours

placebo/no treatment

Given the well-established role of OS in the pathogenesis of SDF [76], we aimed to identify articles that have investigated the effect of AOX therapy on SDF. The very limited number of controlled studies on





Fig. 13. Funnel plot of the sperm progressive motility in infertile patients treated with antioxidants compared to placebo or untreated infertile controls.

Placebo

AOXs and SDF, likely precluded our ability to further evaluate the effect of AOX on SDF. However, several prospective studies reported a significant reduction in SDF from baseline after AOX therapy in infertile men, regardless of the assay used or the type of AOX. For example, supplementation of NAC for three months resulted in significant reductions in DNA fragmentation as measured by TUNEL assay (from 19.3% to 15.1%, p=0.01) [77]. Supplying a combination AOX of vitamin C, vitamin E, and CoQ10 resulted in significant improvement in DNA fragmentation index (DFI) as measured by Sperm Chromatin Structure Assay (SCSA) [78]. Significant reductions in SDF percentage as measured by Sperm Chromatin Dispersion (SCD) were also reported after three months of CoQ10 treatment [79]. Two trials investigated AOX therapy after varicocelectomy in men with clinical varicocele; both reported no additional benefit of AOX in reduction of SDF after varicocelectomy in these men compared to varicocelectomy

		AOX		/no	treatme	ent		Mean difference	Mean difference
Study or subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, random, 95% CI	IV, random, 95% CI
1.11.1 Three months or less									
Azizollahi 2013 [32] (1)	48.6	32.6	26	34.1	21.9	9	0.0%	14.50 [-4.52, 33.52]	
Azizollahi 2013 [32] (2)	40.8	35.6	32	34.1	20.6	8	0.0%	6.70 [-12.17, 25.57]	
Azizollahi 2013 [32] (3)	37.9	27.5	29	34.1	20.6	8	0.0%	3.80 [-13.63, 21.23]	
Balercia 2005 [33] (1)	34.9	9.2	15	22.3	7.8	5	2.9%	12.60 [4.33, 20.87]	
Balercia 2005 [33] (2)	33.9	8.4	14	22.3	7.8	5	2.9%	11.60 [3.47, 19.73]	
Balercia 2005 [33] (3)	38.9	7.1	15	22.3	7.8	5	2.9%	16.60 [8.88, 24.32]	
Boonyarangkul 2015 [46] (1)	20.4	15.4	15	18.1	13.4	15	2.7%	2.30 [-8.03, 12.63]	
Cyrus 2015 [31]	54.5	18.3	46	44.9	21.4	69	0.0%	9.60 [2.29, 16.91]	
da Silva 2013 [49]	48.26	10.72	23	49.65	11.93	26	3.1%	-1.39 [-7.73, 4.95]	-
Dawson 1990 [70] (1)	94	32	10	49	25.3	5	1.1%	45.00 [15.25, 74.75]	
Dawson 1990 [70] (2)	51	22.1	10	49	25.3	5	1.3%	2.00 [-24.07, 28.07]	
Eslamian 2020 [51] (1)	27.93	2.78	45	25.83	2.63	45	3.3%	2.10 [0.98, 3.22]	
Eslamian 2020 [51] (2)	26.1	2.78	45	25.83	2.63	45	3.3%	0.27 [-0.85, 1.39]	4
Eslamian 2020 [51] (3)	25.71	3.39	45	25.83	2.63	45	3.3%	-0.12 [-1.37, 1.13]	4
Gopinath 2013 [37] (1)	27.8	15.55	46	14.39	12.29	36	3.1%	13.41 [7.38, 19.44]	
Gopinath 2013 [37] (2)	27.67	14.59	43	14.39	12.29	36	3.1%	13.28 [7.35, 19.21]	
Haghighian 2015 [53]	33.48	2.91	23	27.14	2.36	21	3.3%	6.34 [4.78, 7.90]	-
Martinez-Soto 2010 [56]	37.8	3.2	21	44.4	2.8	15	3.3%	-6.60 [-8.57, -4.63]	-
Moslemi Mehni 2014 [57]	24.6	1.5	51	3.3	2.7	59	3.3%	21.30 [20.50, 22.10]	
Morgante 2010 [58]	40.3	6.4	90	25.1	4.2	90	3.3%	15.20 [13.62, 16.78]	-
Nadjarzadeh 2011 [59]	28.9	14.8	23	24.3	13.6	24	2.9%	4.60 [-3.54, 12.74]	+-
Nouri 2019 [60]	15	8.88	17	15.15	12.61	19	3.0%	-0.15 [-7.22, 6.92]	+
Peivandi 2010 [62]	30	0.2	15	9	0.9	15	3.3%	21.00 [20.53, 21.47]	
Rolf 1999 [63] (1)	34.1	11.8	14	33.9	16.3	15	2.7%	0.20 [-10.11, 10.51]	
Rolf 1999 [63] (2)	37.6	11.1	14	35.3	15.7	15	2.8%	2.30 [-7.55, 12.15]	+-
Subtotal (95% CI)			594			546	61.1%	7.78 [2.76, 12.80]	•
Heterogeneity: Tau ² =120.50; Cl	hi ² =3,256.	18, df=2	0 (p<0.0	0001); I ²	=99%			• • •	
Test for overall effect: Z=3.04 (p	o=0.002)								
1 11 2 Six months									
Azizollobi 2012 [22] (4)	10.0	00.0		10.0	10.0				
Azizollahi 2013 [32] (4)	42.3	23.2	32	40.3	19.2	8	0.0%	2.00 [-13.54, 17.54]	
Azizoliani 2013 [32] (5)	40	25	26	40.3	20.4	9	0.0%	-0.30 [-16.73, 16.13]	
Azizoliani 2013 [32] (6)	43	30.2	29	40.3	19.2	8	0.0%	2.70 [-14.56, 19.96]	
Balercia 2005 [33] (4)	43.8	7.1	15	24	8.5	5	2.9%	19.80 [11.53, 28.07]	
Balercia 2005 [55] (5)	38.1	8.2	14	24	8.5	5	2.9%	14.10 [5.50, 22.70]	
Balercia 2005 [55] (6)	37.5	9.2	15	24	8.5	5	2.9%	13.50 [4.71, 22.29]	
Blomborg Jopson 2019 [60]	15.1	7.3	30	10.1	3.3	30	3.3%	5.00 [2.13, 7.87]	
Biomberg Jensen 2018 [69]	31	23	129	35	23	131	3.1%	-4.00 [-9.59, 1.59]	=
Boonyarangkui 2015 [46] (1)	15	10.1	15	17.3	16.6	15	2.8%	-2.30 [-12.13, 7.53]	
Conjuncth 2012 [27] (1)	28.6	8.2	45	24.5	1.2	49	3.3%	4.10 [0.97, 7.23]	
Gopinath 2013 [37] (1)	31.77	19.04	46	16.31	13.82	36	3.0%	15.46 [8.34, 22.58]	
Gopinath 2013 [37] (2)	31.45	15.93	43	16.31	13.82	36	3.0%	15.14 [8.58, 21.70]	
Nizilay 2019 [20] (1)	24.17	7.31	18	23.08	4.81	9	0.0%	1.09 [-3.52, 5.70]	
Rizilay 2019 [20] (2)	29.02	8.2	39	26.11	6.11	17	0.0%	2.91 [-0.97, 6.79]	
Subtotal (95% CI)	2-47.00		352	1 ² -0201		312	27.1%	8.61 [3.97, 13.26]	•
Therefore a superily affects Z = 38.45; Chi	=47.96,0	u≓8 (p<(.00001)	; 1 =83%					· · · · · · · · · · · · · · · · · · ·
rest for overall effect: Z=3.63 (p	p=0.0003)								-100 -50 0 50 100
									Favours Favours placebo/no treatment AOX







Test for subgroup differences: Chi²=1.02, df=2 (p=0.60); I²=0%



Fig. 15. Funnel plot of the progressive sperm motility in infertile patients treated with antioxidants compared to placebo or untreated infertile controls, after the removal of studies including patients with varicocele undergoing varicocele repair.

alone, signifying the importance of addressing the underlying condition when possible, rather than empiric AOX supplementation [29,80]. One trial on astaxanthin supplementation reported no reduction in SDF compared to placebo [81], while another on folic acid reported SDF improvement only in carriers of MTHFR gene 677 thymidine/thymidine polymorphism [82]. Conversely, a recent multicenter RCT administering folic acid and zinc or placebo to 2,370 infertile men for six months reported a significantly lower SDF in patients compared to controls [83]. Therefore, it is difficult to reach a firm conclusion as to the impact of AOX on levels of SDF due to many factors including the small number of available studies, the variable AOXs regimens, the different assays used for SDF, and the different conditions associated with SDF. Additional welldesigned studies are warranted.

4. Impact of AOX therapy on seminal OS indices

Fig. 14. Continued.

Favours AOX

The most pragmatic use of AOX in male infertility is in cases of elevated seminal OS for men classified as having MOSI. Normally there is a homeostasis between ROS and AOX. If the scale tips towards ROS, then dietary supplementation with AOX may help restore this balance and improve seminal quality. TAC is a measure of total AOX present in the seminal plasma and provides a measure of reductive potential [84]. Studies have demonstrated that infertile men have lower TAC when compared to fertile men, and semen parameters such as concentration, motility, and morphology have been positively correlated with TAC [85]. Our analysis identified that seminal TAC improved after treatment with AOX. There was also a significant decrease in seminal MDA, an indicator of lipid peroxidation, after treatment with AOX. However, significant inter-study heterogeneity was found. Several earlier studies have demonstrated improvement in OS and a decrease in MDA after treatment with vitamin C, vitamin E, betacarotene, zinc, selenium, and NAC used either alone or in combination [44,47,61,86,87]. Our meta-analysis is consistent with the results of these previous studies and, as far as we know, this is the first meta-analysis assessing the impact of AOX on TAC and MDA. However, while AOXs seem to improve seminal OS indices, clinicians need also to be aware that over treatment with AOXs can lead to toxicity and reductive stress [88]. Thus, identification and selection of patients with high risk for MOSI could be useful to maximize the benefits of AOXs on sperm quality and prevent reductive stress toxicity. When the assessment of seminal OS becomes more standardized, this test could be important to identify those who could benefit from AOX.



		A 0 Y		/20	Placebo				
o		AUX		///0	o treatine			Mean difference	Mean difference
Study or subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, random, 95% Cl	IV, random, 95% CI
1.12.1 Three months or less									
Azizollahi 2013 [32] (1)	53.3	15.3	26	44.9	33	8	1.1%	8.40 [-15.21, 32.01]	
Azizollahi 2013 [32] (2)	51.7	17.2	29	44.9	33	8	1.1%	6.80 [-16.91, 30.51]	
Azizollahi 2013 [32] (3)	48.9	27.7	32	44.9	33	8	1.0%	4.00 [-20.80, 28.80]	
Balercia 2005 [33] (1)	59.9	8	15	44.6	7.7	5	1.5%	15.30 [7.43, 23.17]	
Balercia 2005 [33] (2)	56.5	11.6	15	44.6	7.7	5	1.5%	11.90 [2.96, 20.84]	
Balercia 2005 [33] (3)	55.1	10.2	14	44.6	7.7	5	1.5%	10.50 [1.89, 19.11]	
Barekat 2016 [29]	58.2	5.4	15	43.6	4.9	20	1.6%	14.60 [11.12, 18.08]	-
Boonyarangkul 2015 [46] (1)	15	2.61	15	17.33	4.28	15	1.6%	-2.33 [-4.87, 0.21]	-
Ciftci 2009 [47]	31.29	8.62	60	20.33	8.43	60	1.6%	10.96 [7.91, 14.01]	-
Conquer 2000 [48] (1)	39.4	24.3	9	47.2	18.6	5	1.1%	-7.80 [-30.56, 14.96]	
Conquer 2000 [48] (2)	32	16.1	10	47.2	18.6	5	1.2%	-15.20 [-34.31, 3.91]	
Cyrus 2015 [31]	54.5	18.3	41	44.9	21.4	61	1.5%	9.60 [1.84, 17.36]	
Dawson 1990 [70] (1)	51	7	10	49	8	10	1.5%	2.00 [-4.59, 8.59]	
Dawson 1990 [70] (2)	94	10	10	49	8	10	1.5%	45.00 [37.06, 52.94]	
Dimitriadis 2010 [50]	35.6	15.5	26	24.7	10.8	22	1.5%	10.90 [3.43, 18.37]	
Ener 2016 [30] (1)	61.4	18.3	22	42.5	28.7	23	1.4%	18.90 [4.90, 32.90]	
Eslamian 2020 [51] (1)	34.27	4.06	45	33.8	3.36	45	1.6%	0.47 [-1.07, 2.01]	ł
Eslamian 2020 [51] (2)	36.44	3.81	45	33.8	3.36	45	1.6%	2.64 [1.16, 4.12]	e e
Eslamian 2020 [51] (3)	32.67	4.17	45	33.8	3.36	45	1.6%	-1.13 [-2.69, 0.43]	-
Gopinath 2013 [37] (1)	51.6	13	46	42.1	10.6	18	1.5%	9.50 [3.33, 15.67]	
Gopinath 2013 [37] (2)	50.1	11.3	43	42.1	10.6	18	1.5%	8.00 [2.05, 13.95]	
Greco 2005 [52]	41.6	22	32	38.7	21.5	32	1.4%	2.90 [-7.76, 13.56]	
Haghighian 2015 [53]	40.65	4.95	23	36.01	3.16	21	1.6%	4.64 [2.21, 7.07]	-
Lenzi 2003 [54]	11	15.5	43	8.8	10.8	43	1.5%	2.20 [-3.45, 7.85]	
Lu 2018 [55]	62.1	6.7	27	57.1	8.6	27	1.5%	5.00 [0.89, 9.11]	
Martinez-Soto 2010 [56]	41.5	18.7	21	48	15.5	15	1.4%	-6.50 [-17.70, 4.70]	
Morgante 2010 [58]	40.3	6.4	90	25.1	4.2	90	1.6%	15.20 [13.62, 16.78]	-
Nadjarzadeh 2011 [59]	41.91	15.6	23	38.33	18.4	24	1.5%	3.58 [-6.16, 13.32]	
Nouri 2019 [60]	30.7	16.76	17	27.21	15.04	19	1.4%	3.49 [-6.96, 13.94]	<u> </u>
Omu 1998 [39]	59.7	30.4	49	60.8	30.8	48	1.4%	-1.10 [-13.28, 11.08]	
Omu 2008 [61] (1)	49	12	11	24	12	3	1.3%	25.00 [9.68, 40.32]	
Omu 2008 [61] (2)	50	20	14	24	12	2	1.2%	26.00 [6.34, 45.66]	<u> </u>
Omu 2008 [61] (3)	50	18	12	24	12	3	1.3%	26.00 [9.03, 42.97]	— <u> </u>
Peivandi 2010 [62]	48.3	0.2	15	17	0.1	15	1.6%	31.30 [31.19, 31.41]	
Scott 1998 [41] (1)	30.2	5.7	16	15.3	4.1	18	1.6%	14.90 [11.53, 18.27]	
Scott 1998 [41] (2)	27	3.7	30	15.3	4.1	18	1.6%	11.70 [9.39, 14.01]	-
Sigman 2006 [71]	28.6	38.1	12	37.6	33	9	0.9%	-9.00 [-39.49, 21.49]	
Závaczki 2003 [45]	33.5	29.8	10	19	14.4	10	1.2%	14.50 [-6.01, 35.01]	
Subtotal (95% CI)			1,018			838	53.6%	9.02 [2.81, 15.22]	•
Hotorogonoity: Tau ² =344.66: Cl	hi ² -7 325	07 df=3	7 (000 0	0001) 12	-00%				

Test for overall effect: Z=2.85 (p=0.004)

5. What could this study change?

Currently, AOX therapy is being widely used in male infertility management, even though there is only limited evidence and no practical guidelines on the duration or even the type of AOX to be used [73]. Our meta-analysis has provided encouraging evidence, demonstrating the positive impact of AOX therapy on clinical pregnancy rate, seminal parameters, and OS levels in men for whom a careful diagnostic evaluation has excluded major comorbidities, genetic, anatomical, inflammatory, traumatic or testicular cause of male infertility, or associated female infertility (Supplement Table 3). Some of the included studies were performed in a population of men with varicocele who underwent varicocele repair and were subsequently given AOX or placebo or untreated. The exclusion of these varicocele studies did not change the results, suggesting that the effect of AOX on the analyzed outcomes is independent of varicocele repair.

Compared to the last Cochrane review [14], the present study increased the number of RCTs, allowing the study of the largest population analyzed so far (Table 3).

50 Ó 100 Favours placebo/no treatment Favours AOX

-50

-100

Fig. 16. Forest plot of the total sperm motility in infertile patients treated with antioxidants (AOXs) compared to placebo or untreated infertile controls.

This allowed us to confirm the Cochrane's study findings and upgrade the level of evidence of many of the investigated outcomes [14,75,89-91] (Table 3). Moreover, to the best of our knowledge, this is the first study to offer a meta-analytic investigation of seminal levels of TAC and MDA in patients with male infertility after AOX administration and to confirm a positive effect on both of these outcomes.

6. Comparison with other studies

The MOXI trial has investigated the impact of AOX therapy on male infertility [42]. The authors conclude that AOX therapy neither improves semen parameters and DNA integrity, nor improves in vivo pregnancy or live-birth rates among men with male factor infertility. However, its study design had some limitations.

First, only 144 of the required 790 couples were recruited to achieve 80% power for the primary outcome (live-birth rates). Secondly, at baseline, the placebo group had a higher proportion of men with secondary infertility and the AOX group had a lower percentage of morphologically normal sperm. Third, the partici-



Shudy or subgroup Mean SD Total Mean SD Total Weight N, random, 95%, Cl N, random, 95%, Cl 1.12.2 Six months Addatani Zadih 2019 50.2 15.4 30 1.5% 3.89 [-4.13, 11.91] 4.440 4.44 9 1.4% 1.70 [-8.49, 11.89] 4.440 4.44 9 1.4% 2.60 [-8.41, 1.404] 4.440 4.44 9 1.4% 2.60 [-8.41, 1.404] 4.440 4.44 7.68 1.5 1.5% 1.58 1.58 1.98 [-2.2, 2.40]			AOX		/nc	treatm	, ent		Mean difference	e Mean difference CI IV, random, 95% CI	
1.1.2.2 Six months Ardestani Zadeh 2019 [27] 50.29 15.14 30 46.4 16.51 30 1.5% 3.89 [4.13, 11.91] Ardestani Zadeh 2019 [20] 52.4 17.8 29 49.8 13.6 8 1.4% 1.70 [8.49, 11.89] Arzolahi 2013 [32] (2) 52.4 17.8 29 49.8 13.6 8 1.4% 2.60 [8.8, 14.04] Arzolahi 2013 [32] (2) 64.43 1.5 44.6 7.68 15 1.5% 15.8 1.6% 1.021]	Study or subgroup	Mean	SD	Total	Mean SD		Total	Weight	IV, random, 95% CI		
Ardestani Zarden 2019 [27] 50.29 15.14 30 46.4 16.51 30 1.5% 3.89 [4.13, 11.91] Azizolahi 2013 [32] (1) 51.5 10.2 26 49.8 14.4 9 1.4% 1.70 [6.48, 11.09] Azizolahi 2013 [32] (2) 41.8 29 49.8 13.6 8 1.4% 20.6 [8.8, 14.04] Azizolahi 2013 [32] (2) 49.8 11.3 32 49.8 13.6 8 1.4% 20.6 [8.8, 14.04] Azizolahi 2013 [32] (2) 49.8 11.3 32 49.8 13.6 8 1.4% 20.6 [8.8, 14.04] Azizolahi 2013 [33] (4) 64.53 8.41 15 44.6 7.68 15 1.5% 15.83 [9.26, 22.01] Balercia 2005 [33] (6) 60.43 10.46 15 44.6 7.68 15 1.5% 16.83 [9.26, 22.01] Balercia 2005 [33] (6) 61.07 9.07 14 44.6 7.68 15 1.5% 16.83 [9.26, 22.01] Balercia 2005 [33] (6) 61.07 9.07 14 44.6 7.68 15 1.5% 16.83 [9.26, 22.01] Balercia 2005 [34] (3) 44.6 8.3 0.39.4 7.68 30 1.6% 0.00 [-3.67, 3.67] Balercia 2005 [36] 31.7 8.2 52 32.6 9.2 52 1.6% -0.90 [4.25, 2.45] Buesto 2017 [35] 39 8 45 34.6 7.1 49 1.6% 4.40 [1.33, 7.47] Buesto 2018 [36] 31.7 8.2 52 32.6 9.2 52 1.6% -0.90 [4.25, 2.45] Gopinath 2013 [37] (1) 57.4 14.6 46 44.1 9.5 18 1.5% 13.00 [7.21, 19.39] 	1.12.2 Six months										
Azizolahi 2013 [32] (1) 61.5 10.2 26 49.8 14.4 9 1.4% 170 [6.49, 11.89] Azizolahi 2013 [32] (2) 52.4 17.8 29 49.8 13.6 8 1.4% 2.60 [-8.4, 14.04] Azizolahi 2013 [32] (3) 64.5 3 8.41 15 44.6 7.68 15 1.5% 19.39 [14.17.25.69] Balerica 2005 [33] (6) 61.07 9.07 14 44.6 7.68 15 1.5% 16.38 [9.26, 22.0] Balerica 2005 [33] (6) 61.07 9.07 14 44.6 7.68 15 1.5% 16.38 [9.26, 22.0] Balerica 2005 [33] (6) 61.07 9.07 14 44.6 7.68 15 1.5% 16.38 [9.26, 22.40] Balerica 2005 [33] (6) 61.07 9.07 14 44.6 7.68 15 1.5% 16.47 [10.33, 22.61] Balerica 2005 [34] 39.4 6.8 30 39.4 7.68 30 1.6% 0.00 [-3.67, 3.67] Biomberg Jensen 2018 [69] 11 22.7 129 445 2.3.1 131 1.5% 4.00 [9.57, 1.57] Buseto 2018 [36] 31.7 8.2 52 32.6 9.2 52 1.6% -0.00 [-4.25, 2.45] Ener 2016 [30] (2) 60.1 16.1 22 48 34.2 23 1.3% 12.10 [3.41, 27.61] Gopinah 2013 [37] (1) 57.4 14.6 46 44.1 9.5 18 1.5% 13.0 [7.21, 19.39] — Gopinah 2013 [37] (2) 55.8 11.9 43 44.1 9.5 18 1.5% 13.0 [7.21, 19.39] — Kraley 2019 [28] (2) 41.2 11.2 39 34.42 7.51 17.15% 6.56 [0.3, 17.26] — Kraley 2019 [28] (2) 41.2 11.2 39 34.42 7.51 17.15% 6.56 [1.57, 17.16] Harrisologi [61] 26.1 2.9 105 22.9 2.2 35 1.6% 6.30 [5.38, 7.22] Safarnigad 2009 [66] (1) 26.1 2.9 105 22.9 2.2 35 1.6% 1.50 [3.58, 7.6] Safarnigad 2009 [66] (2) 2.2 .9 104 22.9 2.2 35 1.6% 1.50 [3.58, 7.2] Safarnigad 2009 [66] (2) 2.4.8 2.9 105 22.9 2.2 35 1.6% (5.30 [5.38, 7.22] Safarnigad 2009 [66] (2) 2.4.8 2.9 105 22.9 2.2 35 1.6% (5.03 [5.38, 7.2] Safarnigad 2009 [66] (2) 2.4.8 2.9 105 22.9 2.2 35 1.6% (5.03 [5.38, 7.2] Safarnigad 2009 [66] (2) 2.4.8 2.9 105 22.9 2.2 35 1.6% (5.03 [5.38, 7.2] Safarnigad 2009 [66] (2) 2.4.8 2.9 105 22.9 2.2 35 1.6% (5.03 [5.38, 7.2] Safarnigad 2009 [66] (2) 2.2 .9 104 22.9 2.2 35 1.6% (5.03 [5.38, 7.2] Safarnigad 2009 [67] 2.4.2 1.0 2 8.8 31 1.2 1.5% (5.03 [5.38, 7.2] Safarnigad 2009 [67] 2.4.2 1.0 2 8.8 31 1.2 1.5% (5.03 [5.38, 7.2] Safarnigad 2009 [67] 2.4.2 1.0 2 8.8 31 1.5 1.5% (5.03 [5.38, 7.2] Safarnigad 2009 [67] 4.2 2.1 88 2.8 2.2 1.10 5 1.5% (5.0 [1.6.4, 1.24] Baleric	Ardestani Zadeh 2019 [27]	50.29	15.14	30	46.4	16.51	30	1.5%	3.89 [-4.13, 11.91]	+-	
Azizolahi 2013 [32] (2) 52.4 17.8 29 49.8 13.6 8 1.4% 260 [-8.4, 14.04] Azizolahi 2013 [32] (3) 49.8 11.3 32 49.8 13.6 8 1.4% 0.00 [-10.21, 10.21] Balercia 2005 [33] (4) 64.53 8.41 15 44.6 7.68 15 1.5% 15.83 [9.26, 22.40] Balercia 2005 [33] (5) 60.43 10.46 15 44.6 7.68 15 1.5% 15.83 [9.26, 22.40] Balercia 2005 [33] (6) 61.07 9.07 14 44.6 7.68 15 1.5% 15.83 [9.26, 22.40] Balercia 2005 [33] (6) 61.07 9.07 14 44.6 7.68 30 1.6% 0.00 [-3.67, 3.67] Balercia 2018 [36] 31.7 8.2 52 32.6 9.2 52 1.6% -0.90 [-4.25, 24.6] Buesto 2017 [35] 39 8 45 34.6 7.1 49 1.6% 4.40 [1.33, 7.47] Buseto 2018 [36] 31.7 8.2 52 32.6 9.2 52 1.6% -0.90 [-4.25, 24.6] Gopinath 2013 [37] (1) 57.4 14.6 46 44.1 9.5 18 1.5% 11.30 [7.21, 19.39] Gopinath 2013 [37] (2) 55.8 11.9 43 44.1 9.5 18 1.5% 13.30 [7.21, 19.39] Gopinath 2013 [37] (2) 55.8 11.9 43 44.1 9.5 18 1.5% 13.30 [7.21, 19.39] Gopinath 2013 [37] (2) 55.8 11.9 43 44.1 9.5 18 1.5% 13.00 [7.7, 18] Gopinath 2013 [37] (2) 55.8 11.9 43 44.1 9.5 18 1.5% 13.00 [7.21, 19.39] Stafanejad 2009 [66] (1) 1.2.1 1.2 39 34.42 7.51 17 1.5% 6.78 [1.77, 11.79] Balercia 2009 [66] (2) 2.9 2.9 1.04 22.9 2.2 35 1.6% 6.30 [5.38, 7.22] Stafanejad 2009 [66] (1) 2.1 2.9 105 22.9 2.2 35 1.6% 6.30 [5.38, 7.22] Stafanejad 2009 [66] (2) 2.9 2.9 1.04 22.9 2.2 35 1.6% 6.30 [5.38, 7.22] Stafanejad 2009 [66] (1) 2.3 2.4 12 40 33 9 1.0% -7.70 [-3.32, 17.84] Stafanejad 2009 [66] (1) 2.3 2.4 12 40 33 9 1.0% -7.70 [-3.32, 17.84] Stafanejad 2009 [66] (1) 5.3 2.3 (p.4.2 7 10 5 1.5% 13.00 [7.02, 18.98] Stabtotal (65% C) -1, 192 Heterogeneity: Tau ² =13.58; Chi ² =40.6 40, di=23 (p.40.0001); i ² =94% Test for overall effect: Z=6.54 (p-0.00001); i ² =94% Test for overall effect: Z=6.54 (p-0.00001); i ² =94% Test for overall effect: Z=6.54 (p.0.00001); i ² =94% Test for overall effect: Z=6.54 (p.0.00001); i ² =94% Test for overall effect: Z=0.20 (p.60, 0) Subtotal (65% C) -2 2.20 (p.60, 0) Subtotal (65% C) -2 2.20 (p.60, 0) Subtotal (65% C) -2 2.20 (p.60, 0)	Azizollahi 2013 [32] (1)	51.5	10.2	26	49.8	14.4	9	1.4%	1.70 [-8.49, 11.89]		
Adzolatiki 2013 [32] (3) 40,8 11,3 32 49,8 13,6 8 1.4% 0.00 [-1.02,10.2 ⁺] Balerica 2005 [33] (4) 64,53 8,41 15 44,6 7,68 15 1.5% 15,83 [9.26,22.40] Balerica 2005 [33] (5) 61,07 9.07 14 44,6 7,68 15 1.5% 16,37 [0.3,22,6 ⁺] Balerica 2009 [54] 39,4 6,8 30 39,4 7,68 30 16% 0.00 [-3,67,3,67] Blencia 2009 [24] 39,4 6,8 30 39,4 7,68 30 16% 0.00 [-3,67,3,67] Busetto 2018 [36] 31,7 8,2 52 32,6 9,2 52 1,6% -0.90 [-4,25,2.45] Ensetto 2018 [36] 31,7 8,2 52 32,6 9,2 52 1,6% -0.90 [-4,25,2.45] Ensetto 2018 [36] 31,7 8,2 52 32,6 9,2 52 1,6% -0.90 [-4,25,2.45] Ensetto 2018 [36] 31,7 8,2 52 32,6 9,2 52 1,6% -0.90 [-4,25,2.45] Ensetto 2018 [37] (1) 57,4 14,6 46 44,1 9,5 18 1,5% 11,70 [6,05,17,35] Ensetto 2018 [37] (1) 57,4 14,6 46 44,41 9,5 18 1,5% 13,30 [7,21,19,39] Gopinath 2013 [37] (2) 56,8 11,9 43 44,1 9,5 18 1,5% 15,0 [-6,67,61,7,7,11] Ensetto 2018 [36] 31,1 1,35 30 29,6 9,5 26 1,5% 6,76 [1,77,11,79] Ensetto 2019 [28] (2) 41,2 11,2 9 34,24 7,51 17 1,5% 6,67,61,7,35] Ensetto 2019 [28] (2) 41,2 11,2 9 39,44 47 7,51 17 1,5% 6,67,61,7,35] Ensetto 2019 [28] (2) 41,2 11,2 9 39,44 2,751 17 1,5% 6,678 [1,77,11,79] Ensetto 2019 [28] (2) 41,2 11,2 9 39,44 2,751 17 1,5% 6,678 [1,77,11,79] Ensetto 2019 [28] (2) 41,2 11,2 9 105 22,9 2,2 35 1,6% 6,30 [5,38,7,22] Safarinejad 2009 [66] (3) 2,4,8 2,9 105 52,9 2,2 35 1,6% 6,30 [5,38,7,22] Safarinejad 2009 [66] (3) 2,4,8 2,9 105 52,9 12,8 35 1,5% 13,00 (7,02,18,98] Safarinejad 2009 [66] (3) 2,4,8 2,9 105 52,9 12,8 35 1,5% 13,00 (7,02,18,98] Safarinejad 2009 [67] 3,2,3 2,4,2 12 40 33 9 1,0% -7,70 [-3,34,17,84] Enseto 2008 [33] (8) 50,6 5,7 5,7 54,3 1,67 -40,4,0,4f=23 (red.00001); r ² =94% Test or overall effect: Z=6,54 (p<0,00001); r ² =94% Test or overall effect: Z=6,54 (p<0,00001); r ² =94% Test or overall effect: Z=6,24 (p<0,00001); r ² =94% Test or overall effect: Z=20 (p=,00001); r ² =94% Test or overall effect: Z=20 (p=,00001); r ² =94% Test or overall effect: Z=20 (p=,00001); r ²	Azizollahi 2013 [32] (2)	52.4	17.8	29	49.8	13.6	8	1.4%	2.60 [-8.84, 14.04]	_ <u>_</u>	
Balerica 2005 [33] (4) 64.53 8.41 15 44.6 7.68 15 1.5% 9.23 [1.47, 25.69]	Azizollahi 2013 [32] (3)	49.8	11.3	32	49.8	13.6	8	1.4%	0.00 [-10.21, 10.21]		
Balerica 2005 [33] (5) 60.43 10.46 15 44.6 7.68 15 1.5% 15.83 [9.26, 22.40]	Balercia 2005 [33] (4)	64.53	8.41	15	44.6	7.68	15	1.5%	19.93 [14.17, 25.69]	-	
Balercia 2005 [33] (6) 61.07 9.07 14 44.6 7.68 15 15% 16.47 [10.33, 22.61] Balercia 2009 [34] 39.4 6.8 30 39.4 7.68 30 1.6% 0.00 [-5.67, 3.67] Busetto 2017 [35] 39 8 45 34.6 7.1 49 1.6% 4.00 [-5.67, 1.57] Busetto 2017 [36] 31.7 8.2 52 32.6 9.2 52 1.6% -0.90 [-4.25, 2.45] Ener 2016 [30] (2) 60.1 16.1 22 48 34.2 23 1.3% 12.10 [-3.41, 27.61] Gopinath 2013 [37] (1) 57.4 14.6 46 44.1 9.5 18 1.5% 13.07 [21, 19.39] Gopinath 2013 [37] (2) 55.8 11.9 43 44.1 9.5 18 1.5% 6.65 [0.34, 12.96] Kizlay 2019 [28] (1) 36.83 9.6 18 30.18 6.88 9 1.5% 6.65 [0.34, 12.96] Kizlay 2019 [28] (2) 41.2 11.2 39 34.42 7.51 17 1.5% 6.78 [1.77, 11.79] Eaterial 2009 [66] (1) 26.1 2.9 105 22.9 2.2 36 1.6% 3.05 [2.8, 4.11] Safarinejad 2009 [66] (2) 29.2 2.9 104 22.9 2.2 35 1.6% 6.30 [5.38, 7.22] Safarinejad 2009 [66] (2) 24.8 2.9 105 22.9 2.2 35 1.6% 6.30 [5.38, 7.22] Safarinejad 2009 [66] (2) 24.8 2.9 105 22.9 2.2 35 1.6% 1.90 [0.89, 2.82] Safarinejad 2009 [66] (2) 24.8 2.9 105 22.9 2.2 35 1.6% 1.90 [0.89, 2.82] Safarinejad 2009 [66] (2) 24.8 2.9 105 22.9 2.2 35 1.6% 1.90 [0.89, 2.82] Safarinejad 2009 [66] (2) 24.8 2.9 105 22.9 2.2 35 1.6% 1.90 [0.89, 2.82] Safarinejad 2009 [66] (3) 24.8 2.9 105 22.9 2.2 35 1.6% 1.90 [0.89, 5.11] Subtotal (95% C) 1.122 40 33 9 1.0% -7.70 [-33.24, 17.84] Subtotal (95% C) 1.123 Nine menths or more Balercia 2005 [33] (7) 5.4.3 9 1.5 42.7 10 5 1.5% 11.60 [1.72, 21.48] Balercia 2005 [33] (7) 5.4.3 9 1.5 42.7 10 5 1.5% 7.90 [-1.33, 17.13] Balercia 2005 [33] (7) 5.4.3 9 1.5 42.7 10 5 1.5% 7.90 [-1.33, 17.13] Balercia 2005 [33] (7) 5.4.3 9 1.5 42.7 10 5 1.5% 7.90 [-1.33, 17.13] Balercia 2005 [33] (7) 5.4.3 9 1.5 42.7 10 5 1.5% 7.90 [-1.33, 17.13] Balercia 2005 [33] (7) 5.4.3 9 1.5 42.7 10 5 1.5% 7.90 [-1.33, 17.13] Balercia 2005 [33] (8) 50.6 5.7 1.5 42.7 10 5 1.5% 7.90 [-1.33, 17.13] Balercia 2005 [33] (8) 49 7.8 1.4 42.7 10 5 1.5% 6.30 [-3.3, 15.97] Heterogeneity: Tau ² = 2.1; (2) = 2.3 30 1.6% 2.40 [-6.0, 0.0001]; i ¹ = 94% Test for overall effect: Z=6.54 (pc-0.00001); i ² = 94% Test	Balercia 2005 [33] (5)	60.43	10.46	15	44.6	7.68	15	1.5%	15.83 [9.26, 22.40]		
Balercia 2009 [34] 39.4 6.8 30 39.4 7.68 30 16% 0.00 [3.67, 3.67] Biomberg Jensen 2018 [69] 41 22.7 129 45 23.1 131 1.5% 4.00 [-3.7, 3.67] Biomberg Jensen 2018 [69] 41 22.7 129 45 23.1 131 1.5% 4.00 [-3.7, 7.47] Buselto 2017 [55] 39 8 45 34.6 7.1 49 1.6% 4.40 [1.33, 7.47] Buselto 2018 [36] 31.7 8.2 52 32.6 9.2 52 1.6% -0.90 [-4.25, 2.45] Ener 2016 [30] (2) 60.1 16.1 22 48 34.2 23 1.3% 12.10 [-4.25, 2.45] Gopinat 2013 [37] (1) 57.4 14.6 46 44.1 9.5 18 1.5% 13.30 [7.2, 19.39] Gopinat 2013 [37] (2) 55.8 11.9 43 44.1 9.5 18 1.5% 13.30 [7.2, 19.39] Gopinat 2013 [37] (2) 55.8 11.9 43 44.1 9.5 18 1.5% 15% 13.30 [7.2, 19.39] Hereogole [66] (1) 26.1 2.9 105 22.9 2.2 36 1.6% 6.30 [5.38, 7.22] Safarinejad 2009 [66] (2) 29.2 2.9 104 22.9 2.2 35 1.6% 6.30 [5.38, 7.22] Safarinejad 2009 [66] (3) 24.8 2.9 105 22.9 2.2 35 1.6% 6.30 [5.38, 7.22] Safarinejad 2009 [66] (3) 24.8 2.9 105 22.9 2.2 35 1.6% 6.30 [5.38, 7.22] Safarinejad 2009 [67] (2) 25.2 2.9 2.2 35 1.6% 6.30 [3.38, 7.22] Safarinejad 2009 [67] (3) 24.8 2.9 105 22.9 2.2 35 1.6% 6.30 [3.38, 7.22] Safarinejad 2009 [67] (3) 24.8 2.9 105 22.9 2.2 35 1.6% 1.00 (1.98, 2.82] Safarinejad 2009 [67] (3) 24.8 2.9 105 22.9 2.2 35 1.6% 1.00 (1.98, 2.82] Safarinejad 2009 [67] 32.3 24.2 12 40 33 9 1.0% -7.70 [3.324, 17.84] Heterogeneity: Tau ² = 1.58; Ch ² = 406.40, df= 23 (p=0.00001); I ² = 94% Test for overall effect: Z=6.54 (p=0.00001) Heterogeneity: Tau ² = 1.55; Ch ² = 406.40, df= 23 (p=0.00001); I ² = 94% Test for overall effect: Z=6.54 (p=0.00001); I ² = 94% Test for overall effect: Z=2.80, 1, dt=6 (p<0.00001); I ² = 94% Test for overall effect: Z=2.20 (p=0.3) Total (95% CI) 2.516 1.936 100.0% 7.52 [3.1, 1, 1.94] 4.	Balercia 2005 [33] (6)	61.07	9.07	14	44.6	7.68	15	1.5%	16.47 [10.33, 22.61]		
Biomberg Jensen 2018 [69] 41 22.7 129 45 23.1 131 1.5% 4.00 [-9.57, 1.57] Buselto 2017 [35] 39 8 445 34.6 7.1 49 1.6% 4.40 [-3.7, 747] Buselto 2018 [36] 31.7 82 52 32.6 9.2 52 1.6% -0.90 [-4.25, 2.45] Ener 2016 [30] (2) 60.1 16.1 22 48 34.2 23 1.3% 12.10 [-3.41, 27.61] Gopinath 2013 [37] (1) 57.4 14.6 46 44.1 9.5 18 1.5% 13.0 [7.21, 19.39] Gopinath 2013 [37] (2) 55.8 11.9 43 44.1 9.5 18 1.5% 13.0 [7.21, 19.39] Kizilay 2019 [28] (1) 36.83 9.6 18 30.18 6.88 9 1.5% 6.65 [0.34, 12.96] Kizilay 2019 [28] (2) 41.2 11.2 39 34.42 7.51 17 1.5% 6.78 [1.77, 11.79] Ener 2016 [30] (2) 41.2 11.2 39 34.42 7.51 17 1.5% 6.78 [1.77, 11.79] Ener 2009 [66] (1) 26.1 2.9 105 22.9 2.2 36 1.6% 3.20 [2.29, 4.11] Safarinejad 2009 [66] (2) 29.2 2.9 104 22.9 2.2 35 1.6% 1.50 [-4.56, 7.56] Safarinejad 2009 [66] (2) 29.2 2.9 104 22.9 2.2 35 1.6% 1.50 [-3.67, 7.6] Safarinejad 2009 [66] (2) 29.2 2.9 104 22.9 2.2 35 1.6% 4.50 [3.89, 5.11] Safarinejad 2009 [66] (2) 29.2 2.9 104 22.9 2.2 35 1.6% 4.50 [3.89, 5.11] Safarinejad 2009 [67] 27.6 2.2 98 23.1 2.1 96 1.6% 4.50 [3.89, 5.11] Safarinejad 2012 [64] 35.8 2.7 101 25.4 2.1 102 1.6% 10.40 [9.73, 11.07] Subicital (95% CI) 1.122 1.23 Nine months or more Balercia 2005 [33] (7) 54.3 9 15 42.7 10 5 1.5% 13.00 [7.02, 18.98] 1.5% 6.21 [4.35, 8.07] 1.12 1.12 Nine months or more Balercia 2005 [33] (9) 49 7.8 14 42.7 10 5 1.5% 6.30 [-3.37, 7.15, 97] Balercia 2005 [33] (9) 49 7.8 14 42.7 10 5 1.5% 6.30 [-3.37, 7.15, 97] Balercia 2005 [33] (9) 49 7.8 14 42.7 10 5 1.5% 6.30 [-3.37, 7.15, 97] Balercia 2005 [33] (9) 49 7.8 14 42.7 10 5 1.5% 6.30 [-3.37, 7.15, 97] Balercia 2005 [33] (9) 49 7.8 14 42.7 10 5 1.5% 6.30 [-3.37, 7.15, 97] Balercia 2005 [33] (9) 49 7.8 14 42.7 10 5 1.5% 6.30 [-3.37, 7.15, 97] Balercia 2005 [33] (9) 49 7.8 14 42.7 10 5 1.5% 7.90 [-1.33, 7.15, 97] Balercia 2005 [33] (9) 49 7.8 14 42.7 10 5 1.5% 6.20 [-3.37, 7.15, 97] Balercia 2005 [33] (9) 49 7.8 14 42.7 10 5 1.5% 7.90 [-1.33, 7.15, 97] Balercia 2005 [33] (9) 49 7.8 14 42.7 10 5 1.5% 6.20 [-3.37	Balercia 2009 [34]	39.4	6.8	30	39.4	7.68	30	1.6%	0.00 [-3.67, 3.67]	+	
Busetto 2017 [35] 39 8 45 34.6 7.1 49 1.6% 4.40 [1.33, 7.47] Busetto 2018 [36] 31.7 6.2 52 32.6 9.2 52 1.6% 0.90 [4.25, 2.45] Ener 2016 [30] (2) 60.1 16.1 22 48 34.2 23 1.3% 12.10 [3.41, 27.61] Gopinath 2013 [37] (2) 55.8 11.9 43 44.1 9.5 18 1.5% 11.70 [6.05, 17.35] Gopinath 2013 [37] (2) 55.8 11.9 43 44.1 9.5 18 1.5% 17.0 [6.05, 17.35] Kizlay 2019 [28] (1) 36.83 9.6 18 30.18 6.88 9 1.5% 6.65 [0.34, 12.96] Kizlay 2019 [28] (2) 41.2 11.2 39 34.42 7.51 17 1.5% 6.76 [1.77, 11.79] Lenzi 2003 [54] 31.1 13.5 30 29.6 9.5 22.9 2.2 36 1.6% 3.20 [2.4, 67, 66] Safarinejad 2009 [66] (2) 29.2 2.9 104 22.9 2.2 35 1.6% 6.30 [5.38, 7.22] Safarinejad 2009 [66] (2) 29.2 2.9 104 22.9 2.2 35 1.6% 6.30 [5.38, 7.22] Safarinejad 2009 [66] (3) 24.8 2.9 105 22.9 2.2 35 1.6% 1.90 [0.90, 2.82] Safarinejad 2009 [67] 27.6 2.2 98 23.1 2.1 96 1.6% 4.50 [3.80, 5.11] Safarinejad 2009 [67] 27.6 2.2 98 23.1 2.1 96 1.6% 4.50 [3.80, 5.11] Safarinejad 2009 [67] 27.6 2.2 98 23.1 2.1 96 1.6% 4.50 [3.80, 5.11] Safarinejad 2009 [67] 32.3 24.2 12 40 33 9 1.0% -7.70 [-33.24, 17.84] Heterogeneity: Tau ² + 13.56: Chi ² = 40.6 40, df = 23 (p-0.00001); l ² = 94% Test for overall effect: Z=6.54 (p<0.00001); l ² = 94% Test for overall effect: Z=6.54 (p<0.00001); l ² = 94% Test for overall effect: Z=6.54 (p<0.00001); l ² = 94% Test for overall effect: Z=6.54 (p<0.00001); l ² = 94% Test for overall effect: Z=6.54 (p<0.00001); l ² = 94% Test for overall effect: Z=6.54 (p<0.00001); l ² = 94% Test for overall effect: Z=6.54 (p<0.00001); l ² = 94% Test for overall effect: Z=6.54 (p<0.00001); l ² = 94% Test for overall effect: Z=6.54 (p<0.00001); l ² = 94% Test for overall effect: Z=6.54 (p<0.00001); l ² = 94% Test for overall effect: Z=2.20 (p=0.03) 1016 (95% C1) 2.516 1.936 100.0% 7.52 13.11 1.194	Blomberg Jensen 2018 [69]	41	22.7	129	45	23.1	131	1.5%	-4.00 [-9.57, 1.57]		
Busetto 2018 [36] 31.7 8.2 52 32.6 9.2 52 1.6% -0.90 [-4.25, 2.45] Ener 2016 [30] (2) 60.1 16.1 22 48 34.2 23 1.3% 12.10 [-3.41, Z7.61] Gopinath 2013 [37] (1) 57.4 14.6 46 44.1 9.5 18 1.5% 12.10 [-3.41, Z7.61] Gopinath 2013 [37] (2) 55.8 11.9 43 44.1 9.5 18 1.5% 11.70 [6.05, 17.35] Fixelay 2019 [28] (1) 36.83 9.6 18 30.18 6.88 9 15% 6.65 [0.34, 12.96] Ener 2016 [30] (2) 41.2 11.2 39 34.42 7.51 17 1.5% 6.76 [1.77, 11.79] Lenzi 2003 [54] 31.1 13.5 30 29.6 9.5 26 1.5% 1.50 [-4.56, 7.56] Safarinejad 2009 [66] (1) 26.1 2.9 105 22.9 2.2 35 1.6% 6.30 [5.38, 7.22] Safarinejad 2009 [66] (2) 29.2 2.9 104 22.9 2.2 35 1.6% 6.30 [5.38, 7.22] Safarinejad 2009 [66] (2) 29.2 2.9 104 22.9 2.2 35 1.6% 1.90 [0.98, 2.82] Safarinejad 2009 [67] 27.6 2.2 98 23.1 2.1 96 1.6% 4.50 [3.89, 5.11] Safarinejad 2009 [67] 27.6 2.2 98 23.1 2.1 96 1.6% 4.50 [3.89, 5.11] Safarinejad 2009 [67] 27.6 2.2 98 23.1 2.1 96 1.6% 4.50 [3.89, 5.11] Heterogenetity: Tau ² =13.58; Chi ² =406.40, dt=23 (p-0.00001); l ² =94% Test for overall effect: Z=6.54 (p<0.00001) 1.12 Balercia 2005 [33] (9) 49 7.8 14 42.7 10 5 1.5% 11.60 [1.72, 21.48] Balercia 2005 [33] (9) 49 7.8 14 42.7 10 5 1.5% 6.30 [-3.37, 15.97] Balercia 2005 [33] (9) 49 7.8 14 42.7 10 5 1.5% 6.30 [-3.37, 15.97] Balercia 2005 [33] (9) 49 7.8 14 42.7 10 5 1.5% 6.30 [-3.37, 15.97] Balercia 2005 [33] (9) 49 7.8 14 42.7 10 5 1.5% 6.30 [-3.37, 15.97] Balercia 2005 [33] (9) 49 7.8 14 42.7 10 5 1.5% 6.30 [-3.37, 15.97] Balercia 2005 [33] (9) 49 7.8 14 42.7 10 5 1.5% 1.40 [0.79, 2.01] Safarinejad 2009 [67] 24.2 2.1 98 22.8 2.2 96 1.6% 1.40 [0.79, 2.01] Safarinejad 2009 [67] 24.2 2.1 98 22.8 2.2 113 1.6% 5.40 [4.80, 6.00] Subtotal (95% Cl) 2.19 2.24 112 25.8 2.2 113 1.6% 5.40 [4.80, 6.00] Subtotal (95% Cl) 2.516 1.936 100.0% 7.52 [3.11, 11.94]	Busetto 2017 [35]	39	8	45	34.6	7.1	49	1.6%	4.40 [1.33, 7.47]	<u> </u>	
Ener 2016 [30] (2) 60.1 16.1 22 48 34.2 23 1.3% 12.10 [$3.41, 27.61$] Gopinath 2013 [37] (1) 57.4 14.6 46 44.1 9.5 18 1.5% 11.70 [$6.05, 17.35$] Gopinath 2013 [37] (2) 55.8 19.9 43 44.1 9.5 18 1.5% 17.0 [$6.05, 17.35$] Kizilay 2019 [28] (1) 36.83 9.6 18 30.18 6.88 9 15.% 6.66 [$0.34, 12.96$] Kizilay 2019 [28] (2) 41.2 11.2 39 34.42 7.51 17 1.5% 6.76 [$1.77, 11.79$] Lenzi 2003 [54] 31.1 13.5 30 29.6 9.5 26 1.5% 15.0 [$4.56, 7.56$] Safarinejad 2009 [66] (2) 29.2 2.9 104 22.9 2.2 35 1.6% 6.30 [$5.38, 7.22$] Safarinejad 2009 [66] (2) 29.2 2.9 105 22.9 2.2 35 1.6% 6.30 [$5.38, 7.22$] Safarinejad 2009 [66] (2) 29.2 2.9 104 22.9 2.2 35 1.6% 6.30 [$5.38, 7.22$] Safarinejad 2009 [67] 7.6 2.2 98 2.3.1 2.1 96 1.6% 4.50 [$3.98, 5.11$] Safarinejad 2009 [67] 7.2 6 2.2 98 2.3.1 2.1 96 1.6% 4.50 [$3.98, 5.11$] Safarinejad 2012 [64] 35.8 2.7 101 25.4 2.1 102 1.6% 10.40 [$9.73, 11.07$] Safarinejad 2012 [64] 35.8 2.7 101 25.4 2.1 102 1.6% 10.40 [$9.73, 11.07$] Subtotal (95% CI) Ligg 2 (1.192 Subtotal (95% CI) Ligg 2 (1.192 Subtotal (95% CI) Safarinejad 2005 [33] (7) 54.3 9 15 42.7 10 5 1.5% 13.00 [$7.2, 21.8.8$] Safarinejad 2005 [33] (7) 54.3 9 15 42.7 10 5 1.5% 7.90 [$-1.33, 17.13$] Balercia 2005 [33] (8) 50.6 5.7 15 42.7 10 5 1.5% 7.90 [$-1.33, 17.13$] Balercia 2005 [33] (9) 49 7.8 14 42.7 10 5 1.5% 6.30 [$-3.37, 15.97$] Balercia 2005 [33] (9) 49 7.8 14 42.7 10 5 1.5% 6.30 [$-3.37, 15.97$] Balercia 2005 [33] (9) 49 7.8 14 42.7 10 5 1.5% 6.30 [$-3.37, 15.97$] Balercia 2005 [33] (9) 49 7.8 14 42.7 10 5 1.5% 6.30 [$-3.37, 15.97$] Balercia 2005 [33] (9) 49 7.8 14 42.7 10 5 1.5% 6.30 [$-3.37, 15.97$] Balercia 2005 [33] (9) 49 7.8 14 42.7 10 5 1.5% 6.30 [$-3.37, 15.97$] Balercia 2005 [33] (9) 49 7.8 14 42.7 10 5 1.5% 6.30 [$-3.37, 15.97$] Balercia 2005 [33] (9) 49 7.8 14 42.7 10 5 1.5% 6.40 [$-3.20, -8.48, 12.88$] Safarinejad 2012 [64] 31.2 2.4 112 25.8 2.2 113 1.6% 5.40 [$4.80, 6.00$] Subtotal (95% CI) Subtotal (95% CI) Subtotal (95% CI) Subtotal (Busetto 2018 [36]	31.7	8.2	52	32.6	9.2	52	1.6%	-0.90 [-4.25, 2.45]	4	
Gopinath 2013 [37] (1) 57.4 14.6 46 44.1 9.5 18 1.5% 13.30 [7.21, 19.39]	Ener 2016 [30] (2)	60.1	16.1	22	48	34.2	23	1.3%	12.10 [-3.41, 27.61]		
Gopinath 2013 [37] (2) 55.8 11.9 43 44.1 9.5 18 1.5% 11.70 [6.05, 17.35]	Gopinath 2013 [37] (1)	57.4	14.6	46	44.1	9.5	18	1.5%	13.30 [7.21, 19.39]		
Kizilay 2019 [28] (1) 36.83 9.6 18 30.18 6.88 9 1.5% 6.65 [0.34, 12.96] Kizilay 2019 [28] (2) 41.2 11.2 39 34.42 7.51 17 1.5% 6.67 [1.77, 11.79] Lenzi 2003 [54] 31.1 13.5 30 29.6 9.5 26 1.5% 1.50 [4.56, 7.56] Safarinejad 2009 [66] (1) 26.1 2.9 105 22.9 2.2 35 1.6% 3.20 [2.29, 4.11] Safarinejad 2009 [66] (2) 29.2 2.9 104 22.9 2.2 35 1.6% 4.50 [3.88, 7.21] Safarinejad 2009 [67] 27.6 2.2 98 23.1 2.1 106 1.6% 4.50 [3.89, 5.11] . Safarinejad 2012 [64] 35.8 2.7 101 25.4 2.1 102 1.6% 1.00 [9.73, 11.07] . Subtotal (95% CI) 1,192 82 35 1.5% 13.00 [7.02, 18.98] . . Subtotal (95% CI) 1,192 821 35.9% 6.21 [4.35, 8.07] . . Heterogeneity: Tau ² = 1	Gopinath 2013 [37] (2)	55.8	11.9	43	44.1	9.5	18	1.5%	11.70 [6.05, 17.35]		
Kizilay 2019 [28] (2) 41.2 11.2 39 34.42 7.51 17 1.5% 6.78 [1.77, 11.79] Lenzi 2003 [54] 31.1 13.5 30 29.6 9.5 26 1.5% 1.50 [-4.56, 7.56] Safarinejad 2009 [66] (1) 26.1 2.9 105 22.9 2.2 35 1.6% 6.30 [5.38, 7.22] - Safarinejad 2009 [66] (3) 24.8 2.9 105 22.9 2.2 35 1.6% 4.50 [3.89, 5.11] - Safarinejad 2009 [67] 27.6 2.2 98 23.1 2.1 96 1.6% 4.50 [3.89, 5.11] - Safarinejad 2012 [64] 35.8 2.7 101 25.4 2.1 102 1.6% 1.040 [9.73, 11.07] - Sigman 2006 [71] 32.3 24.2 12 40 33 9 1.0% 7.70 [-33.24, 17.84] - Subtotal (65% CI) 1.192 821 35.9% 6.21 [4.35, 8.07] - - Heterogeneity: Tau ² =13.58; Chi ² =406.40, dt=23 (p<0.00001); l ² =94% 1.5% 1.5% 1.5% 1.60 [1.72, 21.48]	Kızılay 2019 [28] (1)	36.83	9.6	18	30.18	6.88	9	1.5%	6.65 [0.34, 12.96]		
Lenzi 2003 [54] 31.1 13.5 30 29.6 9.5 26 1.5% 1.50 [.1.4,56, 7.56] Safarinejad 2009 [66] (1) 26.1 2.9 105 22.9 2.2 35 1.6% 6.30 [5.38, 7.22] Safarinejad 2009 [66] (3) 24.8 2.9 105 22.9 2.2 35 1.6% 1.90 [0.98, 2.82] Safarinejad 2009 [67] 27.6 2.2 98 23.1 2.1 96 1.6% 4.50 [3.89, 5.11] Safarinejad 2012 [64] 35.8 2.7 101 25.4 2.1 102 1.6% 10.40 [9.73, 11.07] Sigman 2006 [71] 32.3 24.2 12 40 33 9 1.0% -7.70 [-3.2.4, 17.84] Subtotal (95% Cl) 1, 192 821 35.9 12.8 35 1.5% 13.00 [7.02, 18.98] Heterogeneity: Tau ² =13.58; Chi ² =406.40, df=23 (p<0.00001); l ² =94% Test for overall effect: Z=6.54 (p<0.00001) 1.12.3 Nine months or more Balercia 2005 [33] (9) 49 7.8 14 42.7 10 5 1.5% 1.60 [1.72, 21.48] Balercia 2005 [33] (9) 49 7.8 14 42.7 10 5 1.5% 6.30 [-3.37, 15.97] Balercia 2005 [33] (9) 49 7.8 14 42.7 10 5 1.5% 6.30 [-3.37, 15.97] Balercia 2005 [33] (9) 49 7.8 14 42.7 10 5 1.5% 6.30 [-3.37, 15.97] Balercia 2005 [33] (9) 49 7.8 14 42.7 10 5 1.5% 6.30 [-3.37, 15.97] Balercia 2005 [33] (9) 49 7.8 14 42.7 10 5 1.5% 6.30 [-3.37, 15.97] Balercia 2005 [33] (9) 49 7.8 14 42.7 10 5 1.5% 6.30 [-3.37, 15.97] Balercia 2005 [33] (9) 49 7.8 14 42.7 10 5 1.5% 6.30 [-3.37, 15.97] Balercia 2005 [33] (9) 49 7.8 14 42.7 10 5 1.5% 6.30 [-3.37, 15.97] Balercia 2005 [33] (9) 49 7.8 14 42.7 10 5 1.5% 6.30 [-3.37, 15.97] Balercia 2005 [33] (9) 49 7.8 14 42.7 10 5 1.5% 6.30 [-3.37, 15.97] Balercia 2005 [33] (9) 49 7.8 14 42.7 10 5 1.5% 6.30 [-3.37, 15.97] Balercia 2005 [33] (9) 49 7.8 14 42.7 10 5 1.5% 6.30 [-3.37, 15.97] Balercia 2005 [33] (9) 49 7.8 14 42.7 10 5 1.5% 6.30 [-3.37, 15.97] Balercia 2005 [33] (9) 49 7.8 14 42.7 10 5 1.5% 6.30 [-3.37, 15.97] Balercia 2005 [33] (9) 49 7.8 14 42.7 10 5 1.5% 6.30 [-3.37, 15.97] Balercia 2005 [33] (9) 49 7.8 14 42.7 10 5 1.5% 6.30 [-3.37, 15.97] Balercia 2005 [33] (9) 49 7.8 14 42.7 10 5 1.5% 6.30 [-3.37, 15.97] Balercia 2005 [33] (9) 49 7.8 14 42.7 10 5 1.5% 6.30 [-3.37, 15.97] Balercia 2005 [33] (9) 49 7.8 14 42.7 10 5 1.5% 6.20 [-3.37, 15.97] Balercia 2005 [33] (9)	Kızılay 2019 [28] (2)	41.2	11.2	39	34.42	7.51	17	1.5%	6 78 [1 77 11 79]		
Safarinejad 2009 [66] (1) 26.1 2.9 105 22.9 2.2 36 1.6% 3.20 [2.29, 4.11] Safarinejad 2009 [66] (2) 29.2 2.9 104 22.9 2.2 35 1.6% 6.30 [5.38, 7.22] Safarinejad 2009 [67] 27.6 2.2 98 23.1 2.1 96 1.6% 4.50 [3.89, 5.11] Safarinejad 2012 [64] 35.8 2.7 101 25.4 2.1 102 1.6% 10.40 [9.73, 11.07] Sigman 2006 [71] 32.3 24.2 12 40 33 9 1.0% -7.70 [-3.32,4, 17.84] Subtotal (95% CI) 1,192 821 35.9% 6.21 [4.35, 8.07] Heterogeneity: Tau ² = 13.58; Chi ² = 406.40, df = 23 (p<0.00001); l ² = 94% Test for overall effect: Z = 6.54 (p<0.00001) Heterogeneity: Tau ² = 13.58; Chi ² = 406.40, df = 23 (p<0.00001); l ² = 94% Test for overall effect: Z = 6.54 (p<0.00001) Heterogeneity: Tau ² = 13.68; Chi ² = 406.40, df = 23 (p<0.00001); l ² = 94% Test for overall effect: Z = 6.54 (p<0.00001) Heterogeneity: Tau ² = 13.68; Chi ² = 406.40, df = 23 (p<0.00001); l ² = 94% Test for overall effect: Z = 6.54 (p<0.00001) Heterogeneity: Tau ² = 13.58; Chi ² = 406.40, df = 23 (p<0.00001); l ² = 94% Test for overall effect: Z = 6.54 (p<0.00001) Heterogeneity: Tau ² = 13.28; Chi ² = 40, 20 (p<0.00001); l ² = 94% Test for overall effect: Z = 6.54 (p<0.00001) Heterogeneity: Tau ² = 8.21; Chi ² = 96.3 30 35.3 8 30 1.6% -240 (p<0.44, 12.48] Safarinejad 2009 [67] 24.2 2.1 98 22.8 2.2 96 1.6% 1.40 [0.79, 2.01] Safarinejad 2012 [64] 31.2 2.4 112 25.8 2.2 113 1.6% 5.40 [4.80, 6.00] Subtotal (95% CI) 306 277 10.5% 3.29 [0.36, 6.23] Heterogeneity: Tau ² = 8.21; Chi ² = 8.01, df = 6 (p<0.00001); l ² = 94% Test for overall effect: Z = 2.20 (p=0.03) Total (95% CI) 2,516 1.936 100.0% 7.52 [3.11, 11.94]	Lenzi 2003 [54]	31.1	13.5	30	29.6	9.5	26	1.5%	1 50 [-4 56 7 56]	4	
Safarinejad 2009 [66] (2) 29.2 2.9 104 22.9 2.2 35 1.6% 6.30 [5.30, 7.22] Safarinejad 2009 [67] 27.6 2.2 92.2 35 1.6% 1.50 [0.98, 2.82] Safarinejad 2009 [67] 27.6 2.2 98 23.1 2.1 96 1.6% 4.50 [3.89, 5.11] Safarinejad 2012 [64] 35.8 2.7 101 25.4 2.1 102 1.6% 10.40 [9.73, 11.07] Sigman 2006 [71] 32.3 24.2 12 40 33 9 1.0% -7.70 [-33.24, 17.84] Subictal (95% CI) 1,192 821 35.9% 6.21 [4.35, 8.07] - Heterogeneity: Tau ² =13.58; Chi ² =406.40, df=23 (p<0.00001); l ² =94% 821 35.9% 6.21 [4.35, 8.07] Heterogeneity: Tau ² =13.58; Chi ² =406.40, 3 9 15 42.7 10 5 1.5% 13.00 [7.02, 18.98] Balercia 2005 [33] (7) 54.3 9 15 42.7 10 5 1.5% 7.90 [-1.33, 17.13] Balercia 2005 [33] (9) 49 7.8 14 42.7 10 5	Safarinejad 2009 [66] (1)	26.1	2.9	105	22.9	2.2	36	1.6%	3.20 [2.29, 4.11]		
Safarinejad 2009 [66] (3) 24.8 2.9 105 22.9 2.2 35 1.6% 1.90 [0.98, 2.82] Safarinejad 2009 [67] 27.6 2.2 98 23.1 2.1 96 1.6% 4.50 [3.89, 5.11] Safarinejad 2012 [64] 35.8 2.7 101 25.4 2.1 106 1.6% 1.40 [9.73, 11.07] Sigman 2006 [71] 32.3 2.4.2 12 40 33 9 1.0% -7.70 [-3.2.4, 17.84] Subitan 1996 [44] 48.9 15.5 52 35.9 12.8 35 1.5% 13.00 [7.02, 18.98] Hetrogeneity: Tau ² =13.58; Chi ² =406.40, df=23 (p<0.00001); l ² =94% 821 35.9% 6.21 [4.35, 8.07] Test for overall effect: Z=6.54 (p<0.00001)	Safarinejad 2009 [66] (2)	29.2	2.9	104	22.9	2.2	35	1.6%	6.30 [5.38, 7.22]		
Safarinejad 2009 [67] 27.6 2.2 98 23.1 2.1 96 1.6% 4.50 [3.89, 5.11] Safarinejad 2012 [64] 35.8 2.7 101 25.4 2.1 102 1.6% 10.40 [9.73, 11.07] - Sigman 2006 [71] 32.3 24.2 12 40 33 9 1.0% -7.70 [-33.24, 17.84] Subtotal (95% CI) 1.192 82 35.9% 6.21 [4.35, 8.07] - Heterogeneity: Tau ² =13.58; Chi ² =406.40, df=23 (p<0.00001); l ² =94% 821 35.9% 6.21 [4.35, 8.07] Test for overall effect: Z=6.54 (p<0.00001)	Safarinejad 2009 [66] (3)	24.8	2.9	105	22.9	2.2	35	1.6%	1.90 [0.98, 2.82]		
Safarinejad 2012 [64] 35.8 2.7 101 25.4 2.1 102 1.8% 10.40 [9.73, 11.07] . Sigman 2006 [71] 32.3 24.2 12 40 33 9 1.0% -7.70 [-33.24, 17.84] Suleiman 1996 [44] 48.9 15.5 52 35.9 12.8 35 1.5% 13.00 [7.02, 18.98] Subtotal (95% CI) 1,192 821 35.9% 6.21 [4.35, 8.07] . Heterogeneity: Tau ⁻ =13.58; Chi ² =406.40, df=23 (p<0.00001); l ² =94% 821 35.9% 6.21 [4.35, 8.07] 112.3 Nine months or more Balercia 2005 [33] (7) 54.3 9 15.42.7 10 5 1.5% 7.90 [-1.33, 17.13] Balercia 2005 [33] (9) 49 7.8 14 42.7 10 5 1.5% 6.30 [-3.37, 15.97] Balercia 2005 [33] (9) 49 7.8 14 42.7 10 5 1.5% 6.30 [-3.37, 15.97] Balercia 2009 [34] 32.9 6.3 30 35.3 8 30 1.6% -2.40 [-6.04, 1.24] - Safarinejad 2009 [67] 24.2	Safarinejad 2009 [67]	27.6	2.2	98	23.1	2.1	96	1.6%	4.50 [3.89, 5.11]		
Sigman 2006 [71] 32.3 24.2 12 40 33 9 1.0% -7.70 [-33.24, 17.84] Suleiman 1996 [44] 48.9 15.5 52 35.9 12.8 35 1.5% 13.00 [7.02, 18.98] Heterogeneity: Tau ² =13.58; Chi ² =406.40, df=23 (p<0.00001); l ² =94% 821 35.9% 6.21 [4.35, 8.07] Test for overall effect: Z=6.54 (p<0.00001)	Safarinejad 2012 [64]	35.8	2.7	101	25.4	2.1	102	1.6%	10.40 [9.73, 11.07]	-	
Suleiman 1996 [44] 48.9 15.5 52 35.9 12.8 35 1.5% 13.00 [7.02, 18.98]	Sigman 2006 [71]	32.3	24.2	12	40	33	9	1.0%	-7.70 [-33.24, 17.84]		
Subtotal (95% CI) 1,192 821 35.9% 6.21 [4.35, 8.07] Heterogeneity: Tau ² =13.56; Chi ² =406.40, df=23 (p<0.00001); l ² =94% 821 35.9% 6.21 [4.35, 8.07] 1.12.3 Nine months or more Balercia 2005 [33] (7) 54.3 9 15 42.7 10 5 1.5% 11.60 [1.72, 21.48] Balercia 2005 [33] (9) 49 7.8 14 42.7 10 5 1.5% 7.90 [-1.33, 17.13] Balercia 2005 [33] (9) 49 7.8 14 42.7 10 5 1.5% 6.30 [-3.37, 15.97] Balercia 2009 [34] 32.9 6.3 30 35.3 8 30 1.6% 2.40 [-6.04, 1.24] Ener 2016 [30] (3) 59.3 16.2 2.2 96 1.6% 1.40 [0.79, 2.01] Safarinejad 2009 [67] 24.2 2.1 98 2.2 96 1.6% 1.40 [0.79, 2.01] Safarinejad 2012 [64] 31.2 2.4 112 25.8 2.2 113 1.6% 5.40 [4.80, 6.00] Nubtotal (95% CI) 306 277 10.5% 3.29 [0.36, 6.23] Heterogeneity: Tau ² =8.21; Chi ² =98.01, df=6	Suleiman 1996 [44]	48.9	15.5	52	35.9	12.8	35	1.5%	13.00 [7.02, 18.98]		
Heterogeneity: Tau ² =13.58; Ch ² =406.40, df=23 (p<0.00001); l ² =94% Test for overall effect: Z=6.54 (p<0.00001) 1.12.3 Nine months or more Balercia 2005 [33] (7) 54.3 9 15 42.7 10 5 1.5% 7.90 [-1.33, 17.13] Balercia 2005 [33] (8) 50.6 5.7 15 42.7 10 5 1.5% 6.30 [-3.37, 15.97] Balercia 2005 [33] (9) 49 7.8 14 42.7 10 5 1.5% 6.30 [-3.37, 15.97] Balercia 2009 [34] 32.9 6.3 30 35.3 8 30 1.6% -2.40 [-6.04, 1.24] Ener 2016 [30] (3) 59.3 16.2 22 57.1 20.2 23 1.4% 2.20 [-8.48, 12.88] Safarinejad 2009 [67] 24.2 2.1 98 22.8 2.2 96 1.6% 1.40 [0.79, 2.01] Safarinejad 2002 [67] 24.2 2.1 198 22.8 2.2 96 1.6% 1.40 [0.79, 2.01] Safarinejad 2012 [64] 31.2 2.4 112 25.8 2.2 113 1.6% 5.40 [4.80, 6.00] Subtotal (95% CI) 2,516 1.936 100.0% 7.52 [3.11, 11.94]	Subtotal (95% CI)			1.192			821	35.9%	6.21 [4.35, 8.07]	*	
Test for overall effect: Z=6.54 (p<0.00001)	Heterogeneity: Tau ² =13.58; Ch	ni ² =406.40	, df=23 (p	0.0000	01); I ² =94	1%				, i i i i i i i i i i i i i i i i i i i	
1.12.3 Nine months or more Balercia 2005 [33] (7) 54.3 9 15 42.7 10 5 1.5% 11.60 [1.72, 21.48] Balercia 2005 [33] (8) 50.6 5.7 15 42.7 10 5 1.5% 7.90 [-1.33, 17.13] Balercia 2005 [33] (9) 49 7.8 14 42.7 10 5 1.5% 6.30 [-3.37, 15.97] Balercia 2009 [34] 32.9 6.3 30 35.3 8 30 1.6% -2.40 [-6.04, 1.24] Ener 2016 [30] (3) 59.3 16.2 2.2 57.1 20.2 2.3 1.4% 2.20 [-8.48, 12.88] Safarinejad 2002 [67] 24.2 2.1 98 22.2 96 1.6% 1.40 [0.79, 2.01] Safarinejad 2012 [64] 31.2 2.4 112 25.8 2.2 113 1.6% 5.40 [4.80, 6.00] Subtotal (95% CI) 306 277 10.5% 3.29 [0.36, 6.23] 10.5% 10.5% 3.29 [0.36, 6.23] Heterogeneity: Tau ² =8.2.1; Chi ² =98.01, df=6 (p<0.00001); l ² =94% 1.936 100.0% 7.52 [3.11, 11.94] 4 </td <td>Test for overall effect: Z=6.54 (</td> <td>(p<0.0000</td> <td>1)</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>	Test for overall effect: Z=6.54 ((p<0.0000	1)								
Balercia 2005 [33] (7) 54.3 9 15 42.7 10 5 1.5% 11.60 [1.72, 21.48] Balercia 2005 [33] (8) 50.6 5.7 15 42.7 10 5 1.5% 7.90 [-1.33, 17.13] Balercia 2005 [33] (9) 49 7.8 14 42.7 10 5 1.5% 6.30 [-3.37, 15.97] Balercia 2009 [34] 32.9 6.3 30 35.3 8 30 1.6% -2.40 [-6.04, 1.24] Ener 2016 [30] (3) 59.3 16.2 22 57.1 20.2 23 1.4% 2.20 [-6.44, 12.48] Safarinejad 2009 [67] 24.2 2.1 98 22.8 2.2 96 1.6% 1.40 [0.79, 2.01] Safarinejad 2002 [67] 24.2 2.4 112 25.8 2.2 113 1.6% 5.40 [4.80, 6.00] Subtotal (95% Cl) 3.06 277 10.5% 3.29 [0.36, 6.23] Heterogeneity: Tau ² =8.21; Chi ² =98.01, df=6 (p<0.00001); l ² =94% Total (95% Cl) 2,516 1.936 100.0% 7.52 [3.11, 11.94]	1.12.3 Nine months or more										
Balercia 2005 [33] (8) 50,6 5.7 15 42.7 10 5 1.5% 7.90 [-1.33, 17.13] Balercia 2005 [33] (9) 49 7.8 14 42.7 10 5 1.5% 6.30 [-3.37, 15.97] Balercia 2005 [34] 32.9 6.3 30 35.3 8 30 1.6% -2.40 [-6.04, 1.24] Ener 2016 [30] (3) 59.3 16.2 22 57.1 20.2 23 1.4% 2.20 [-8.48, 12.88] Safarinejad 2009 [67] 24.2 2.1 98 22.8 2.2 96 1.6% 1.40 [0.79, 2.01] Safarinejad 2012 [64] 31.2 2.4 112 25.8 2.2 113 1.6% 5.40 [4.80, 6.00] Subtotal (95% Cl) 306 277 10.5% 3.29 [0.36, 6.23] Heterogeneity: Tau ² =8.21; Chi ² =98.01, df=6 (p<0.00001); l ² =94% Total (95% Cl) 2,516 1.936 100.0% 7.52 [3.11, 11.94]	Balercia 2005 [33] (7)	54.3	9	15	42.7	10	5	1.5%	11.60 [1.72, 21 48]		
Balercia 2005 [33] (9) 49 7.8 14 42.7 10 5 1.5% 6.30 [3.37, 15.97] Balercia 2009 [34] 32.9 6.3 30 35.3 8 30 1.6% -2.40 [-6.04, 1.24] Ener 2016 [30] (3) 59.3 16.2 22 57.1 20.2 23 1.4% 2.20 [-8.48, 12.88] Safarinejad 2009 [67] 24.2 2.1 98 22.8 2.2 96 1.6% 1.40 [0.79, 2.01] Safarinejad 2012 [64] 31.2 2.4 112 25.8 2.2 113 1.6% 5.40 [4.80, 6.00] Subtotal (95% CI) 26,516 1.936 100.0% 7.52 [3.11, 11.94]	Balercia 2005 [33] (8)	50.6	5.7	15	42.7	10	5	1.5%	7.90 [-1.33, 17,13]		
Balercia 2009 [34] 32.9 6.3 30 35.3 8 30 1.6% -2.40 [-6.04, 1.24] - Ener 2016 [30] (3) 59.3 16.2 22 57.1 20.2 23 1.4% 2.20 [-6.48, 12.88] Safarinejad 2009 [67] 24.2 2.1 98 22.8 2.2 96 1.6% 1.40 [0.79, 2.01] Safarinejad 2012 [64] 31.2 2.4 112 25.8 2.2 113 1.6% 5.40 [4.80, 6.00] Subtotal (95% CI) 306 277 10.5% 3.29 [0.36, 6.23] Heterogeneity: Tau ² =8.21; Chi ² =98.01, df=6 (p<0.00001); l ² =94% Test for overall effect: Z=2.20 (p=0.03) Total (95% CI) 2,516 1.936 100.0% 7.52 [3.11, 11.94]	Balercia 2005 [33] (9)	49	7.8	14	42.7	10	5	1.5%	6.30 [-3.37, 15.97]	<u>+</u>	
Ener 2016 [30] (3) 59.3 16.2 22 57.1 20.2 23 1.4% 2.20 [8.48, 12.88] Safarinejad 2009 [67] 24.2 2.1 98 22.8 2.2 96 1.6% 1.40 [0.79, 2.01] Safarinejad 2012 [64] 31.2 2.4 112 25.8 2.2 113 1.6% 5.40 [4.80, 6.00] • Subtotal (95% CI) 306 277 10.5% 3.29 [0.36, 6.23] Heterogeneity: Tau ² =8.21; Chi ² =98.01, df=6 (p<0.00001); l ² =94% Test for overall effect: Z=2.20 (p=0.03) Total (95% CI) 2,516 1.936 100.0% 7.52 [3.11, 11.94] ◆	Balercia 2009 [34]	32.9	6.3	30	35.3	.5	30	1.6%	-2.40 [-6.04, 1.24]	_	
Safarinejad 2009 [67] 24.2 2.1 98 2.2.8 2.2 96 1.6% 1.40 [0.79, 2.01] Safarinejad 2012 [64] 31.2 2.4 112 25.8 2.2 113 1.6% 5.40 [4.80, 6.00] Subtotal (95% CI) 306 277 10.5% 3.29 [0.36, 6.23] Total (95% CI) 2,516 1.936 100.0% 7.52 [3.11, 11.94]	Ener 2016 [30] (3)	59.3	16.2	22	57.1	20.2	23	1.4%	2.20 [-8.48, 12.88]	<u> </u>	
Safarinejad 2012 [64] 31.2 2.4 112 25.8 2.2 113 1.6% 5.40 [4.80, 6.00] Subtotal (95% Cl) 306 277 10.5% 3.29 [0.36, 6.23] Heterogeneity: Tau ² =8.21; Chi ² =98.01, df=6 (p<0.00001); l ² =94% Total (95% Cl) 2,516 1.936 100.0% 7.52 [3.11, 11.94] ◆	Safarinejad 2009 [67]	24.2	2.1	98	22.8	2.2	96	1.6%	1 40 10 79 2 011		
Subtotal (95% Cl) 2,516 1,936 100.0% 7.52 [3.11, 11.94] ◆	Safarineiad 2012 [64]	31.2	2.1	112	25.8	2.2	113	1.6%	5 40 [4 80 6 00]		
Heterogeneity: Tau ² =8.21; Chi ² =98.01, df=6 (p<0.00001); l ² =94% Test for overall effect: Z=2.20 (p=0.03) Total (95% Cl) 2,516 1,936 100.0% 7.52 [3.11, 11.94] ◆	Subtotal (95% CI)	01.2	2.4	306	20.0	2.2	277	10.5%	3 29 [0 36 6 22]		
Test for overall effect: Z=2.20 (p=0.03) Total (95% Cl) 2,516 1,936 100.0% 7.52 [3.11, 11.94] ♦	Heterogeneity: Tau ² =8.21: Chi	² =98.01. d	f=6 (p<0.	00001):	$ ^{2}=94\%$		2.1	10.3 %	5.25 [0.50, 0.25]	ľ	
Total (95% Cl) 2,516 1,936 100.0% 7.52 [3,11, 11.94] ♦	Test for overall effect: Z=2.20 ((p=0.03)	(p .o.	,							
	Total (95% CI)			2 5 1 6			1 936	100.0%	7 52 [3 11 11 94]		
Heterogeneity: Tau ² =323.24: Chi ² =39.332.92. df=68 (p<0.00001): l ² =100%	Heterogeneity: Tau ² =323 24 0	chi ² =39.33	2.92. df=	68 (p<0	00001)	² =100%	1,350	100.0 %	1.02 [3.11, 11.34]	· · · · · · · ·	
Test for overall effect. Z=3.34 (p=0.0008)	Test for overall effect: Z=3.34	(p=0.0008))	(p .o.						-100 -50 0 50 100	

Test for subgroup differences: Chi^2 =3.95, df=2 (p=0.14); l^2 =49.4%



Fig. 17. Funnel plot of the sperm total motility in infertile patients treated with antioxidants compared to placebo or untreated infertile controls.

pants were assigned to either AOX or placebo based on semen parameters and female partner's age, while other important issues related to the underlying etiological factors for diagnoses of male infertility were ignored. This may be an additional source of selection bias since some genital abnormalities such as varicocele may impact the outcome of AOX therapy of infertile men [36,92].

Fig. 16. Continued.

Favours placebo/no treatment Favours AOX

Fourth, the MOXI trial used a combined AOX formula containing vitamin C (500 mg), vitamin E (400 mg), selenium (0.20 mg), LC (1,000 mg), zinc (20 mg), folic acid (1,000 mg), lycopene (10 mg), and vitamin D (2,000 IU). The authors state that they selected this formulation based on the finding of a previous Cochrane systematic review reporting that each individual component has a positive impact on sperm structure or function and/or pregnancy rates after assisted reproductive technique (ART). However, it remains unclear whether the formulation chosen in the MOXI trial is appropriate or not.

Fifth, the authors of the MOXI trial state that AOX therapy was given for at least 3 months and up to 6 months. The US Food and Drug Administration (FDA) recommends a minimum duration of 26 weeks for as-

https://doi.org/10.5534/wjmh.220067



	Placebo							Moon difforence	Moon difforence
Study or subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, random, 95% Cl	IV, random, 95% Cl
1.4.1 Three months or less									
Alahamar 2021 [79]	0	0	0	0	0	0		Not estimable	
Ardestani Zadeh 2019 [27] Azizollahi 2013 [32] (1)	22.5	11	30	18.7	7.8	30	1.6%	3.80 [-1.03, 8.63]	
Azizollahi 2013 [32] (2)	51.7	17.2	29	44.9	33	8	1.1%	6.80 [-16.91, 30.51]	
Azizollahi 2013 [32] (3)	48.9	27.7	32	44.9	33	8	1.1%	4.00 [-20.80, 28.80]	
Balercia 2005 [33] (1) Balercia 2005 [33] (2)	59.9 56.5	8 11 6	15 15	44.6	7.7	5	1.6%	15.30 [7.43, 23.17]	
Balercia 2005 [33] (3)	55.1	10.2	14	44.6	7.7	5	1.6%	10.50 [1.89, 19.11]	
Barekat 2016 [29]	58.2	5.4	15	43.6	4.9	20	1.7%	14.60 [11.12 18.08]	-
Ciffici 2009 [47] Conquer 2000 [48] (1)	31.29 39.4	8.62 24.3	60	20.33	8.43 18.6	60	1.7%	10.96 [7.91, 14.01]	
Conquer 2000 [48] (2)	32	16.1	10	47.2	18.6	5	1.3%	-15.20 [-34.31, 3.91]	
Cyrus 2015 [31]	54.5	18.3	41	44.9	21.4	61	1.6%	9.60 [1.84, 17.36]	
Dimitriadis 2010 [50]	35.6	15.5	26	24.7	10.8	22	1.6%	10.90 [3.43, 18.37]	
Eslamian 2020 [51] (1)	36.44	3.81	45	33.8	3.36	45	1.4%	2.64 [1.16, 4.12]	
Eslamian 2020 [51] (2)	34.27	4.06	45	33.8	3.36	45	1.7%	0.47 [-1.07, 2.01]	ł
Eslamian 2020 [51] (3)	32.67	4.17	45	33.8	3.36	45	1.7%	-1.13 [-2.69, 0.43]	
Gopinath 2013 [37] (1) Gopinath 2013 [37] (2)	51.6 50.1	13	46 43	42.1	10.6	18 18	1.6%	9.50 [3.33, 15.67]	
Greco 2005 [52]	41.6	22	32	38.7	21.5	32	1.5%	2.90 [-7.76, 13.56]	
Haghighian 2015 [53]	40.65	4.95	23	36.01	3.16	21	1.7%	4.64 [2.21, 7.07]	-
Lenzi 2003 [54]	11	15.5	43	8.8	10.8	43	1.6%	2.20 [-3.45, 7.85]	+
Martinez-Soto 2010 [56]	41.5	18.7	21	48	15.5	15	1.5%	-6.50 [-17.70, 4.70]	
Morgante 2010 [58]	40.3	6.4	90	25.1	4.2	90	1.7%	15.20 [13.62, 16.78]	-
Nadjarzadeh 2011 [59]	0	0	0	0	0	0		Not estimable	
Nadjarzaden 2011 [59] Nouri 2019 [60]	41.91 30.7	15.6	23	38.33	18.4	24	1.5%	3.58 [-6.16, 13.32]	<u> </u>
Omu 2008 [61] (1)	49	10.70	11	24	13.04	3	1.4%	25.00 [9.68, 40.32]	
Omu 2008 [61] (2)	50	20	14	24	12	2	1.3%	26.00 [6.34, 45.66]	<u> </u>
Omu 2008 [61] (3) Poivandi 2010 [62]	50	18	12	24	12	3	1.4%	26.00 [9.03, 42.97]	
Scott 1998 [41] (1)	46.3	0.2 5.7	15	15.3	4.1	15	1.7%	31.30 [31.19, 31.41] 14 90 [11 53 18 27]	
Scott 1998 [41] (2)	27	3.7	30	15.3	4.1	18	1.7%	11.70 [9.39, 14.01]	-
Sigman 2006 [71]	28.6	38.1	12	37.6	33	9	1.0%	-9.00 [-39.49, 21.49]	
Subtotal (95% CI)	33.5	29.8	10 937	19	14.4	10 758	1.2%	14.50 [-6.01, 35.01] 8 75 [2 27 15 23]	
Heterogeneity: Tau ² =333.30; C	hi ² =6,543.	31, df=3	3 (p<0.0	0001); I ² :	=99%	100	50.170	0.10 [2.21, 10.20]	ľ
Test for overall effect: Z=2.65 (p=0.008)								
1.4.2 Six months									
Ardestani Zadeh 2019 [27]	50.29	15.14	30	46.4	16.51	30	1.6%	3.89 [-4.13, 11.91]	+
Azizollahi 2013 [32] (4)	51.5	10.2	26	49.8	14.4	9	1.5%	1.70 [-8.49, 11.89]	
Azizollahi 2013 [32] (5) Azizollahi 2013 [32] (6)	52.4 49.8	17.8	29 32	49.8 49.8	13.6 13.6	8	1.5%	2.60 [-8.84, 14.04]	
Balercia 2005 [33] (4)	64.53	8.41	15	44.6	7.68	15	1.6%	19.93 [14.17, 25.69]	
Balercia 2005 [33] (5)	60.43	10.46	15	44.6	7.68	15	1.6%	15.83 [9.26, 22.40]	
Balercia 2005 [33] (6) Balercia 2009 [34]	61.07	9.07	14	44.6	7.68	15	1.6%	16.47 [10.33, 22.61]	1
Blomberg Jensen 2018 [69]	39.4 41	22.7	129	39.4 45	23.1	131	1.6%	-4.00 [-9.57, 1.57]	_ _
Busetto 2017 [35]	39	8	45	34.6	7.1	49	1.7%	4.40 [1.33, 7.47]	-
Busetto 2018 [36]	31.7	8.2	52	32.6	9.2	52	1.7%	-0.90 [-4.25, 2.45]	-
Gopinath 2013 [37] (1)	57.4	16.1 14.6	22 46	48 44.1	34.2 9.5	23 18	1.4% 1.6%	12.10 [-3.41, 27.61] 13 30 [7 21 19 39]	
Gopinath 2013 [37] (2)	55.8	11.9	43	44.1	9.5	18	1.6%	11.70 [6.05, 17.35]	
Kızılay 2019 [28] (1)	36.83	9.6	18	30.18	6.88	9	1.6%	6.65 [0.34, 12.96]	
Kizilay 2019 [28] (2) Lenzi 2003 [54]	41.2	11.2	39	34.42	7.51	17	1.6%	6.78 [1.77, 11.79]	
Safarinejad 2009 [66] (1)	26.1	2.9	105	22.9	2.2	36	1.7%	3.20 [2.29, 4.11]	-
Safarinejad 2009 [66] (2)	29.2	2.9	104	22.9	2.2	35	1.7%	6.30 [5.38, 7.22]	-
Safarinejad 2009 [66] (3)	24.8	2.9	105	22.9	2.2	35	1.7%	1.90 [0.98, 2.82]	
Safarinejad 2009 [67] Safarinejad 2012 [64]	27.6 35.8	2.2	98 101	25.1	2.1	96 102	1.7%	4.50 [3.89, 5.11] 10.40 [9.73, 11.07]	
Sigman 2006 [71]	32.3	24.2	12	40	33	9	1.1%	-7.70 [-33.24, 17.84]	
Suleiman 1996 [44]	48.9	15.5	52	35.9	12.8	35	1.6%	13.00 [7.02, 18.98]	
Heterogeneity: Tau ² =13.58: Ch	i ² =406 40	df=23 (r	1,192 <0.0000	$(1) \cdot 1^2 = 94$.%	821	38.2%	6.21 [4.35, 8.07]	*
Test for overall effect: Z=6.54 (p<0.00001)		,,,, 0.	.,.				
1.4.3 Nine months or more									
Balercia 2005 [33] (7)	54.3	9	15	42.7	10	5	1.5%	11.60 [1.72, 21.48]	
Balercia 2005 [33] (8)	50.6	5.7	15	42.7	10	5	1.6%	7.90 [-1.33, 17.13]	<u>+</u>
Balercia 2005 [33] (9) Balercia 2009 [34]	49 32.0	7.8	14	42.7	10 9	5	1.6%	6.30 [-3.37, 15.97]	1-
Ener 2016 [30] (3)	59.3	16.2	30 22	57.1	20.2	30 23	1.5%	2.20 [-8.48, 12.88]	4
Safarinejad 2009 [67]	24.2	2.1	98	22.8	2.2	96	1.7%	1.40 [0.79, 2.01]	ł
Safarinejad 2012 [64]	31.2	2.4	112	25.8	2.2	113	1.7%	5.40 [4.80, 6.00]	Ľ
Heterogeneity: Tau ² =8.21: Chi ²	=98.01. df	=6 (p<0	306 00001):	l ² =94%		277	11.2%	3.29 [0.36, 6.23]	Ē
Test for overall effect: Z=2.20 (p=0.03)		. /						
Total (95% CI)			2 4 3 5			1 856	100.0%	7 29 [2 75 11 23]	
Heterogeneity: Tau ² =321.95; C	hi ² =38,723	3.58, df=	64 (p<0.	00001); I	² =100%	1,000	100.070		
Test for overall effect: Z=3.15 (p=0.002)	df=0 /	0.400 /2	-45.000					-100 -50 0 50 100
rest for subgroup differences:	oni =3.70,	u=2 (p=	יט. ט); I	-43.9%					Favours Favours placebo/no treatment AOX





ent durations of AOX therapy may add an important

confounder that may impact the interpretation of the results. Lastly, ovarian stimulation with clomiphene

sessing the impact of a therapeutic agent used for the treatment of male factor infertility. Using differ-



Fig. 19. Funnel plot of the total sperm motility in infertile patients treated with antioxidants compared to placebo or untreated infertile controls, after the removal of studies including patients with varico-cele undergoing varicocele repair.

p<0.1 p<0.05 Morphology . p<0.01 0 p-value=0.04 • 2 Standard error 4 6 8 10 12 10 10 20 30 -20 0 Mean difference Funnel plot

Fig. 21. Funnel plot of the sperm morphology in infertile patients treated with antioxidants compared to placebo or untreated infertile controls.

				, I	lacebo				
Study on otherson		AUX	-	/no	treatme	ent T / I		Mean difference	Mean difference
Study or subgroup	Mean	SD	Iotai	Mean	SD	Iotai	weight	IV, random, 95% CI	IV, random, 95% CI
1.13.1 Three months or less									
Azizollahi 2013 [32] (1)	49.9	2.2	29	38.1	2.5	10	5.5%	11.80 [10.06, 13.54]	•
Azizollahi 2013 [32] (2)	53	2.8	26	38.1	2.5	10	5.3%	14.90 [13.01, 16.79]	• • •
Azizollahi 2013 [32] (3)	48	2.3	32	38.1	2.5	5	4.7%	9.90 [7.57, 12.23]	\longrightarrow
Barekat 2016 [29]	2.71	0.3	15	1.9	0.2	20	7.0%	0.81 [0.63, 0.99]	
Cyrus 2015 [31]	75.3	13.1	41	67.5	16.4	61	1.8%	7.80 [2.05, 13.55]	$ \longrightarrow$
da Silva 2013 [49]	23.91	3.68	23	24.23	3.06	26	5.3%	-0.32 [-2.23, 1.59]	
Dimitriadis 2010 [50]	25.8	9.8	26	23.7	8.1	22	2.1%	2.10 [-2.96, 7.16]	
Eslamian 2020 [51]	14.44	3.16	45	14.36	3.4	45	6.0%	0.08 [-1.28, 1.44]	
Greco 2005 [52]	8	7.1	32	11.6	7.8	32	3.2%	-3.60 [-7.25, 0.05]	
Haghighian 2015 [53]	15.39	3.6	23	13.8	3.73	21	4.9%	1.59 [-0.58, 3.76]	
Lu 2018 [55]	5.3	0.3	27	4.2	0.3	27	7.0%	1.10 [0.94, 1.26]	
Nadjarzadeh 2011 [59]	6.52	5.1	23	6.29	4.3	24	4.2%	0.23 [-2.47, 2.93]	
Nouri 2019 [60]	1.88	0.99	17	1.78	1.08	19	6.7%	0.10 [-0.58, 0.78]	<u>_</u>
Omu 2008 [61] (1)	72	14	11	69	16	2	0.1%	3.00 [-20.67, 26.67]	·
Omu 2008 [61] (2)	72	16	12	69	16	4	0.2%	3.00 [-15,11, 21,11]	·
Omu 2008 [61] (3)	72	20	14	69	16	2	0.1%	3 00 [-21 52 27 52]	·
Rolf 1999 [63] (1)	12.2	5.4	14	13.3	11.4	15	1.5%	-1 10 [-7 53 5 33]	
Rolf 1999 [63] (2)	13.4	7.8	14	14.4	8.6	15	1.7%	-1 00 [-6 97 4 97]	
Závaczki 2003 [45]	57.2	12.5	10	42.8	14.8	10	0.5%	14 40 [2 39 26 41]	
Subtotal (95% CI)	01.2	12.0	434	12.0	11.0	370	67.7%	3 30 [2 26 4 34]	· · · · · · · · · · · · · · · · · · ·
Heterogeneity: Tau ² =2.66; Chi ² =	445.41. d	f=18 (p<	0.00001): ² =96%	,	0.0	0	0.00 [2.20, 1.01]	-
Test for overall effect: Z=6.23 (p	<0.00001)		,,					
u.		,							
1.13.2 Six months									
Azizollahi 2013 [32] (4)	56.6	2.2	29	48.4	9.9	5	0.9%	8.20 [-0.51, 16.91]	
Azizollahi 2013 [32] (5)	53.7	1.7	26	48.4	9.9	5	0.9%	5.30 [-3.40, 14.00]	
Azizollahi 2013 [32] (6)	53.2	2.7	32	48.4	9.9	15	2.1%	4.80 [-0.30, 9.90]	
Busetto 2017 [35]	17.7	15.2	44	15.7	9.4	49	2.0%	2.00 [-3.21, 7.21]	
Safarinejad 2009 [66] (1)	9.2	2.9	105	7.2	2.6	106	6.7%	2.00 [1.26, 2.74]	
Safarinejad 2009 [67]	9.6	2.4	98	7.8	2.1	96	6.8%	1.80 [1.17, 2.43]	
Safarinejad 2012 [64]	17.6	4.4	101	14.8	4.1	102	6.2%	2.80 [1.63, 3.97]	
Subtotal (95% CI)			435			378	25.6%	2 06 [1 62 2 50]	•
Heterogeneity: Tau ² =0.00; Chi ² =	5.76. df=	6 (p=0.4	5): 1 ² =0%	6		0.0	20.070	2.000 [1.02, 2.00]	, ·
Test for overall effect: Z=9.15 (p	<0.00001)	.,						
u.		,							
1.13.3 Nine months or more									
Safarinejad 2011 [65]	12.8	2.6	106	7.5	2.7	105	6.7%	5 30 [4 58 6 02]	
Subtotal (95% CI)			106			105	6.7%	5 30 [4 58 6 02]	•
Heterogeneity: Not applicable							0.1 /0	0.00 [4.00, 0.02]	Ť
Test for overall effect: Z=14.52 (p<0.0000	1)							
Total (95% CI)			975			853	100.0%	3.28 [2.40, 4.17]	•
Heterogeneity: Tau ² =2.88; Chi ² =	598.39, d	f=26 (p<	0.00001); I ² =96%					
Test for overall effect: Z=7.31 (p-	<0.00001)							-10 -5 0 5 10
Test for subgroup differences: C	hi ² =57.34	, df=2 (p	<0.0000	1); I ² =96.	5%				Favours Eavours
									placebo/no treatment AOX

Fig. 20. Forest plot of the sperm morphology in infertile patients treated with antioxidants (AOXs) compared to placebo or untreated infertile controls.

difference om, 95% Cl



		AOX		/no	treatm	ent		Mean difference	Mean difference
Study or subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, random, 95% CI	IV, random, 95% CI
1.13.1 Three months or less									
Azizollahi 2013 [32] (1)	49.9	22	29	38.1	2.5	10		Not estimable	
Azizollahi 2013 [32] (2)	53	2.8	26	38.1	2.5	10		Not estimable	
Azizollahi 2013 [32] (3)	48	2.3	32	38.1	2.5	5		Not estimable	
Barekat 2016 [29]	2.71	0.3	15	1.9	0.2	20		Not estimable	
Cyrus 2015 [31]	75.3	13.1	41	67.5	16.4	61		Not estimable	
da Silva 2013 [49]	23.91	3.68	23	24.23	3.06	26	8.1%	-0.32 [-2.23, 1.59]	
Dimitriadis 2010 [50]	25.8	9.8	26	23.7	8.1	22	3.7%	2.10 [-2.96, 7.16]	
Eslamian 2020 [51]	14.44	3.16	45	14.36	3.4	45	9.0%	0.08 [-1.28, 1.44]	
Greco 2005 [52]	8	7.1	32	11.6	7.8	32	5.3%	-3.60 [-7.25, 0.05]	
Haghighian 2015 [53]	15.39	3.6	23	13.8	3.73	21	7.7%	1.59 [-0.58, 3.76]	
Lu 2018 [55]	5.3	0.3	27	4.2	0.3	27	0.0%	1.10 [0.94, 1.26]	
Nadjarzadeh 2011 [59]	6.52	5.1	23	6.29	4.3	24	6.8%	0.23 [-2.47, 2.93]	
Nouri 2019 [60]	1.88	0.99	17	1.78	1.08	19	9.8%	0.10 [-0.58, 0.78]	+
Omu 2008 [61] (1)	72	14	11	69	16	2	0.3%	3.00 [-20.67, 26.67]	<
Omu 2008 [61] (2)	72	16	12	69	16	4	0.4%	3.00 [-15.11, 21.11]	<
Omu 2008 [61] (3)	72	20	14	69	16	2	0.2%	3.00 [-21.52, 27.52]	<
Rolf 1999 [63] (1)	12.2	5.4	14	13.3	11.4	15	2.6%	-1.10 [-7.53, 5.33]	
Rolf 1999 [63] (2)	13.4	7.8	14	14.4	8.6	15	2.9%	-1.00 [-6.97, 4.97]	
Závaczki 2003 [45]	57.2	12.5	10	42.8	14.8	10	0.9%	14.40 [2.39, 26.41]	· · · · · · · · · · · · · · · · · · ·
Subtotal (95% CI)			264			237	57.8%	0.12 [-0.48, 0.73]	+
Heterogeneity: Tau ² =0.06; Chi ²	=12.46, df	=12 (p=0).41); I ² =	4%					
Test for overall effect: Z=0.40 (p	o=0.69)								
1.13.2 Six months									
Azizollahi 2013 [32] (4)	56.6	2.2	29	48.4	9.9	5		Not estimable	
Azizollahi 2013 [32] (5)	53.7	1.7	26	48.4	9.9	5		Not estimable	
Azizollahi 2013 [32] (6)	53.2	2.7	32	48.4	9.9	15		Not estimable	
Busetto 2017 [35]	17.7	15.2	44	15.7	9.4	49	3.5%	2.00 [-3.21, 7.21]	
Safarinejad 2009 [66] (1)	9.2	2.9	105	7.2	2.6	106	9.8%	2.00 [1.26, 2.74]	
Safarinejad 2009 [67]	9.6	2.4	98	7.8	2.1	96	9.9%	1.80 [1.17, 2.43]	
Safarinejad 2012 [64]	17.6	4.4	101	14.8	4.1	102	9.3%	2.80 [1.63, 3.97]	
Subtotal (95% CI)			348			353	32.4%	2.02 [1.57, 2.46]	•
Heterogeneity: Tau ² =0.00; Chi ²	=2.17, df=	3 (p=0.5	4); I ² =0%	6					
Test for overall effect: Z=8.90 (p	o<0.00001)							
1.13.3 Nine months or more									
Safarinejad 2011 [65]	12.8	2.6	106	7.5	2.7	105	9.8%	5.30 [4.58, 6.02]	
Subtotal (95% CI)			106			105	9.8%	5.30 [4.58, 6.02]	•
Heterogeneity: Not applicable									
Test for overall effect: Z=14.52	(p<0.0000	1)							
Total (95% CI)			718			695	100.0%	1.34 [0.13, 2.56]	•
Heterogeneity: Tau ² =3.79; Chi ²	=144.42, c	if=17 (p<	0.00001); I ² =88%					
Test for overall effect: Z=2.16 (p	o=0.03)								-10 -5 0 5 10

Placobo

Test for subgroup differences: Chi²=117.78, df=2 (p<0.00001); I²=98.3%



Fig. 23. Funnel plot of the sperm morphology in infertile patients treated with antioxidants compared to placebo or untreated infertile controls, after the removal of studies including patients with varico-cele undergoing varicocele repair.

citrate followed by intrauterine insemination (IUI) was used for couples who had not conceived after a trial with AOX *vs.* placebo. Thus, there is a concern of having heterogeneous responses due to combining AOX supplementation with IUI.

repair.

Favours placebo/no treat

Favours AOX Fig. 22. Forest plot of the sperm morphology in infertile patients treated with antioxidants (AOXs) compared to placebo or untreated infertile controls, after the removal of studies including patients with varicocele undergoing varicocele

Several meta-analyses have evaluated the potential benefit of AOX for treatment of male infertility. Despite being considered the gold standard, the last Cochrane meta-analysis [14] has some objective limitations, that the present study has overcome (Table 3). Compared to the last Cochrane review, our study increased the number of RCTs, and investigated the largest population analyzed so far on this topic. This allowed us to score the evidence on clinical pregnancy as moderate-quality and, accordingly, the analysis of this outcome resulted in minimal inter-study heterogeneity (Table 3). Regarding live-birth rate, the population analyzed in the present study is smaller than that assessed in the Cochrane meta-analysis, since we focused only on spontaneous pregnancies. Also, some of the outcomes of the present study, such as sperm morphology, seminal levels of TAC and of MDA, were not analyzed in the study by Smits et al [14]. In addition, concerning



		AOX		F /no	lacebo treatme	ent		Std. Mean difference		Std. I	/lean dif	fference	
Study or subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, random, 95% CI		IV, ra	andom,	95% CI	
1.14.1 Three months or less													
Barekat 2016 [29]	89.8	5.4	15	85.9	1.7	20	33.1%	1.02 [0.30, 1.73]				_	
Greco 2005 [52]	9.1	7.2	32	22.9	7.9	32	33.8%	-1.80 [-2.39, -1.22]					
Martinez-Soto 2010 [56]	11	9.8	21	25.1	16	15	33.1%	-1.08 [-1.80, -0.37]					
Subtotal (95% CI) Heterogeneity: Tau ² =2.02; Chi Test for overall effect: Z=0.75	i ² =36.62, df= (p=0.45)	=2 (p<0.	68 00001);	I ² =95%		67	100.0%	-0.63 [-2.29, 1.02]			•		
Total (95% CI) Heterogeneity: Tau ² =2.02; Chi Test for overall effect: Z=0.75 Test for subgroup differences:	i ² =36.62, df= (p=0.45) Not applica	=2 (p<0. ble	68 00001);	I ² =95%		67	100.0%	-0.63 [-2.29, 1.02]	-10 placel	-5 Favours	0 tment	5 Favours AOX	1 10 (

Fig. 24. Forest plot of the sperm DNA fragmentation in infertile patients treated with antioxidants (AOXs) compared to placebo or untreated infertile controls.

		AOX		F /no	lacebo treatme	ent		Std. Mean difference		Std.	Mean dif	ference	
Study or subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, random, 95% CI		IV, r	andom, 9	95% CI	
1.14.1 Three months or less													
Barekat 2016 [29]	89.8	5.4	15	85.9	1.7	20		Not estimable					
Greco 2005 [52]	9.1	7.2	32	22.9	7.9	32	54.1%	-1.80 [-2.39, -1.22]			-		
Martinez-Soto 2010 [56]	11	9.8	21	25.1	16	15	45.9%	-1.08 [-1.80, -0.37]					
Subtotal (95% CI) Heterogeneity: Tau ² =0.15; Chi ² = Test for overall effect: Z=4.11 (pe	2.33, df=1 <0.0001)	l (p=0.1	53 3); I ² =57	%		47	100.0%	-1.47 [-2.18, -0.77]			•		
Total (95% CI) Heterogeneity: Tau ² =0.15; Chi ² = Test for overall effect: Z=4.11 (p- Test for subgroup differences: N	2.33, df=1 <0.0001) ot applical	l (p=0.1 ble	53 3); I ² =57	%		47	100.0%	-1.47 [-2.18, -0.77]	-10 place	-5 Favours bo/no trea	• 0 atment	5 Favours AOX	10

Fig. 25. Forest plot of the sperm DNA fragmentation in infertile patients treated with antioxidants (AOXs) compared to placebo or untreated infertile controls, after the removal of studies including patients with varicocele undergoing varicocele repair.

		AOX		/no	treatme	ent		Mean difference	Me	an differe	ence	
Study or subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, random, 95% CI	I IV, r	andom, 9	5% CI	
1.15.1 Three months or less												
Eslamian 2020 [51]	1.12	0.36	45	1.01	0.34	45	16.2%	0.11 [-0.03, 0.25]				
Haghighian 2015 [53]	1.78	0.4	23	1.13	0.42	21	16.0%	0.65 [0.41, 0.89]				
Lu 2018 [55]	2.78	0.26	27	2.21	0.26	27	16.2%	0.57 [0.43 ,0.71]		- F		
Nadjarzadeh 2011 [59]	4.45	0.36	23	4.27	0.73	24	15.6%	0.18 [-0.15, 0.51]		- F		
Nouri 2019 [60]	3.24	0.64	17	2.44	0.46	19	15.5%	0.80 [0.43, 1.17]		•		
Omu 2008 [61] (1)	8	2	11	2	1	2	6.6%	6.00 [4.18, 7.82]				
Omu 2008 [61] (2)	10	3	12	2	1	2	5.3%	8.00 [5.81, 10.19]				
Omu 2008 [61] (3)	10	2	14	2	1	4	8.6%	8.00 [6.57, 9.43]				
Subtotal (95% CI)			172			144	100.0%	1.87 [1.26, 2.48]		•		
Heterogeneity: Tau ² =0.59; Chi ² =	=220.46, c	if=7 (p<0	0.00001); I ² =97%								
Test for overall effect: Z=6.02 (p	<0.00001)										
Total (95% CI) Heterogeneity: Tau ² =0.59; Chi ² =	=220.46, c	if=7 (p<0	172); I ² =97%		144	100.0%	1.87 [1.26, 2.48]	L	•		
Test for overall effect: Z=6.02 (p<0.00001)									-20 -10	ò	10	20
Test for subgroup differences: Not applicable								Favours placebo/no trea	atment	Favours AOX		

Placebo

Fig. 26. Forest plot of the total antioxidant (AOX) capacity in infertile patients treated with antioxidants compared to placebo or untreated infertile controls.

		AOX		F /no	Placebo treatme	ent		Mean difference	Mean difference
Study or subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, random, 95% CI	IV, random, 95% CI
1.16.1 Three months or less									
Eslamian 2020 [51]	0.66	0.19	45	0.82	0.31	45	19.5%	-0.16 [-0.27, -0.05]	•
Haghighian 2015 [53]	0.67	0.24	23	0.98	0.33	21	18.5%	-0.31 [-0.48, -0.14]	-
Lu 2018 [55]	0.46	0.06	27	0.61	0.7	27	16.5%	-0.15 [-0.42, 0.12]	+
Nadjarzadeh 2011 [59]	3.42	0.34	23	3.61	0.32	24	18.1%	-0.19 [-0.38, 0.00]	-
Nouri 2019 [60]	0.79	0.15	17	0.85	0.22	19	19.3%	-0.06 [-0.18, 0.06]	•
Omu 2008 [61] (1)	4	2	11	10	3	4	0.6%	-6.00 [-9.17, -2.83]	
Omu 2008 [61] (2)	4	2	12	10	3	2	0.3%	-6.00 [-10.31, -1.69]	←────
Omu 2008 [61] (3)	4	2	14	10	3	2	0.3%	-6.00 [-10.29, -1.71]	<
Subtotal (95% CI)			172	_		144	93.1%	-0.22 [-0.41, -0.03]	•
Heterogeneity: Tau ² =0.04; Chi ² =	32.84, df	=7 (p<0.	0001); l ⁱ	² =79%					
Test for overall effect: Z=2.22 (p	=0.03)								
1.16.2 Six months									
Suleiman 1996 [44]	7.1	2.2	52	9.4	1.5	35	6.9%	-2.30 [-3.08, -1.52]	
Subtotal (95% CI)			52			35	6.9%	-2.30 [-3.08, -1.52]	•
Heterogeneity: Not applicable									
Test for overall effect: Z=5.80 (p	<0.00001)							
Total (95% CI)			224			179	100.0%	-0.39 [-0.65, -0.14]	*
Heterogeneity: Tau ² =0.08; Chi ² =	61.71, df	=8 (p<0.	00001);	l ² =87%					
Test for overall effect: Z=3.08 (p	=0.002)								-10 -5 0 5 10
Test for subgroup differences: C	hi ² =26.04	, df=1 (p	0.000	01); I ² =96	.2%				Favours Favours
									placebo/no treatment AOX

Fig. 27. Forest plot of the malondialdehyde in infertile patients treated with antioxidants (AOXs) compared to placebo or untreated infertile controls.



Table 3. Comparison of the findings of the present study with the last Cochrane meta-analysis [14]

	Present meta-a	analysis	Cochrane meta-analysis [14]			
Outcome	Summary of the results	Number of participants (n studies)	Summary of the results	Number of participants (n studies)		
Spontaneous pregnancy rate ^a	OR 1.97 (95% CI: 1.28, 3.04); n=190 events; p<0.01; $I^2=20\%$; χ^2 p=0.20 (Fig. 2)	1,355 (16 RCTs)	OR 2.97 (95% Cl: 1.20, 2.67); n=105 events; p<0.05; l ² =0%	786 (11 RCTs)		
Live-birth rate ^a	OR 1.21 (95% Cl: 0.53, 2.76); n=65 events; p=0.64 (Fig. 6)	388 (4 RCTs)	OR 1.79 (95% CI: 1.20, 2.67); n=124 events; p<0.05; l ² =40%	750 (7 RCTs)		
Miscarriage rate ^a	OR 1.01 (95% Cl: 0.34, 3.00); n=13 events; p=0.98 (Fig. 7)	459 (4 RCTs)	OR 1.74 (95% 0.40, 7.60); n=8 events; p=0.46	247 (3 RCTs)		
Sperm concentration	MD 5.93 mil/mL (95% Cl: 4.43, 7.43); p<0.01; l^2 =94%; χ^2 p<0.01 (Fig. 8)	4,310 (36 RCTs)	Overall effect not assessed ^b	3,456 (26 RCTs)		
Progressive sperm motility	$\begin{array}{l} \mbox{MD 7.21\% (95\% Cl: 3.66, 10.76);} \\ \mbox{p<0.01; } l^2 \mbox{=} 99\%; \\ \mbox{\chi}^2 \mbox{ p<0.01 (Fig. 12)} \end{array}$	2,345 (20 RCTs)	Overall effect not assessed ^b	1,523 (15 RCTs)		
Total sperm motility	$\begin{array}{l} \text{MD 7.52\% (95\% CI: 3.11, 11.94);} \\ p{<}0.01; \ l^{2}{=}100\%; \\ \chi^{2} \ p{<}0.01 \ (\text{Fig. 16}) \end{array}$	4,452 (36 RCTs)	Overall effect not assessed ^b	3,456 (25 RCTs)		
Sperm morphology	MD 3.28% (95% CI: 2.40, 4.17); p<0.01; I^2 =96%; χ^2 p<0.01 (Fig. 20)	1,828 (18 RCTs)	Not assessed	Not assessed		
Sperm DNA fragmentation	SMD -0.63 (95% Cl: -2.29, 1.02); p=0.45 (Fig. 24)	135 (3 RCTs)	MD -5.0 (95% Cl: -12.61, 2.61); p=0.20	254 (6 RCTs)		
Seminal TAC levels	MD 1.87 (95% CI: 1.26, 2.48; $p<0.01$; $I^2=97\%$; $\chi^2 p<0.01$ (Fig. 26)	316 (6 RCTs)	Not assessed	Not assessed		
Seminal MDA levels	MD -0.39 (95% Cl: -0.65, -0.14; p<0.01; l ² =87%; χ ² p<0.01 (Fig. 27)	403 (7 RCTs)	Not assessed	Not assessed		

CI: confidence interval, MD: mean difference, MDA: malondialdehyde acid, OR: odds ratio, RCT: randomized controlled trial, SMD: standardized mean difference, TAC: total antioxidant capacity.

^aOnly spontaneous events were considered in the present meta-analysis.

^bSubgroup analysis based on treatment duration was performed.

the conventional sperm parameters (sperm concentration, progressive and total motility), the Cochrane review provided the results of the sub-group analysis only (*e.g.*, effect of a single AOX, or of a specific time of assessment), without analyzing the overall effect (hence, independently from the time and the specific AOX used). The detailed analysis of the differences in the sample size, in the number of RCTs included for each outcome, and in the results between the present study and the Cochrane meta-analysis is detailed in Table 3.

Pitfalls of the Cochrane and several other meta-analyses are highlighted in the strengths and weakness analysis provided in Table 4. If we consider the previous meta-analyses, the number of analyzed studies has generally been limited most of the time [75,90], thus providing very-low or low-quality evidence. Furthermore, some meta-analyses evaluated the impact of only one or two AOX, failing to provide a comprehensive picture on their use in male infertility [75,90] (Table 4). Comprehensively, the present study analyzed the largest cohort so far, which allowed to upgrade the level of the evidence.

7. Limitations of the study

The present meta-analysis demonstrates the positive impact of AOX on spontaneous pregnancy, seminal OS indices and basic sperm parameters. However, the limited number of controlled studies investigating the effect of AOXs on live-birth rate and SDF prevented us from reaching a firm conclusion about these outcomes. This study is also not evaluating the effects of AOXs based on subgroup analysis. The heterogeneity in the



Table 4. Summary of the strengths and weakness of the meta-analyses on AOX published in the last ten years

Society	Year	Strengths	Weakness
Present study	2022	Evidence based on the highest number of RCTs and on the largest population analyzed so far Highest level of evidence provided so far Absence of inter-study heterogeneity for clinical pregnancy Evidence on seminal indices of OS (TAC and MDA) Sub-analysis performed after the exclusion of patients with varicocele Evidence on RCTs only Score of the QoE using the GRADE system	Limited number of controlled trials on live-birth rate, mis- carriage and SDF Inter-study heterogeneity for secondary outcomes No subgroup analysis according to the type of AOX, and heterogeneity in the formulation of AOX analyzed
[14]	2019	Subgroup analysis according to the type of AOX Evidence on RCTs only Score of the QoE using the GRADE system High number of studies Absence of inter-study heterogeneity for clinical pregnancy	Limited number of controlled trials on live-birth rate, mis- carriage, and SDF Inter-study heterogeneity for secondary outcomes Only the Cochrane Risk of Bias of RCTs is used for QoE No details on the training of researchers are provided Patients with varicocele are included in the analysis Evidence on seminal indices of OS (<i>e.g.</i> , TAC and MDA) is not provided Low, very-low QoE
[89]	2021	Evidence on RCTs only High selected cohort (idiopathic asthenozoospermia) Absence of heterogeneity in the formulation of AOX anal- ysed	The idiopathic etiology is not clearly mentioned in the in- clusion criteria of the included studies Only two AOXs are analyzed (N-acetyl-cysteine, L-carnitine/ L-acetyl-carnitine) Limited number of studies (n=7) Only the Cochrane Risk of Bias of RCTs is used for QoE No details on the training of researchers are provided
[90]	2021	Evidence on RCTs only High selected cohort (idiopathic infertility) Absence of heterogeneity in the formulation of AOX ana- lyzed	Limited number of studies (n=3) Only the Cochrane Risk of Bias of RCTs is used for QoE No details on the training of researchers are provided Inter-study heterogeneity Only one antioxidant is analyzed (N-Acetyl-cysteine)
[91]	2014	Evidence on RCTs only Score of the QoE using the GRADE system	Low sample size for each assessed outcome Only the Cochrane Risk of Bias of RCTs is used for QoE No details on the training of researchers are provided Inter-study heterogeneity Low, very-low QoE
[75]	2013	Evidence on RCTs only Absence of heterogeneity in the formulation of AOX anal- ysed	Limited number of studies (n=3) Only the Cochrane Risk of Bias of RCTs is used for QoE No details on the training of researchers are provided Only one AOX is analyzed (Co-enzyme Q10) Inter-study heterogeneity

AOX: antioxidant, GRADE: Grading of Recommendations Assessment, Development and Evaluation, MDA: malondialdehyde acid, OS: oxidative stress, RCT: randomized controlled trial, QoE: quality of evidence, TAC: total antioxidant capacity.

formulations studied in the literature also resulted in the presence of outliers encountered during our analysis, but we were able to adjust for this in our statistical approach. This foreseeable and expected outcome represents the limitation of the present study, based on the scarcity of well-designed studies to be included in such a meta-analysis. Beside these limitations, it is important to underline that until now there are no robust studies that have investigated the relationship between micronutrient patterns and infertility and have highlighted the role of AOXs in those patients with specific nutrient deficiency.

Despite this, our study was still capable of generating statistical results that are consistent with the scientific narrative. However, we need more well-designed large RCTs to reach more definitive conclusions. These points are highlighted in the Strengths, Weaknesses, Opportunities, and Threats (SWOT) analysis, which is shown in Fig. 28.





Fig. 28. Strengths, Weaknesses, Opportunities, and Threats (SWOT) analysis of the present study. AOX: antioxidant, MDA: malondialdehyde acid, ORP: oxidation-reduction potential, RCT: randomized controlled trial, SDF: sperm DNA fragmentation, TAC: total antioxidant capacity.

CONCLUSIONS

Our study included the largest population analyzed for the impact of AOX therapy on male infertility. The current meta-analysis demonstrates low to moderate evidence on the positive impact of AOX therapy on spontaneous pregnancy rate, and conventional sperm parameters in infertile men. Additionally, our results provide a very low to low evidence on the potential positive effect of AOX therapy on levels of seminal TAC and MDA in infertile men. The exclusion of studies that examined patients treated with AOX or placebo or untreated after varicocele repair did not change the results. This suggests that the effect of AOX on the analyzed outcomes is independent of varicocele repair. Compared to the last Cochrane review in 2019 [14], our study increased the number of RCTs included in the meta-analysis, creating the largest population analyzed with regards to the benefits of AOXs on male fertility. Also, some of the outcomes of the present study, such as sperm morphology, seminal levels of TAC and of MDA, had not been analyzed in the 2019 Cochrane review [14].

Finally, the present analysis provides additional evidence in favor of recommending the use of AOX therapy in male infertility (Table 5). The results of the current meta-analysis may help update those guidelines of the scientific societies that do not express a clear position on the use of AOX for the treatment of the infertile male due to the lack of evidence [22,93-95] (Table 6). For the clinical use of AOX to be standardized, further studies are needed, as at present there is not a specific AOX or AOX combination with a particular dosing that can be recommended for infertile men due to the heterogeneity of the available data.

Accordingly, based on our results, the following suggestions can be made on the use of AOX for the treatment of patients with male infertility:

- 1. We suggest the use of AOX to improve spontaneous pregnancy rates in patients diagnosed with IMI after a careful diagnostic work-up and the exclusion of major causes of infertility, and in those with varicocele following varicocele repair (2 ØØØO).
- 2. We suggest the use of AOX to improve conventional sperm parameters in couples diagnosed with IMI after a careful diagnostic work-up and the exclusion of other causes of infertility, and in those with varicocele following varicocele repair (2 ØØØO).
- 3. We suggest the use of AOX to improve the seminal indices of OS (TAC and MDA) in patients diagnosed with IMI and OS (2 ØØOO).

The present study identifies the need for further RCTs assessing the impact of AOX on live-birth rate, miscarriage rate, and SDF, as only few studies have analyzed these outcomes in infertile patients treated



Table 5. Summary of the findings of the present study

Outcome	Results	Number of participants (n studies)	Level of the evidence (scored using the GRADE ^a system)
Spontaneous pregnancy rate	OR 1.97 (95% CI: 1.28, 3.04); n=190 events; p<0.01; $l^2=20\%$; χ^2 p=0.20 (Fig. 2)	1,355 (16 RCTs)	$\oplus \oplus \oplus \bigcirc$ (Moderate) ^b
Live-birth rate	OR 1.21 (95% Cl: 0.53, 2.76); n=65 events; p=0.64 (Fig. 6)	388 (4 RCTs)	$\bigoplus \bigcirc \bigcirc \bigcirc$ (Very low) ^{b,c,d}
Miscarriage rate	OR 1.01 (95% Cl: 0.34, 3.00); n=13 events; p=0.98 (Fig. 7)	459 (4 RCTs)	$\bigoplus \bigcirc \bigcirc \bigcirc$ (Very low) ^{b,c,d}
Sperm concentration	MD 5.93 mil/mL (95% Cl: 4.43, 7.43); p<0.01; I ² =94%; χ ² p<0.01 (Fig. 8)	4,310 (35 RCTs)	$\oplus \oplus \oplus \bigcirc$ (Moderate) ^b
Progressive sperm motility	MD 7.21% (95% CI: 3.66, 10.76); p<0.01; I^2 =99%; χ^2 p<0.01 (Fig. 12)	2,345 (20 RCTs)	$\bigoplus \bigoplus \bigoplus \bigcirc$ (Moderate) ^b
Total sperm motility	MD 7.52% (95% CI: 3.11, 11.94); p<0.01; l ² =100%; χ^2 p<0.01 (Fig. 16)	4,452 (36 RCTs)	$\oplus \oplus \oplus \bigcirc$ (Moderate) ^b
Sperm morphology	MD 3.28% (95% CI: 2.40, 4.17); p<0.01; $l^2=96\%$; χ^2 p<0.01 (Fig. 20)	1,828 (18 RCTs)	$\bigoplus \bigoplus \bigcirc \bigcirc$ (Low) ^{b,c}
Sperm DNA fragmentation	SMD -0.63 (95% Cl: -2.29, 1.02); p=0.45 (Fig. 24)	135 (3 RCTs)	$\bigoplus \ominus \ominus \ominus$ (Very low) ^{b,c,d}
Seminal TAC levels	MD 1.87 (95% Cl: 1.26, 2.48; p<0.01; l ² =97%; χ ² p<0.01 (Fig. 26)	316 (6 RCTs)	$\bigoplus \bigoplus \bigcirc \bigcirc$ (Low) ^{b,c}
Seminal MDA levels	MD -0.39 (95% CI: -0.65, -0.14; p<0.01; l ² =87%; χ ² p<0.01 (Fig. 27)	403 (7 RCTs)	$\oplus \oplus \ominus \ominus$ (Low) ^{b,c}

CI: confidence interval, GRADE: Grading of Recommendations Assessment, Development and Evaluation, MD: mean difference, MDA: malondialdehyde acid, OR: odds ratio, RCT: randomized controlled trial, SMD: standardized mean difference, TAC: total antioxidant capacity.

^aHigh level: We are very confident that the true effect lies close to that of the estimate of the effect. Moderate level: We are moderately confident in the effect estimate. The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. Low level: Our confidence in the effect estimate is limited. The true effect may be substantially different from the estimate of the effect. Very low level: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. ^bDowngraded one level for risk of bias: lack of allocation concealment, lack of blinding and incomplete accounting of patients and outcome events.

^cDowngraded one level for serious imprecision: small sample size.

^dDowngraded one level for serious imprecision: crossing the line of no effect.

Table 6. Summary of the Societies' recommendations on the use of AOX for the treatment of male infertility

Society	Year	Recommendation
European Academy of Andrology (EAA) [92]	2018	Recommendation 9. According to the current evidence, we cannot recommend either for or against antioxidants, and for antiestrogens (tamoxifen or clomiphene) or aromatase inhibitors (20000)
American Urological Association (AUA)/American Society for Reproductive Medicine (ASRM) [22]	2021	Recommendation 43. Clinicians should counsel patients that the benefits of supplements (<i>e.g.</i> , antioxidants, vitamins) are of questionable clinical utility in treating male infertility. Existing data are inadequate to provide recommendation for specific agents to use for this purpose (Conditional Recommendation; Evidence Level: Grade B) Current data suggest that they are likely not harmful, but it is questionable whether they will provide tangible improvements in fertility outcomes
Italian Society of Andrology and Sexual Medicine (SIAMS) [93]	2021	 We recommend against treatment with nutraceuticals/antioxidants in unselected infertile men to increase sperm parameters (Expert Opinion) We suggest considering the use of nutraceuticals/antioxidants in selected patients with idiopathic oligozoospermia and/or asthenozoospermia and/or clear signs of high OS, since in some cases they might improve sperm parameters (2, ØOOO) We cannot recommend either for or against the use of nutraceuticals/antioxidants to increase pregnancy rate (Expert Opinion)
European Association of Urology – Sexual and Reproductive Health Guidelines [94]	2022	No clear recommendation can be made for treatment of patients with idiopathic infertility us- ing antioxidants, although antioxidant use may improve semen parameters (weak)

AOX: antioxidant, OS: oxidative stress.

with AOX compared to placebo-treated or untreated controls. Finally, the ideal treatment duration, as well as best therapeutic regimen (single *vs.* combined AOX) remains unknown and further studies will be needed to address these issues.

Conflict of Interest

The authors have nothing to disclose.

Funding

None.

Acknowledgements

Authors are thankful to the Global Andrology Forum for its support of this study.

Author Contribution

Conceptualization: AA, RS. Data curation: R.Sa, RC, AH. Formal analysis: RC, AH. Funding acquisition: None. Investigation: GS, SK, AF. Methodology: R.Sa, RC, AH. Project administration: AA, RS. Supervision: FB, TAAMH. Validation: AR, AZ, GC, MG, PK, EK, GC, TT, GP, HJP, RAG, SM, GMB, MEB, AK, EC, GIR, AEC, RFA, CNJ. Writing – original draft: RC, GS, R.Sa, FB, AF. Writing – review & editing & final approval: AA, RS.

Supplementary Materials

Supplementary materials can be found *via* https://doi. org/10.5534/wjmh.220067.

REFERENCES

- 1. Agarwal A, Baskaran S, Parekh N, Cho CL, Henkel R, Vij S, et al. Male infertility. Lancet 2021;397:319-33.
- 2. Irvine DS. Epidemiology and aetiology of male infertility. Hum Reprod 1998;13 Suppl 1:33-44.
- Salonia A, Bettocchi C, Boeri L, Capogrosso P, Carvalho J, Cilesiz NC, et al.; EAU Working Group on Male Sexual and reproductive health. European Association of Urology guidelines on sexual and reproductive health-2021 update: male sexual dysfunction. Eur Urol 2021;80:333-57.
- 4. Sharma RK, Agarwal A. Role of reactive oxygen species in male infertility. Urology 1996;48:835-50.
- 5. Takeshima T, Usui K, Mori K, Asai T, Yasuda K, Kuroda S,

et al. Oxidative stress and male infertility. Reprod Med Biol 2020;20:41-52.

- Agarwal A, Mulgund A, Alshahrani S, Assidi M, Abuzenadah AM, Sharma R, et al. Reactive oxygen species and sperm DNA damage in infertile men presenting with low level leukocytospermia. Reprod Biol Endocrinol 2014;12:126.
- Bui AD, Sharma R, Henkel R, Agarwal A. Reactive oxygen species impact on sperm DNA and its role in male infertility. Andrologia 2018;50:e13012.
- Walczak-Jedrzejowska R, Wolski JK, Slowikowska-Hilczer J. The role of oxidative stress and antioxidants in male fertility. CEJU 2013;66:60-7.
- Agarwal A, Cho CL, Esteves SC, Majzoub A. Reactive oxygen species and sperm DNA fragmentation. Transl Androl Urol 2017;6(Suppl 4):S695-6.
- Aitken RJ. Reactive oxygen species as mediators of sperm capacitation and pathological damage. Mol Reprod Dev 2017;84:1039-52.
- 11. Alvarez JG, Storey BT. Differential incorporation of fatty acids into and peroxidative loss of fatty acids from phospholipids of human spermatozoa. Mol Reprod Dev 1995;42:334-46.
- Agarwal A, Parekh N, Panner Selvam MK, Henkel R, Shah R, Homa ST, et al. Male oxidative stress infertility (MOSI): proposed terminology and clinical practice guidelines for management of idiopathic male infertility. World J Mens Health 2019;37:296-312.
- Barati E, Nikzad H, Karimian M. Oxidative stress and male infertility: current knowledge of pathophysiology and role of antioxidant therapy in disease management. Cell Mol Life Sci 2020;77:93-113.
- Smits RM, Mackenzie-Proctor R, Yazdani A, Stankiewicz MT, Jordan V, Showell MG. Antioxidants for male subfertility. Cochrane Database Syst Rev 2019;3:CD007411.
- 15. Ali M, Martinez M, Parekh N. Are antioxidants a viable treatment option for male infertility? Andrologia 2021;53:e13644.
- Agarwal A, Leisegang K, Majzoub A, Henkel R, Finelli R, Panner Selvam MK, et al. Utility of Antioxidants in the Treatment of Male Infertility: Clinical Guidelines Based on a Systematic Review and Analysis of Evidence. World J Mens Health. 2021;39:233-290.
- Wei G, Zhou Z, Cui Y, Huang Y, Wan Z, Che X, et al. A Meta-Analysis of the Efficacy of L-Carnitine/L-Acetyl-Carnitine or N-Acetyl-Cysteine in Men With Idiopathic Asthenozoospermia. Am J Mens Health. 2021;15:15579883211011371.
- Zhang X, Cui Y, Dong L, Sun M, Zhang Y. The efficacy of combined l-carnitine and l-acetyl carnitine in men with idiopathic oligoasthenoteratozoospermia: a systematic review and meta-analysis. Andrologia 2020;52:e13470.



- Wang J, Wang T, Ding W, Wu J, Wu G, Wang Y, et al. Efficacy of antioxidant therapy on sperm quality measurements after varicocelectomy: a systematic review and meta-analysis. Andrologia 2019;51:e13396.
- 20. Bahmyari R, Zare M, Sharma R, Agarwal A, Halvaei I. The efficacy of antioxidants in sperm parameters and production of reactive oxygen species levels during the freeze-thaw process: a systematic review and meta-analysis. Andrologia 2020;52:e13514.
- Salonia A, Bettocchi C, Carvalho J, Corona G, Jones TH, Kadioğlu A, et al. Sexual and reproductive health. Arnhem: European Association of Urology; 2022;282.
- Schlegel PN, Sigman M, Collura B, De Jonge CJ, Eisenberg ML, Lamb DJ, et al. Diagnosis and treatment of infertility in men: AUA/ASRM guideline part I. J Urol 2021;205:36-43.
- Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, et al.; PRISMA-P Group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ 2015;350:g7647.
- 24. Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 2019;366:l4898.
- 25. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17:1-12.
- Schulz KF, Altman DG, Moher D; CONSORT Group. CON-SORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ 2010;340:c332.
- Ardestani Zadeh A, Arab D, Kia NS, Heshmati S, Amirkhalili SN. The role of vitamin E - selenium - folic acid supplementation in improving sperm parameters after varicocelectomy: a randomized clinical trial. Urol J 2019;16:495-500.
- Kızılay F, Altay B. Evaluation of the effects of antioxidant treatment on sperm parameters and pregnancy rates in infertile patients after varicocelectomy: a randomized controlled trial. Int J Impot Res 2019;31:424-31.
- 29. Barekat F, Tavalaee M, Deemeh MR, Bahreinian M, Azadi L, Abbasi H, et al. A preliminary study: N-acetyl-L-cysteine improves semen quality following varicocelectomy. Int J Fertil Steril 2016;10:120-6.
- Ener K, Aldemir M, Işık E, Okulu E, Özcan MF, Uğurlu M, et al. The impact of vitamin E supplementation on semen parameters and pregnancy rates after varicocelectomy: a randomised controlled study. Andrologia 2016;48:829-34.
- 31. Cyrus A, Kabir A, Goodarzi D, Moghimi M. The effect of adjuvant vitamin C after varicocele surgery on sperm quality and quantity in infertile men: a double blind placebo con-

trolled clinical trial. Int Braz J Urol 2015;41:230-8.

- 32. Azizollahi G, Azizollahi S, Babaei H, Kianinejad M, Baneshi MR, Nematollahi-mahani SN. Effects of supplement therapy on sperm parameters, protamine content and acrosomal integrity of varicocelectomized subjects. J Assist Reprod Genet 2013;30:593-9.
- 33. Balercia G, Regoli F, Armeni T, Koverech A, Mantero F, Boscaro M. Placebo-controlled double-blind randomized trial on the use of L-carnitine, L-acetylcarnitine, or combined Lcarnitine and L-acetylcarnitine in men with idiopathic asthenozoospermia. Fertil Steril 2005;84:662-71.
- Balercia G, Buldreghini E, Vignini A, Tiano L, Paggi F, Amoroso S, et al. Coenzyme Q10 treatment in infertile men with idiopathic asthenozoospermia: a placebo-controlled, doubleblind randomized trial. Fertil Steril 2009;91:1785-92.
- 35. Busetto GM, Virmani A, Antonini G, Ragonesi G, Del Giudice F, Agarwal A, et al. Effect of antioxidant supplementation on sperm parameters in oligo-astheno-teratozoospermia, with and without varicocele: a double blind place controlled (DBPC) study. Eur Urol Suppl 2017;16:e782.
- 36. Busetto GM, Agarwal A, Virmani A, Antonini G, Ragonesi G, Del Giudice F, et al. Effect of metabolic and antioxidant supplementation on sperm parameters in oligo-astheno-ter-atozoospermia, with and without varicocele: a double-blind placebo-controlled study. Andrologia 2018;50:e12927.
- 37. Gopinath PM, Kalra B, Saxena A, Malik S, Kochhar K, Kalra S, et al. Fixed dose combination therapy of antioxidants in treatment of idiopathic oligoasthenozoospermia: results of a randomized, double-blind, placebo-controlled clinical trial. IJIFM 2013;4:6-13.
- 38. Kopets R, Kuibida I, Chernyavska I, Cherepanyn V, Mazo R, Fedevych V, et al. Dietary supplementation with a novel lcarnitine multi-micronutrient in idiopathic male subfertility involving oligo-, astheno-, teratozoospermia: a randomized clinical study. Andrology 2020;8:1184-93.
- Omu AE, Dashti H, Al-Othman S. Treatment of asthenozoospermia with zinc sulphate: andrological, immunological and obstetric outcome. Eur J Obstet Gynecol Reprod Biol 1998;79:179-84.
- 40. Paradiso Galatioto G, Gravina GL, Angelozzi G, Sacchetti A, Innominato PF, Pace G, et al. May antioxidant therapy improve sperm parameters of men with persistent oligospermia after retrograde embolization for varicocele? World J Urol 2008;26:97-102.
- 41. Scott R, MacPherson A, Yates RW, Hussain B, Dixon J. The effect of oral selenium supplementation on human sperm motility. Br J Urol 1998;82:76-80.
- 42. Steiner AZ, Hansen KR, Barnhart KT, Cedars MI, Legro RS,

Diamond MP, et al.; Reproductive Medicine Network. The effect of antioxidants on male factor infertility: the males, antioxidants, and infertility (MOXI) randomized clinical trial. Fertil Steril 2020;113:552-60.e3.

- Stenqvist A, Oleszczuk K, Leijonhufvud I, Giwercman A. Impact of antioxidant treatment on DNA fragmentation index: a double-blind placebo-controlled randomized trial. Andrology 2018;6:811-6.
- 44. Suleiman SA, Ali ME, Zaki ZM, el-Malik EM, Nasr MA. Lipid peroxidation and human sperm motility: protective role of vitamin E. J Androl 1996;17:530-7.
- 45. Závaczki Z, Szöllősi J, Kiss SA, Koloszár S, Fejes I, Kovács L, et al. Magnesium-orotate supplementation for idiopathic infertile male patients: a randomized, placebo-controlled clinical pilot study. Magnes Res 2003;16:131-6.
- 46. Boonyarangkul A, Vinayanuvattikhun N, Chiamchanya C, Visutakul P. Comparative study of the effects of tamoxifen citrate and folate on semen quality of the infertile male with semen abnormality. J Med Assoc Thai 2015;98:1057-63.
- 47. Ciftci H, Verit A, Savas M, Yeni E, Erel O. Effects of N-acetylcysteine on semen parameters and oxidative/antioxidant status. Urology 2009;74:73-6.
- Conquer JA, Martin JB, Tummon I, Watson L, Tekpetey F. Effect of DHA supplementation on DHA status and sperm motility in asthenozoospermic males. Lipids 2000;35:149-54.
- da Silva TM, Maia MCS, Arruda JT, Approbato FC, Mendonça CR, Approbato MS. Folic acid does not improve semen parametrs in subfertile men: a double-blin, randomized, placebo-controlled study. JBRA Assist Reprod 2013;17:152-7.
- 50. Dimitriadis F, Tsambalas S, Tsounapi P, Kawamura H, Vlachopoulou E, Haliasos N, et al. Effects of phosphodiesterase-5 inhibitors on Leydig cell secretory function in oligoasthenospermic infertile men: a randomized trial. BJU Int 2010;106:1181-5.
- 51. Eslamian G, Amirjannati N, Noori N, Sadeghi MR, Hekmatdoost A. Effects of coadministration of DHA and vitamin E on spermatogram, seminal oxidative stress, and sperm phospholipids in asthenozoospermic men: a randomized controlled trial. Am J Clin Nutr 2020;112:707-19.
- 52. Greco E, Iacobelli M, Rienzi L, Ubaldi F, Ferrero S, Tesarik J. Reduction of the incidence of sperm DNA fragmentation by oral antioxidant treatment. J Androl 2005;26:349-53.
- 53. Haghighian HK, Haidari F, Mohammadi-Asl J, Dadfar M. Randomized, triple-blind, placebo-controlled clinical trial examining the effects of alpha-lipoic acid supplement on the spermatogram and seminal oxidative stress in infertile men. Fertil Steril 2015;104:318-24.
- 54. Lenzi A, Lombardo F, Sgrò P, Salacone P, Caponecchia L,

Dondero F, et al. Use of carnitine therapy in selected cases of male factor infertility: a double-blind crossover trial. Fertil Steril 2003;79:292-300.

- 55. Lu XL, Liu JJ, Li JT, Yang QA, Zhang JM. Melatonin therapy adds extra benefit to varicecelectomy in terms of sperm parameters, hormonal profile and total antioxidant capacity: a placebo-controlled, double-blind trial. Andrologia 2018;50:e13033.
- Martinez-Soto JC, Domingo JC, Cordobilla B, Palbero L, Pellicer A, Landeras J. Effect of dietary DHA supplementation on sperm DNA integrity. Fertil Steril 2010;94:S235-6.
- 57. Moslemi Mehni N, Ketabchi AA, Hosseini E. Combination effect of Pentoxifylline and L-carnitine on idiopathic oligoasthenoteratozoospermia. Iran J Reprod Med 2014;12:817-24.
- 58. Morgante G, Scolaro V, Tosti C, Di Sabatino A, Piomboni P, De Leo V. [Treatment with carnitine, acetyl carnitine, L-arginine and ginseng improves sperm motility and sexual health in men with asthenopermia]. Minerva Urol Nefrol 2010;62:213-8. Italian.
- 59. Nadjarzadeh A, Sadeghi MR, Amirjannati N, Vafa MR, Motevalian SA, Gohari MR, et al. Coenzyme Q₁₀ improves seminal oxidative defense but does not affect on semen parameters in idiopathic oligoasthenoteratozoospermia: a randomized double-blind, placebo controlled trial. J Endocrinol Invest 2011;34:e224-8.
- 60. Nouri M, Amani R, Nasr-Esfahani M, Tarrahi MJ. The effects of lycopene supplement on the spermatogram and seminal oxidative stress in infertile men: a randomized, double-blind, placebo-controlled clinical trial. Phytother Res 2019;33:3203-11.
- Omu AE, Al-Azemi MK, Kehinde EO, Anim JT, Oriowo MA, Mathew TC. Indications of the mechanisms involved in improved sperm parameters by zinc therapy. Med Princ Pract 2008;17:108-16.
- 62. Peivandi S, Karimpour A, Moslemizadeh N. Effects of L-carnitine on infertile men's spermogram; a randomized clinical trial. J Reprod Infertil 2010;10:245-51.
- 63. Rolf C, Cooper TG, Yeung CH, Nieschlag E. Antioxidant treatment of patients with asthenozoospermia or moderate oligoasthenozoospermia with high-dose vitamin C and vitamin E: a randomized, placebo-controlled, double-blind study. Hum Reprod 1999;14:1028-33.
- 64. Safarinejad MR, Safarinejad S, Shafiei N, Safarinejad S. Effects of the reduced form of coenzyme Q10 (ubiquinol) on semen parameters in men with idiopathic infertility: a double-blind, placebo controlled, randomized study. J Urol 2012;188:526-31.
- 65. Safarinejad MR. Effect of omega-3 polyunsaturated fatty

acid supplementation on semen profile and enzymatic antioxidant capacity of seminal plasma in infertile men with idiopathic oligoasthenoteratospermia: a double-blind, placebocontrolled, randomised study. Andrologia 2011;43:38-47.

The World Journal of

MEN's HEALTH

- Safarinejad MR, Safarinejad S. Efficacy of selenium and/or Nacetyl-cysteine for improving semen parameters in infertile men: a double-blind, placebo controlled, randomized study. J Urol 2009;181:741-51.
- 67. Safarinejad MR. Efficacy of coenzyme Q10 on semen parameters, sperm function and reproductive hormones in infertile men. J Urol 2009;182:237-48.
- 68. Stanislavov R, Nikolova V, Rohdewald P. Improvement of seminal parameters with Prelox: a randomized, doubleblind, placebo-controlled, cross-over trial. Phytother Res 2009;23:297-302.
- Blomberg Jensen M, Lawaetz JG, Petersen JH, Juul A, Jørgensen N. Effects of vitamin D supplementation on semen quality, reproductive hormones, and live birth rate: a randomized clinical trial. J Clin Endocrinol Metab 2018;103:870-81.
- Dawson EB, Harris WA, Powell LC. Relationship between ascorbic acid and male fertility. World Rev Nutr Diet 1990;62:1-26.
- Sigman M, Glass S, Campagnone J, Pryor JL. Carnitine for the treatment of idiopathic asthenospermia: a randomized, double-blind, placebo-controlled trial. Fertil Steril 2006;85:1409-14.
- 72. Imamovic Kumalic S, Pinter B. Review of clinical trials on effects of oral antioxidants on basic semen and other parameters in idiopathic oligoasthenoteratozoospermia. Biomed Res Int 2014;2014:426951.
- 73. Majzoub A, Agarwal A. Systematic review of antioxidant types and doses in male infertility: benefits on semen parameters, advanced sperm function, assisted reproduction and live-birth rate. Arab J Urol 2018;16:113-24.
- Ross C, Morriss A, Khairy M, Khalaf Y, Braude P, Coomarasamy A, et al. A systematic review of the effect of oral antioxidants on male infertility. Reprod Biomed Online 2010;20:711-23.
- 75. Lafuente R, González-Comadrán M, Solà I, López G, Brassesco M, Carreras R, et al. Coenzyme Q10 and male infertility: a meta-analysis. J Assist Reprod Genet 2013;30:1147-56.
- Muratori M, Marchiani S, Tamburrino L, Baldi E. Sperm DNA fragmentation: mechanisms of origin. Adv Exp Med Biol 2019;1166:75-85.
- 77. Jannatifar R, Cheraghi E, Nasr-Esfahani MH, Piroozmanesh H. Association of heat shock protein A2 expression and sperm quality after N-acetyl-cysteine supplementation in asthenoterato-zoospermic infertile men. Andrologia 2021;53:e14024.

- 78. Salehi P, Zahra Shahrokhi S, Kamran T, Ajami A, Taghiyar S, Reza Deemeh M. Effect of antioxidant therapy on the sperm DNA integrity improvement; a longitudinal cohort study. Int J Reprod Biomed 2019;17:99-106.
- Alahmar AT, Sengupta P, Dutta S, Calogero AE. Coenzyme Q10, oxidative stress markers, and sperm DNA damage in men with idiopathic oligoasthenoteratospermia. Clin Exp Reprod Med 2021;48:150-5.
- Pourmand G, Movahedin M, Dehghani S, Mehrsai A, Ahmadi A, Pourhosein M, et al. Does L-carnitine therapy add any extra benefit to standard inguinal varicocelectomy in terms of deoxyribonucleic acid damage or sperm quality factor indices: a randomized study. Urology 2014;84:821-5.
- Kumalic SI, Klun IV, Bokal EV, Pinter B. Effect of the oral intake of astaxanthin on semen parameters in patients with oligo-astheno-teratozoospermia: a randomized double-blind placebo-controlled trial. Radiol Oncol 2020;55:97-105.
- Huang WJ, Lu XL, Li JT, Zhang JM. Effects of folic acid on oligozoospermia with MTHFR polymorphisms in term of seminal parameters, DNA fragmentation, and live birth rate: a double-blind, randomized, placebo-controlled trial. Andrology 2020;8:110-6.
- 83. Schisterman EF, Sjaarda LA, Clemons T, Carrell DT, Perkins NJ, Johnstone E, et al. Effect of folic acid and zinc supplementation in men on semen quality and live birth among couples undergoing infertility treatment: a randomized clinical trial. JAMA 2020;323:35-48. Erratum in: JAMA 2020;323:1194.
- Gupta S, Finelli R, Agarwal A, Henkel R. Total antioxidant capacity-Relevance, methods and clinical implications. Andrologia 2021;53:e13624.
- Dutta S, Majzoub A, Agarwal A. Oxidative stress and sperm function: a systematic review on evaluation and management. Arab J Urol 2019;17:87-97.
- 86. Comhaire FH, Christophe AB, Zalata AA, Dhooge WS, Mahmoud AM, Depuydt CE. The effects of combined conventional treatment, oral antioxidants and essential fatty acids on sperm biology in subfertile men. Prostaglandins Leukot Essent Fatty Acids 2000;63:159-65.
- 87. Keskes-Ammar L, Feki-Chakroun N, Rebai T, Sahnoun Z, Ghozzi H, Hammami S, et al. Sperm oxidative stress and the effect of an oral vitamin E and selenium supplement on semen quality in infertile men. Arch Androl 2003;49:83-94.
- Halliwell B. The antioxidant paradox. Lancet 2000;355:1179-80.
- Wei G, Zhou Z, Cui Y, Huang Y, Wan Z, Che X, et al. A metaanalysis of the efficacy of L-carnitine/L-acetyl-carnitine or Nacetyl-cysteine in men with idiopathic asthenozoospermia. Am J Mens Health 2021;15:15579883211011371.



- 90. Zhou Z, Cui Y, Zhang X, Zhang Y. The role of N-acetyl-cysteine (NAC) orally daily on the sperm parameters and serum hormones in idiopathic infertile men: a systematic review and meta-analysis of randomised controlled trials. Andrologia 2021;53:e13953.
- Showell MG, Mackenzie-Proctor R, Brown J, Yazdani A, Stankiewicz MT, Hart RJ. Antioxidants for male subfertility. Cochrane Database Syst Rev 2014;12:CD007411.
- 92. Su JS, Farber NJ, Vij SC. Pathophysiology and treatment options of varicocele: an overview. Andrologia 2021;53:e13576.
- 93. Colpi GM, Francavilla S, Haidl G, Link K, Behre HM, Goulis DG, et al. European Academy of Andrology guideline

management of oligo-astheno-teratozoospermia. Andrology 2018;6:513-24.

- 94. Ferlin A, Calogero AE, Krausz C, Lombardo F, Paoli D, Rago R, et al. Management of male factor infertility: position statement from the Italian Society of Andrology and Sexual Medicine (SIAMS): endorsing organization: Italian Society of Embryology, Reproduction, and Research (SIERR). J Endocrinol Invest 2022;45:1085-113.
- 95. European Association of Urology. Sexual and reproductive health [Internet]. Arnhem: European Association of Urology; c2022 [cited 2022 Apr 12]. Available from: https://uroweb. org/guidelines/sexual-and-reproductive-health.